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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
Overview of the Dopaminergic System 
Dopamine (3,4-Dihydroxyphenethylamine; DA) is a catecholamine neurotransmitter that plays 
several important roles in the human central nervous system (CNS). Within the CNS, there are four 
major dopaminergic pathways: the tuberoinfundibular pathway, the nigrostriatal pathway, the 
mesocortical pathway, and the mesolimbic pathway (Fig. 1). The tuberoinfundibular pathway 
consists of DA neurons that project from the hypothalamus to the pituitary gland. These neurons 
mediate the secretion of prolactin, a hormone that stimulates lactation(Fitzgerald and Dinan, 
2008). The nigrostriatal pathway consists of DA neurons that project from the substantia nigra to 
the striatum, which play an important role in voluntary motor control. Interestingly, these 
neurons are vulnerable to damage, and their death results in a Parkinsonian syndrome(Beitz, 
2014). The mesocortical pathway consists of DA neurons that project from the ventral tegmental 
area (VTA) to the frontal lobes of the cerebrum, particularly the prefrontal cortex. The 
mesocortical pathway is involved in cognitive processing, motivation, and emotion(Miller and 
Cohen, 2001). Lastly, the mesolimbic pathway consists of DA neurons that originate in the VTA 
and project to the nucleus accumbens. The mesolimbic pathway is important in mediating 
reward and pleasure(Wise, 1998).  
 
Within these dopaminergic pathways, DA neurotransmission modulates the physiological and 
behavioral processes of executive function, movement, motivation, mood, and reward(Bjorklund 
and Dunnett, 2007). Alterations in DA neurotransmission are thought to contribute to the  
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Figure 1. Schematic illustration of dopaminergic pathways. Dopaminergic 
neurons in the ventral tegmental area project to the nucleus accumbens and 
prefrontal cortex to form the mesolimbic and mesocortical pathways, respectively. 
Dopaminergic neurons in the substantia nigra project to the striatum to form the 
nigrostriatal pathway. The tuberoinfundibular pathway is not depicted. Image adapted 
from Neuroscience Exploring the Brain Third Edition by Mark F. Barry, Barry Connor, 
and Mark. F. Paradiso. 
 3 
pathogenesis of neuropsychiatric disorders, including schizophrenia, bipolar disorder, attention-
deficit hyperactivity disorder (ADHD), and drug abuse(Seeman and Niznik, 1990, Volkow et al., 
2007, Cousins et al., 2009, Kristensen et al., 2011). More recently, dysfunctional DA 
neurotransmission has been implicated in the etiology of autism spectrum disorder 
(ASD)(Hamilton et al., 2013, Bowton et al., 2014, Nguyen et al., 2014) . 
 
DA neurotransmission occurs at the synapse and is shaped by synaptic features, which include 
the amount of DA released, the signaling of pre- and postsynaptic DA receptors, and the time 
that DA spends in the synaptic space. The DA transporter (DAT) is a presynaptic protein that 
mediates the high affinity re-uptake of DA from the synaptic space, thereby controlling the post-
synaptic exposure to DA(Kristensen et al., 2011). The DAT regulates the intensity and duration 
of the dopaminergic response, making it a crucial regulator of DA neurotransmission. Therefore, 
a more complete understanding of the events that regulate DAT function in health and disease 
may yield an improved understanding of the etiology of these disorders and result in more 
appropriately targeted pharmacotherapies.  
 
Dopamine Transporter Structure 
The DAT is member of the solute carrier 6 (SLC6) gene family of Na+/Cl- symporters, which 
includes other monoamine transporters, such as the serotonin transporter (SERT) and 
norepinephrine transporter (NET). In the early 1990s, molecular cloning experiments revealed a 
highly conserved amino acid sequence across SLC6 transporters, suggesting a shared general 
structure(Blakely et al., 1991). Indeed, the DAT and other SLC6 transporters consist of a 
membrane topology with 12 transmembrane domain (TMD) helices with intracellular N- and C-
termini and a large glycosylated loop between transmembrane helices III and IV (Fig. 2). This 
topology has been confirmed by the high resolution structure of LeuT, a prokaryotic sodium- 
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Figure 2. Topology of the dopamine transporter (DAT). The DAT is predicted to 
have twelve transmembrane helices with cytoplasmic N- and C-termini. 
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dependent leucine transporter with significant homology to DAT(Yamashita et al., 2005), and, more 
recently, by the high resolution structure of the Drosophila melanogaster DAT (dDATcryst) (Fig. 
3)(Penmatsa et al., 2013). The N-terminus of the DAT has proved difficult to include in a DAT crystal 
structure, thus there are a scarcity of structural insights to this functional domain. However, the N-
terminus of the DAT is recognized as a major regulator of DAT function. The N-terminus contains 
numerous putative phosphorylation sites, including Ser residues located at position 2, 4, 7, 12, and 
13. The phosphorylation of these Ser residues are thought to regulate specific aspects of DAT 
function, particularly DAT-mediated reverse transport of DA(Khoshbouei et al., 2004, Fog et al., 
2006, Bowton et al., 2010). 
 
Dopamine Transporter Function 
A characteristic of the transporters in the SLC6 gene family is the use of the ion concentration 
gradient as the driving force for transporter-mediated re-uptake of their respective substrate(Gu et 
al., 1994). In the case of the DAT, the uptake of DA is coupled with the translocation of two Na+ ions 
and one Cl- ion, resulting in a net movement of two positive charges per DA molecule (since DA is 
positively charged at physiological pH)(Krueger, 1990). In the LeuT, a Cl- independent transporter, 
two distinct sites were discovered to be occupied by Na+ ions, designated Na1 and Na2(Yamashita 
et al., 2005). In dDATcryst, the resolution of the Cl- binding site was resolved in addition to the two Na+ 
binding sites(Penmatsa et al., 2013). The amino acids that comprise these ion binding sites are 
conserved across phylogeny and SLC6 transporters, underscoring their importance in DAT function. 
Both Na+ binding sites and the Cl- binding site are believed to play a role in stabilizing the DAT in the 
presence of substrate, thereby allowing substrate translocation via a conformational change in the 
transporter.  
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Figure 3.  Structure of Drosophila dopamine transporter (dDATcryst). Architecture 
of dDATcryst viewed parallel to membrane. Nortriptyline (a tricyclic antidepressant), 
sodium ions, a chloride ion, and a cholesterol molecule co-crystallized with the 
dDATcryst are shown in sphere representation in magenta, purple, green and yellow, 
respectively. Image adapted from Penmatsa et al. Nature 503, 85-90 (2013). 
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The concept that the DAT assumes conformations required for substrate translocation is reinforced 
by studies exploring zinc regulation of DAT. The DAT contains three endogenous, extracellular-
facing amino acids (His193, His375, and Gln396) that coordinate zinc binding(Norregaard et al., 
1998, Loland et al., 1999)(Fig. 4). Zinc binding to these DAT residues results in an inhibition of DA 
transport but not an inhibition of substrate binding(Norregaard et al., 1998), suggesting that 
conformational changes in extracellular loops (ECLs) 2 and 4 are necessary for substrate 
translocation. A Tyr to Ala mutation in the third intracellular loop of hDAT (hDAT Y335A) (seen in 
Fig. 4) converts the inhibitory action of zinc into a zinc-dependent activation of transporter 
uptake(Loland et al., 2002). Despite normal substrate affinity and surface expression, hDAT Y335A 
displays a dramatic decrease in the Vmax for DA uptake that can be partially recovered in the 
presence of zinc(Loland et al., 2002). Taken together, the dichotomous actions of zinc are 
consistent with a shift in the distribution of conformational states in the transport cycle.   
 
A helpful conceptual model for understanding changes in DAT conformation in the DAT transporter 
cycle is the classical “alternating access” model of transporter function(Jardetzky, 1966). The model 
assumes the DAT is capable of an “outward-facing” conformation, in which extracellular DA, Na+, 
and Cl- are required to bind to the transporter in a fixed ratio and induce a conformational change, 
resulting in an “inward-facing” conformation and the dissociation of the cargo, thereby completing 
the transport of DA from the synaptic space into the cytosol. Thus, the conformational equilibrium 
between “inward”- and “outward”-facing states is determined by binding of ions and substrate and 
mediated by the physical movement of DAT structural domains. 
 
Dopamine Transporter-Mediated Reverse Transport  
There is an inherent asymmetry of ion and substrate concentration, membrane potential, and 
DAT protein structure when using the neuronal cell membrane as the axis of symmetry. This  
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Figure 4. Endogenous zinc binding sites in the human dopamine transporter 
(hDAT) and hDAT Y335A. The hDAT residues that coordinate the binding of zinc are 
illustrated in black. His193 is located in the second extracellular loop, while His375 
and Gln396 are located in the fourth extracellular loop. Additionally, mutation of the 
intracellular Tyr to an Ala at position 335 is highlighted here. Image from Loland et al. 
PNAS 99, 1683-1688 (2002). 
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may seem to suggest that the DAT is only capable of DA re-uptake. However, there are clear 
and documented instances of the reversal of the DAT function, where the net flow of DA, 
mediated by the DAT, travels from the cell cytosol to the extracellular space(Pifl et al., 1995, 
Wall et al., 1995, Khoshbouei et al., 2003). These well-documented conditions in which reverse 
transport is known to occur are: exposure to psychostimulants such as amphetamine (AMPH), 
activation of second messenger signaling pathways and proteins, and DAT coding variants 
identified in neuropsychiatric disease. 
 
Reverse Transport: Amphetamines 
Pharmacological substances have long been used to study the process of DAT-mediated DA 
efflux, not only due to the merit of understanding the molecular events that surround human 
abuse of these substances, but also because these substances provide a mechanism to induce 
the molecular events that are required for reverse transport, allowing this phenomenon to be 
studied. Of these pharmacological substances, AMPH is the gold standard.  
 
AMPH is a psychostimulant that primarily exerts its pharmacological effects by altering DAT 
function(Jones et al., 1998). AMPH and its congeners, including methamphetamine, are 
structurally similar to DA, and are therefore substrates for the DAT (Fig. 5). AMPH competitively 
inhibits DA re-uptake, thereby increasing synaptic DA concentration. Additionally, AMPH elicits 
DAT-mediated DA release in the CNS(Fischer and Cho, 1979, Jones et al., 1998) and in cells 
expressing the DAT(Pifl et al., 1995, Wall et al., 1995, Sitte et al., 1998, Khoshbouei et al., 
2003). AMPH competes with DAT substrates for interaction with the “outward-facing” 
conformation of the DAT. AMPH is translocated into the intracellular space, which increases the 
availability of “inward-facing” binding sites of the DAT(Fischer and Cho, 1979). Once inside the 
cell, AMPH interacts with the vesicular monoamine transporter (VMAT). AMPH is a weak base,  
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Figure 5.  Chemical structure of DAT substrates.  DAT substrates are depicted 
here, including the physiological substrate dopamine and the psychostimulant 
substrates amphetamine and methamphetamine. 
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thus it alters the pH gradient necessary for VMAT to package DA in synaptic vesicles(Sulzer et 
al., 1995). This results in an increase in cytosolic DA concentration. This cytosolic DA has 
access to the “inward-facing” binding sites on the DAT, and, along with the increased 
intracellular Na+ concentration promoted by AMPH translocation, it stimulates a DAT-mediated 
DA efflux(Fischer and Cho, 1979). This increases the synaptic DA concentration, which 
activates downstream signaling pathways. 
 
Reverse Transport: Associated Proteins 
The scope of AMPH’s influence on DAT function is not limited to direct interactions with the DAT 
itself. AMPH can influence the local and transient environment surrounding the DAT, which, in 
turn, can influence the properties of the DAT. Ultimately, exposure to AMPH shifts the DAT from 
a “reluctant” state to a “willing” state, an state that favors reverse transport of DA(Khoshbouei et 
al., 2004). These modulations in DAT function are thought to be mediated, at least in part, by 
the activities of DAT-interacting proteins that become catalytically active in response to AMPH 
exposure.  
 
There are numerous putative phosphorylation sites within the intracellular domains of DAT, 
suggesting that the DAT is amenable to regulation by kinases. Indeed, the distal N-terminal region 
of the DAT contains crucial Ser residues that, when phosphorylated, promote reverse transport 
of DA without affecting DAT uptake function(Khoshbouei et al., 2004). When truncated or 
replaced with non-phosphorylatable Ala residues, the AMPH-induced DA efflux is reduced by 
80%(Khoshbouei et al., 2004). Alternatively, when these Ser are replaced with Asp, which mimics 
phosphorylation, the ability of the DAT to efflux DA remains intact, suggesting that phosphorylation 
of one or more of these Ser are critical for AMPH-induced DA release(Khoshbouei et al., 2004). 
Importantly, these N-terminal residues can be phosphorylated by protein kinase C 
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(PKC)(Giambalvo, 1992, Johnson et al., 2005) and Ca2+/calmodulin-dependent protein kinase II 
(CaMKII)(Fog et al., 2006, Bowton et al., 2010).  
 
Both PKC and CaMKII have been revealed to be major regulators of DAT-mediated reverse 
transport. Researchers have discovered that AMPH exposure can induce an increase in PKC 
activity in vivo(Giambalvo, 1992). Inhibition of PKC prevents AMPH-induced DA efflux in rat 
striatal slices(Kantor and Gnegy, 1998, Johnson et al., 2005), and exposure to phorbol esters, 
compounds that promote PKC activity, induces DA efflux in the absence of AMPH(Cowell et al., 
2000). In the rat striatum, a physical interaction was observed between the DAT and one of the 
PKC family isozymes, PKCβII(Johnson et al., 2005), highlighting tight regulation of the DAT by 
PKC. A physical interaction between CaMKII and the DAT C-terminus has been observed, as 
well(Fog et al., 2006). Disruption of this interaction or inhibition of CaMKII reduces reverse 
transport of DA in both in vitro and in vivo preparations(Fog et al., 2006). Interestingly, AMPH 
treatment increases CaMKII activity in striatal synaptosomes, an effect that can be blocked in the 
absence of extracellular Ca2+ or in the presence of nomifensine, a DAT inhibitor(Iwata et al., 1997). 
This suggests that both Ca2+ and DAT activity are required for AMPH to potentiate CaMKII activity. 
Importantly, AMPH has been shown to increase intracellular Ca2+ in DAT expressing cells, a 
process mediated by DAT activity(Gnegy et al., 2004) and dependent on voltage-gated N- and L-
type Ca2+ channel activity(Kantor et al., 2004). Therefore, AMPH may activate CaMKII and other 
second messenger signaling pathways by increasing intracellular Ca2+ concentration. 
 
A potential mediator of CaMKII’s influence on DAT-mediated reverse transport of DA is the 
protein syntaxin 1 (STX1). STX1 is a member of the soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE) complex, which is required for the docking and release of 
synaptic vesicles(Sudhof and Rothman, 2009). Aside from its role in the SNARE complex, there 
is a growing body of evidence to suggest that STX1 associates with and regulates the function 
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of ion channels and SLC6 transporters, including the DAT(Quick, 2006, Ahmed et al., 2007, 
Dipace et al., 2007, Binda et al., 2008). STX1 was revealed to directly interact with the distal 
region of the DAT N-terminus in both a yeast-two hybrid system(Lee et al., 2004) and in a 
glutathione S-transferase (GST) pull-down assay(Binda et al., 2008). These STX1/DAT 
interactions have been observed to mediate a decrease in the Vmax of DA transport in both rat 
striatal tissues and in heterologous expression systems(Cervinski et al., 2010). The STX1/DAT 
interactions are demonstrated to increase in response to AMPH and play an important role in 
the regulation of AMPH-induced DA efflux, as well(Dipace et al., 2007, Binda et al., 2008). 
STX1/DAT interaction promotes the ability of the DAT to efflux DA(Binda et al., 2008). This 
indicates an asymmetric relationship in the ability of STX1 to regulate DAT uptake and efflux, 
where STX1/DAT interactions inhibit DAT uptake function and potentiate DAT efflux function. 
Moreover, the activity of the CaMKII mediates the STX1/DAT association, the interaction can be 
inhibited through the use of CaMKII inhibitors, and CaMKII inhibition reduces AMPH-induced DA 
efflux preferentially in STX1 expressing cells(Dipace et al., 2007, Binda et al., 2008). These data 
reveal the complexity of the events surrounding reverse transport of DA, including activation of 
protein kinases, DAT N-terminal phosphorylation, and subsequent alterations in N-terminal 
interactions. The sequence and the delineation of the molecular regulators of these events have 
yet to be elucidated. 
 
Reverse Transport: DAT Coding Variants 
In the previous examples of DAT-mediated reverse transport of DA, the efflux of DA was 
stimulated pharmacologically (e.g. by AMPH or phorbol esters) and modulated by key 
associated proteins (e.g. STX1). However, in recent years, there has been a proliferation of data 
outlining instances of DAT coding variations, identified in neuropsychiatric disease populations 
that promote alterations in DAT function, including a constitutive release of DA.  
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One well characterized mutation identified in multiple neuropsychiatric disease populations is 
the hDAT A559V, where an inherited missense mutation induces an Ala to Val substitution at 
site 559. Expressing the hDAT A559V in heterologous cells revealed that the DAT variant 
exhibited normal protein and cell surface expression, as well as normal DA uptake, yet an 
anomalous DA efflux (ADE) that occurred under basal conditions(Mazei-Robison et al., 2008). 
The hDAT A559V variant was more sensitive to intracellular Na+ and cell depolarization than 
hDAT, as seen by increased magnitude of DAT-mediated reverse transport under these 
conditions(Mazei-Robison et al., 2008). Interestingly, both AMPH and methylphenidate (MPH), a 
DAT blocker, inhibited the hDAT A559V-mediated ADE(Mazei-Robison et al., 2008). It was 
further revealed that tonic activation of DAT-associated D2 receptors promoted an activation of 
CaMKII and subsequent DAT N-terminal phosphorylation of Ser residues which, in turn, 
supported hDAT A559V-mediated ADE(Bowton et al., 2010). Most recently, it was observed that 
although hDAT A559V has normal transport of the substrate DA(Mazei-Robison and Blakely, 
2005, Mazei-Robison et al., 2008, Bowton et al., 2010), the hDAT A559V has reduced ability to 
transport AMPH, suggesting that conformational dynamics of the transporter are altered in the 
A559V variant(Bowton et al., 2014). The hDAT A559V is resistant to AMPH-induced cell surface 
redistribution(Bowton et al., 2014), a phenomenon commonly observed in the hDAT(Chen et al., 
2010). This is thought to be linked to the chronic phosphorylation of the five most distal N-
terminal Ser residues and stem from constitutively elevated PKCβ activity(Bowton et al., 2014). 
Interestingly, hDAT A559V was identified in multiple separate disease populations including: a 
bipolar individual, two brothers diagnosed with ADHD, and, importantly, in two probands with 
ASD(Grunhage et al., 2000, Mazei-Robison et al., 2005, Bowton et al., 2014). In all subjects 
with known inheritance, hDAT A559V was transmitted from an unaffected mother to a male child 
with a neurodevelopmental disorder, raising the possibility of a sex effect on penetrance. 
Interestingly, these three neuropsychiatric disorders share specific characteristics, particularly the 
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DA-related trait of hyperactivity. Indeed, ADHD is frequently comorbid with pediatric onset bipolar 
disorder(Faraone and Tsuang, 2003), and a co-occurrence of ADHD symptoms is common in 
ASD(Matson et al., 2013). These shared traits between bipolar disorder, ADHD, and ASD 
suggest dysregulation of common pathways across these neurodevelopmental disorders, with 
DAT regulation as a mediator of one such potential pathway.  
 
Separate studies have identified an adult male with both early-onset parkinsonism and ADHD 
who possesses a de novo missense mutation in the hDAT gene, resulting in Asp to Asn 
substitution at site 421(hDAT D421N)(Hansen et al., 2014). The patient suffered from 
progressive dopaminergic neurodegeneration over the span of eight years, according to DAT 
single-photon emission computed tomography scans and a fluoro-deoxy-glucose-PET/MRI 
scan(Hansen et al., 2014). When the hDAT D421N variant was expressed in heterologous cells, 
it displayed increased levels of total and cell surface expression, yet reduced DA uptake 
capacity and a constitutive ADE, similar to that observed in hDAT A559V(Hansen et al., 2014). 
The dramatically altered function was thought to be due to disrupted Na+ binding at Na2, since 
Asp421 participates in the Na+ coordination at that site(Penmatsa et al., 2013, Hansen et al., 
2014). These data reinforce the important role that Na+ binding plays in substrate translocation 
and in normal DAT function. Furthermore, it highlights the role that DAT genetic variation may 
play in neuropsychiatric disorders, and it supports the notion that DA dysfunction, promoted by 
altered DAT function, can contribute to the pathogenesis of brain disorders. 
 
Dopamine and Autism Spectrum Disorder 
ASD is a neurodevelopmental disorder defined by impairments in social interactions, including 
verbal and non-verbal communication, impairments in social reciprocity, as well as restricted 
interests and repetitive behaviors. Individuals with ASD may display a spectrum of these 
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symptoms and may vary in symptom severity, with some individuals demonstrating above 
average intelligence and others with profound intellectual disability. Currently, no biological test 
for ASD exists. Instead, researchers and clinicians depend on highly sensitive and specific 
behavioral tests involving standardized interviews and psychometric and cognitive 
assessments(Lord et al., 1994, Lord et al., 2000, Wall et al., 2012). ASD is considered one of 
the most common neuropsychiatric diseases in the United States, with a current prevalence 
estimated at 1 in 88(Baio, 2012). While no age of onset is required for a diagnosis, the 
symptoms often present early in life, thus the public health impact of ASD is substantial, since 
support and services are often required throughout the individual’s lifetime. Currently, there is 
no curative treatment or broadly effective pharmacotherapy for the treatment of the multifarious 
symptoms of ASD. Therefore, a more complete understanding of the etiology of ASD may 
improve the rational design of pharmacotherapies and reduce the burden of the disorder. 
 
ASD is one of the most heritable brain disorders(Crawley, 2012), and heritable genetic factors 
are established as important components in the etiology of ASD(Devlin and Scherer, 2012). 
Concordance rates for an ASD diagnosis are estimated at 10% for dizygotic twins and 92% for 
monozygotic twins(Bailey et al., 1995, Ronald and Hoekstra, 2011). Rare genetic variation of 
nucleotides in protein-coding DNA, as well as rare genomic copy number variants are 
established as significant risk factors for ASD(Sebat et al., 2007, Pinto et al., 2010, Levy et al., 
2011, Sanders et al., 2011, Devlin and Scherer, 2012, Sanders et al., 2012). Aside from 
heritable factors, mounting evidence suggests that de novo genetic variation (genetic variation 
present in the progeny, but not either parent) contributes to ASD risk(Iossifov et al., 2012, Neale 
et al., 2012, O'Roak et al., 2012, Sanders et al., 2012). Multiple groups have conducted whole-
exome sequencing of ASD families, and, collectively, these studies point to discrete de novo 
coding variation (single nucleotide variation or small insertion/deletion variants) as contributing 
factors to the genetic risk for ASD(Iossifov et al., 2012, Neale et al., 2012, O'Roak et al., 2012, 
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Sanders et al., 2012). By identifying the genetic locus of these de novo mutations and 
delineating the broader pathways that they function within, it may be possible to more clearly 
understand the risk factors that contribute to the deficits observed in ASD.  
 
Genetic factors within the DA system are becoming increasingly important in understanding the 
etiology of ASD. Variations in genes encoding DA receptors(Reiersen and Todorov, 2011, 
Hettinger et al., 2012, Qian et al., 2013), enzymes important for both DA synthesis and 
catabolism(Yoo et al., 2013, Nguyen et al., 2014), and the DAT(Hamilton et al., 2013, Bowton et 
al., 2014) have been associated with ASD. Medications affecting dopaminergic 
neurotransmission are efficacious in the treatment of some symptoms of ASD(Hosenbocus and 
Chahal, 2012, Hsia et al., 2014). In subjects with ASD, DA dysfunction has been demonstrated 
within brain regions involved in reward processing, including the nucleus accumbens(Scott-Van 
Zeeland et al., 2010, Dichter et al., 2012). The function and expression of the DAT has been 
linked to reward processes(Giros et al., 1996, Volkow et al., 1997, Volkow et al., 2001). Genetic 
variation in the gene that encodes the human DAT alters anticipation and reception of rewards, 
as well as the motivational responses to social-emotional cues(Dreher et al., 2009, Enter et al., 
2012, Hoogman et al., 2013). In humans, functional polymorphisms in the DAT have been 
associated with neuropsychiatric disorders, including ASD(Mazei-Robison and Blakely, 2005, 
Mazei-Robison et al., 2005, Bowton et al., 2010). These data underscore the significance of the 
dopaminergic system in the pathogenesis of ASD and point to dysfunction in dopaminergic 
genes, particularly the DAT gene, as potential risk factors for ASD and related neuropsychiatric 
disorders. 
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CHAPTER II 
PHOSPHATIDYLINOSITOL (4,5)-BISPHOSPHATE REGULATES PSYCHOSTIMULANT 
BEHAVIORS THROUGH ITS INTERACTION WITH THE DOPAMINE TRANSPORTER* 
 
Preface 
This chapter explores the role of DAT-PIP2 interactions in the mechanism of AMPH actions. A 
complete presentation of these data can be found in Hamilton and Belovich et al.(Hamilton et 
al., 2014). 
 
Abuse of AMPH represents a major public health concern, placing a burden on both society and 
the individual due to its profound medical and psychological complications. AMPH’s addictive 
properties are mediated through elevation of extracellular DA by inducing DA efflux via the DAT. 
It is now clear that in order to pharmacologically target AMPH actions, it is essential to 
understand how to precisely manipulate DAT to prevent elevation of extracellular DA. The work 
presented within this chapter demonstrates that PIP2 directly binds, through electrostatic 
interactions, to positively charged DAT N-terminal residues. This interaction is required for 
robust AMPH-induced, DA efflux and behaviors. 
  
PIP2 is a minor phospholipid component of cell membranes, where it participates in signaling 
cascades and acts as a substrate for a number of important signaling proteins. Our data 
demonstrate that PIP2 coordinates complex molecular events underlying AMPH actions, and we 
                                                          
* The work presented in this chapter is in press as Hamilton PJ*, Belovich AN*, Khelashvili G, Saunders C, Erreger K, 
Javitch JA, Sitte HH, Weinstein H, Matthies HJG*, Galli A*. (2014). PIP2 regulates psychostimulant behaviors through 
its interaction with a membrane protein. Nature Chemical Biology 10(7):582-9 
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report that obstructing DAT-PIP2 interaction impairs both DA efflux and AMPH behaviors, 
without altering the DAT physiological function of DA uptake. Using computational modeling, we 
provide the first molecular level description of the direct interaction between DAT and PIP2 and 
resolve how the DAT N-terminal conformations dictate different aspects of the transport cycle.  
 
Furthermore, this chapter presents novel findings in the introduction of the first animal model 
describing the behavioral consequences of disrupting PIP2 interactions with a plasma 
membrane protein, here the DAT. In Drosophila melanogaster, we evaluated the behavioral 
significance of our molecular discoveries by exploring their relevance in AMPH-induced 
behaviors. We report that hindering the DAT-PIP2 interaction in the dopaminergic neurons of 
these flies reduces the psychomotor effects of AMPH exposure, without affecting circadian 
locomotor activity. 
 
The study presented within this chapter has broad implications, including: 1) presenting an in 
vivo framework in which to study the behavioral consequences of PIP2-protein interactions; 2) 
defining the DAT N-terminus as a structural domain that dictates specific aspects of DAT 
transport cycle via its interaction with PIP2, a mechanism that may be conserved across the 
neurotransmitter transporter family; 3) outlining DAT-PIP2 interaction as “druggable” target for 
pharmacotherapies treating AMPH abuse and dependence. 
 
Despite the well-documented role of PIP2 as plasma membrane element that directly interacts 
with ion channels and transporters, before this work, there was no evidence that alterations in 
PIP2 interactions play a significant role at the behavioral level. This work demonstrates this 
concept and presents novel molecular-level insights into the mechanisms underpinning the 
psychomotor effects of AMPH. 
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Abstract 
Phosphatidylinositol (4,5)-bisphosphate (PIP2) regulates the function of ion channels and 
transporters. Here, we demonstrate that PIP2 directly binds the human dopamine (DA) 
transporter (hDAT), a key regulator of DA homeostasis and a target of the psychostimulant 
amphetamine (AMPH). This binding occurs through electrostatic interactions with positively 
charged hDAT N-terminal residues and is shown to facilitate AMPH-induced, DAT-mediated DA 
efflux and the psychomotor properties of AMPH. Substitution of these residues with uncharged 
amino acids reduces hDAT-PIP2 interactions and AMPH-induced DA efflux without altering the 
hDAT physiological function of DA uptake. We evaluated the significance of this interaction in 
vivo using locomotion as a behavioral assay in Drosophila melanogaster. Expression of mutated 
hDAT with reduced PIP2 interaction in Drosophila DA neurons impairs AMPH-induced 
locomotion without altering basal locomotion. We present what is to our knowledge the first 
demonstration of how PIP2 interactions with a membrane protein can regulate the behaviors of 
complex organisms. 
 
Introduction 
The functional regulation of plasma membrane proteins by lipid molecules is an integral 
component of cell function and metabolism(McLaughlin and Murray, 2005, Suh and Hille, 2008). 
Phosphatidylinositol (4,5)-bisphosphate (PIP2) is the phospholipid precursor of the second 
messengers inositol trisphosphate (IP3), diacylglycerol (DAG), and phosphatidylinositol (3,4,5)-
trisphosphate (PIP3), and is, itself, capable of acting as a second messenger and cofactor for 
regulating protein function(Czech, 2000, Suh and Hille, 2008, Whorton and MacKinnon, 2011, 
Ben-Aissa et al., 2012, Kadamur and Ross, 2013). Additionally, PIP2 has been shown to 
modulate, through electrostatic interactions, the in vitro function of ion channels and 
transporters, including the serotonin transporter (SERT)(Suh and Hille, 2008, Buchmayer et al., 
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2013). A sizeable research effort has been dedicated to determining the diversity of cellular 
roles for PIP2 and defining the ubiquity of its electrostatic interactions with various plasma 
membrane proteins, but how these interactions might modulate the behaviors of complex 
organisms in vivo has never been studied.  
 
The plasma membrane dopamine (DA) transporter (DAT) is a presynaptic protein that plays a 
pivotal role in regulating DA neurotransmission by mediating the high-affinity reuptake of 
synaptically-released DA. Gene knockout experiments in multiple organisms, including 
Drosophila melanogaster(Hamilton et al., 2013, Pizzo et al., 2013), point to the DAT as the main 
target for the locomotor stimulatory effects of amphetamine (AMPH)(Giros et al., 1996). AMPH’s 
addictive properties are mediated, at least in part, through elevation of extracellular DA by 
inducing DA efflux through the DAT(Sulzer et al., 2005, Robertson et al., 2009). Thus, in order 
to target and limit AMPH actions pharmacologically, it is essential to understand how to 
precisely manipulate the DAT to prevent DA efflux without altering its physiological function of 
DA uptake.  
 
The DAT N-terminus is a structural domain of functional significance. AMPH targets the N-
terminus to cause posttranslational modifications (e.g. phosphorylation(Cervinski et al., 2005)), 
which are essential for AMPH to cause DA efflux(Khoshbouei et al., 2004, Fog et al., 2006) and 
behaviors(Pizzo et al., 2013). Notably, DAT localization to plasma membrane lipid rafts is also 
vital for DA efflux(Cremona et al.) and AMPH-induced behaviors(Pizzo et al., 2013). In this 
study, we elucidate how plasma membrane PIP2, which is enriched in lipid rafts(Hope and Pike, 
1996, Wang and Richards, 2012), dictates specific aspects of the transport cycle through its 
interactions with the N-terminus of the DAT. In terms of AMPH-induced DA efflux, our 
experimental and computational data demonstrate that the regulatory effect of PIP2 stems from 
its electrostatic association with the N-terminus. Here, we introduce the first animal model 
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(Drosophila melanogaster) in which we evaluate the behavioral consequences of altered PIP2 
interactions with a plasma membrane protein. We reveal that DAT-PIP2 interactions are required 
for AMPH-induced behaviors, thereby presenting PIP2 and its synthetic pathway as novel 
regulators of AMPH abuse. 
 
Results 
DAT associates with PIP2    
In this study, we aimed to determine the modalities of the regulatory function of PIP2 in terms of 
DA homeostasis and AMPH actions. We hypothesized that this regulatory function may be 
mediated through a physical association between DAT and PIP2. Using live confocal imaging, 
we show that in hDAT cells, GFP-hDAT (green) co-localized (yellow) with a plasma membrane 
PIP2 sensor (red) (Fig. 6a). As a PIP2 sensor, we used the pleckstrin homology (PH) domain 
from phospholipase Cδ (PHPLCδ-mRFP) that binds specifically to PIP2 at the plasma membrane 
and has been used to monitor pools of PIP2(Varnai and Balla, 1998). In these cells, we further 
probed the association of hDAT with PIP2 by immunoprecipitating (IP) PIP2 with an anti-PIP2 
antibody and immunoblotting the immunoprecipitates for DAT (IB) with an anti-DAT antibody 
(see below). These data strongly suggest that PIP2 associates with hDAT in this cell line. To 
reveal the association between PIP2 and DAT in brain tissue, immunoprecipitations were 
performed from the striatal tissue of wild-type mice (WT; in presence (+) or absence (-) of the 
anti-PIP2 antibody) or DAT knock out (KO) mice(Giros et al., 1996) (Fig. 6b). In contrast to WT 
mice, DAT-PIP2 association was lacking in DAT KO mice. Moreover, in the absence (-) of the 
PIP2 antibody, no immunoreactivity was detected. These data demonstrate that PIP2 associates 
with the DAT both in cell culture and ex vivo.  
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Figure 6. Phosphatidylinositol (4,5)-bisphosphate (PIP2) interacts with hDAT. (a) 
hDAT and PIP2 co-localize at the plasma membrane. In hDAT expressing cells, GFP-
hDAT (green) co-localizes (yellow) at the plasma membrane with the PIP2 sensor 
PHPLCδ-mRFP (red) (representative image from three live experiments with of 10-15 
cells imaged per experiment). (b) PIP2 associates with endogenous mouse DAT in 
striatal tissue. In striatal lysate, DAT was detected in PIP2 immunoprecipitates using 
an anti-DAT antibody (+). DAT immunoreactivity was absent in the beads fraction (-) 
and in PIP2 immunoprecipitates from DAT knock out (KO) animals (endogenous 
mouse IgG is observed) (representative of n = 3).  
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PIP2 is negatively charged at physiological pH(McLaughlin and Murray, 2005). Electrostatic 
interactions between PIP2 and target proteins are thought to lead to changes in protein 
conformation and, subsequently, their activity(Hilgemann and Ball, 1996, McLaughlin et al., 
2002). It is recognized that PIP2 binds positively charged (basic) residues, such as Arg and Lys, 
possibly in proximity to one or more hydrophobic amino acids(Suh and Hille, 2008). Recently, 
residues K352 and K460 of the SERT (a DAT homolog) have been identified in vitro as possible 
sites that mediate SERT-PIP2 association(Buchmayer et al., 2013). In the DAT, the homologous 
amino acids to K352 and K460 are Lys at position 337 (K337) and Arg at position 443 (R443). 
We reasoned that these two DAT residues represent possible PIP2 binding sites of functional 
significance. However, charge-neutralizing substitution of K337 and R443 to Ala (hDAT K337A-
R443A), to prevent the interaction of these residues with PIP2, caused substantial trafficking of 
the DAT away from the plasma membrane, as assessed by cell surface biotinylation. The 
amount of hDAT K337A-R443A at the cell surface was reduced by 82.6 ± 5.2% (p ≤ 0.01 by 
Student’s t-test; n = 7) with respect to hDAT. Therefore, in DAT, in contrast to SERT, these two 
residues support DAT surface expression, preventing us from determining whether their 
possible interaction with PIP2 regulates any mechanistic aspect of the transport cycle. 
 
The N-terminus of the DAT is a structural domain that has been shown to regulate specific 
aspects of DAT transport cycle, without altering DAT surface expression(Khoshbouei et al., 
2004, Fog et al., 2006, Bowton et al., 2010). It also contains several Lys and Arg residues (Fig. 
7). We therefore sought to determine whether the N-terminus of the DAT directly interacts with 
PIP2 in vitro. To this end, we generated a purified recombinant GST-fused N-terminal DAT 
fragment comprising the first 64 N-terminal amino acids of hDAT (GST-64 hDAT)(Binda et al., 
2008). The lipid binding analysis of the GST-fusion proteins was conducted using liposomes 
composed of mixed lipids (phosphatidylcholine, either with or without PIP2) as previously 
described(Varnai et al., 2002). The GST fusion proteins bound to liposomes were pelleted  
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Figure 7. Sequences of the N-terminal regions of various transporters. The N-
terminal regions of the human dopamine transporter (hDAT), serotonin transporter 
(hSERT), norepinephrine transporter (hNET), and vesicular monoamine transporter 
2 (hVMAT2) are shown; positively charged residues are represented in red. 
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(liposome-pull down) and the binding was assessed by immunoblotting (anti-GST antibody). 
Figure 8a (top) shows the pull down of GST fusion proteins (GST and GST-64 hDAT) by 
liposomes containing (+) PIP2, as compared to liposomes lacking (-) PIP2. The presence (+) or 
absence (-) of PIP2 did not alter pull down of GST alone (GST control). As an additional control, 
we “sequestered” PIP2 by preincubating the liposomes with a basic peptide consisting of the 
sequence of the putative PIP2 binding domain of the Kv7.2 channel fused to the fatty acid 
moiety, palmitic acid(Robbins et al., 2006) (pal-HRQKHFEKRR; positively charged at 
physiological pH)(Robbins et al., 2006). This peptide is known to interact electrostatically with 
the polar head groups of PIP2 to hinder its interaction with plasma membrane proteins(Robbins 
et al., 2006). Preincubation of PIP2-containing liposomes with 3 μM of the basic peptide (pal-
HRQKHFEKRR) inhibited pull down of GST-64 hDAT. Figure 8a (bottom) shows quantitation of 
immunoblots obtained from multiple experiments. Comassie stain was utilized to verify equal 
loading. These in vitro data provide the first evidence of a direct interaction between PIP2 and a 
specific region of a neurotransmitter transporter, the DAT N-terminus.  
 
Computational modeling of hDAT interaction with PIP2 
To obtain molecular level structural insights into hDAT N-terminal interactions with PIP2-
containing membranes, we generated a structural context using a previously described 
homology model of the hDAT(Beuming et al., 2008, Kniazeff et al., 2008, Bisgaard et al., 2011). 
To this we have added a recently constructed model of the DAT N-terminus obtained with a 
combination of structure-prediction methods (Rosetta, Modeller) and atomistic molecular 
dynamics (MD) simulations (see Methods). These in silico modeling steps enabled the 
prediction of 3-dimensional folds of the N-terminal loop segment composed of hDAT residues 1-
59, in the context of the complete transmembrane domain. The resulting hDAT model was used 
in mean-field-level calculations (SCMFM; see Methods) to quantify the electrostatic interaction  
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Figure 8. hDAT-PIP2 electrostatic interactions are mediated by the hDAT N-
terminus. (a) hDAT N-terminus binds directly to PIP2. GST-64 hDAT is enriched in 
liposome-pull downs with liposomes containing PIP2 (+) as compared to liposomes 
lacking PIP2 (-) (** = p ≤ 0.01 by one-way ANOVA followed by Bonferroni post-hoc 
test; n = 3; mean ± s.e.m.). Pull down of GST control was not altered by the presence 
(+) of absence (-) of PIP2 in the liposomes (p ≥ 0.05 by one-way ANOVA followed by 
Bonferroni post-hoc test; n = 3; mean ± s.e.m.). Preincubation of liposome containing 
PIP2 with 3 μM of pal-HRQKHFEKRR (+) inhibited the pull down of GST-64 hDAT 
with liposomes containing PIP2 (** = p ≤ 0.01 by one-way ANOVA followed by 
Bonferroni post-hoc test; n = 3). Full blot is in Supplementary Figure 8. (b) 
Electrostatic potential (EP) isosurfaces (+1kT/e (+ charge)) shown as blue wireframes 
and (-1kT/e (- charge)) as red wireframes calculated for the predicted structure of the 
wild type N-terminus. (c) View from the intracellular side of the N-terminus (model) 
adsorbing on the lipid membrane. For clarity, the orientation of the N-terminus in 
panel (c) was obtained by a 180 rotation of the N-terminus configuration shown in 
panel (b). The level of the PIP2 segregation by the N-terminus is expressed as the 
ratio of local and ambient lipid fraction values, and illustrated in color code (cold 
colors represent an enrichment of PIP2). The positive residues in the N-terminus 
(yellow) that attract PIP2 electrostatically are highlighted.  
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of the N-terminus with PIP2-enriched lipid membranes.  
 
The dominant role of the electrostatic component of the interaction energy between the hDAT 
N-terminus and PIP2-containing membranes was substantiated by the shape and the values of 
the electrostatic potential isosurfaces (EPIs) surrounding the molecular model of the hDAT N-
terminal segment shown in figure 8b. The belt-like arrangement of the Lys/Arg residues 
generates a region of strong positive electrostatic potential (in blue) that favors strong 
interaction with the negatively charged PIP2 lipids. Energy-guided docking of this face of the N-
terminus to the membrane model and solving for the steady state distributions of the charged 
lipid species (PIP2) under the influence of the electrostatic forces it generates(Khelashvili et al., 
2008, Khelashvili et al., 2009, Khelashvili et al., 2012) produces a quantitative estimate of the 
electrostatic component of the interaction energy. Thus, the rearrangement of the PIP2 lipids in 
the electrostatic field of the N-terminal segment is predicted to result in a significantly increased 
concentration of PIP2 near the Lys/Arg belt (Fig. 8c, color coding on the membrane shows the 
segregation of PIP2 (blue) to be 2.5 times larger than the PIP2 ambient concentration 
(yellow/green)). Particularly notable is the strength of the PIP2 interaction mediated by DAT 
residues Lys3 and Lys5. Together, these in silico studies suggest that the interactions between 
the hDAT N-terminus and PIP2 lipids are driven by electrostatic forces.  
 
Disrupting DAT-PIP2 interaction inhibits reverse transport 
We hypothesized that the functional consequence of DAT-PIP2 interaction is to support reverse 
transport of DA. Thus, we disrupted DAT-PIP2 associations in hDAT cells while recording 
AMPH-induced DA efflux with amperometry. The amperometric electrode, a carbon fiber 
electrode juxtaposed to the cell membrane, measures DA efflux by oxidation/reduction 
reactions, with DA efflux represented as a positive current. To simultaneously record DA efflux 
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while delivering compounds to the intracellular milieu, we combined amperometry with the 
whole cell patch clamp (APC) technique(Khoshbouei et al., 2004, Hamilton et al., 2013). The 
whole cell patch electrode controls the intracellular ionic composition, which includes 
DA(Khoshbouei et al., 2004) (see Methods).  
 
First, we perfused hDAT cells through the whole cell electrode with DA and the basic peptide 
pal-HRQKHFEKRR (positively charged at physiological pH and tethered to the plasma 
membrane through the fatty acid moiety, palmitic acid(Robbins et al., 2006)) while recording DA 
efflux with the amperometric electrode (Fig. 9a). We used this peptide to compete against the 
DAT N-terminus for PIP2 interactions as determined in Fig. 8a. Pal-HRQKHFEKRR (3 µM, 10 
minutes of intracellular perfusion) was effective in reducing AMPH-induced DA efflux with 
respect to the efflux obtained with the control peptide pal-HAQKHFEAAA, in which four positive 
residues were substituted with Ala (Fig. 9a, top). Quantitation of the peak amperometric 
currents demonstrates that intracellular perfusion of pal-HRQKHFEKRR significantly reduced 
DA efflux (Fig. 9a, bottom). These data underscore the importance of DAT-PIP2 interactions in 
the regulation of DA efflux and point to the type of interactions as electrostatic in nature. We 
next assessed whether DAT-PIP2 association regulates other DAT functions (e.g. DAT-
mediated inward currents). We recorded hDAT-mediated inward currents from hDAT cells 
voltage clamped at -60 mV with a whole-cell electrode containing either pal-HRQKHFEKRR or 
the control peptide pal-HAQKHFEAAA (3 µM, 10 minutes of intracellular perfusion). We 
stimulated the hDAT-mediated currents by perfusion of either 10 µM AMPH or DA, respectively. 
In contrast to DA efflux, pal-HRQKHFEKRR failed to inhibit hDAT-mediated inward currents, 
with respect to the control peptide, either for AMPH (109 ± 4.9% of control; p ≥ 0.8 by Student’s 
t-test; n = 4) or for DA (98 ± 16% of control; p ≥ 0.9 by Student’s t-test; n = 4).  
 
To further investigate the role of DAT-PIP2 interactions in AMPH regulation of DAT function, we  
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Figure 9. Sequestration or depletion of PIP2 inhibits AMPH-induced DA efflux. 
(a) Sequestering PIP2 with pal-HRQKHFEKRR decreases AMPH-induced DA efflux. 
Top: representative traces from stably transfected hDAT cells after patch delivery of 3 
µM control peptide (pal-HAQKHFEAAA) or PIP2 sequestering peptide (pal-
HRQKHFEKRR) to the cytoplasm of the cell. Arrows indicate the application of 10 µM 
AMPH. Bottom: quantitation of amperometric peak currents for the two different 
treatments. Data are expressed as percentage of vehicle control (*** = p ≤ 0.0001 by 
Student’s t-test; n = 7; mean ± s.e.m.). (b) Depleting PIP2 levels reduces AMPH-
induced DA efflux. Top: representative trace of responses to 1 µM AMPH in stably 
transfected hDAT cells, co-expressing the human muscarinic acetylcholine receptor 1 
(hM1R), before and after exposure to 100 µM acetylcholine (ACh). Bottom: 
quantitation of the amperometric peak currents representing AMPH-induced DA efflux 
before and after ACh-dependent PIP2 depletion (* = p ≤ 0.05 by Student’s t-test; n = 
11).  
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transfected hDAT cells with the human muscarinic acetylcholine (ACh) receptor M1 (hM1R), a 
Gαq coupled receptor. Activation of hM1R activates phospholipase C (PLC), stimulating 
hydrolysis of PIP2 and effectively depleting PIP2 stores(Kadamur and Ross, 2013). Live imaging 
was adopted utilizing mRFP tagged PLC-δ1 PH domain (see Fig. 6a) to detect changes of PIP2 
levels at the plasma membrane induced by ACh, a potent hM1R agonist(Balla et al., 2009). In 
hDAT cells, 5 minutes of ACh (100 μM) decreased surface RFP tagged PLC-δ1 PH domain 
levels to 64 ± 9% of vehicle control (p ≤ 0.009 by Student’s t-test comparing ACh to vehicle; n = 
16). In cells loaded with DA (see Methods), we next quantified the magnitude of AMPH-induced 
DA efflux before and after bath perfusion of ACh (5 minutes, 100 µM) (Fig. 9b, top). 
Quantitation of the change in AMPH-induced DA efflux induced by PIP2 depletion within the 
same cell (Fig. 9b, bottom) demonstrates that ACh exposure significantly decreased DA efflux. 
This decrease was not due to a trafficking phenomenon, since exposure of ACh (5 minutes, 100 
µM) in hM1R-expressing hDAT cells did not cause significant trafficking of hDAT away from the 
plasma membrane as compared to vehicle-treated control (Fig. 10). We next determined 
whether providing an excess of intracellular PIP2 reduces the ability of hM1R agonism to 
decrease DA efflux. For this, we adopted the APC technique(Khoshbouei et al., 2004, Hamilton 
et al., 2013). Inclusion of PIP2 (50 μM) in the whole cell patch pipette solution (10 minutes of 
intracellular perfusion) impaired the ability of ACh (5 minutes, 100 µM) to significantly decrease 
AMPH-induced DA efflux with respect to vehicle control (Fig. 11). Collectively, these data 
demonstrate that impairing the electrostatic interaction between PIP2 and DAT selectively 
inhibits the ability of AMPH to cause DA efflux. 
 
N-terminal lysine residues mediate DAT-PIP2 association 
Since our in silico modeling of the hDAT N-terminus indicated residues Lys3 and Lys5 to be 
essential in facilitating the electrostatic interaction of PIP2 with DAT (Fig. 8c), we hypothesized  
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Figure 10. ACh treatment does not affect hDAT surface expression. 
Representative immunoblots for biotinylated (surface) and total hDAT protein 
fractions from stably transfected hDAT cells, co-expressing the human muscarinic 
acetylcholine receptor 1 (hM1R), treated either with vehicle or 100 µM ACh for 5 min. 
Surface fractions were quantitated, normalized to total hDAT, and expressed as a 
percent of vehicle treated hDAT cells (p ≥ 0.7 by Student’s t-test; n = 3 in duplicate; 
mean ± s.e.m.). 
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Figure 11. Excess intracellular PIP2 levels prevent the ability of ACh to decrease 
AMPH-induced DA efflux. Top: representative traces of AMPH responses obtained 
with the APC technique in stably transfected hDAT cells, co-expressing hM1R, 
perfused intracellularly with 50 μM PIP2. Cells were pre-exposed to either 100 µM 
ACh or vehicle for 5 minutes and DA effluxes induced by 10 µM AMPH were recorded 
in the continuous presence of ACh or vehicle. Bottom: quantitation of the 
amperometric peak currents normalized to vehicle control, and expressed as a 
percent of vehicle treated hDAT cells (p ≥ 0.9 by Student’s t-test; n = 4; mean ± 
s.e.m.). 
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that substitution of these residues with uncharged amino acids (e.g. alanine or asparagine) 
would disrupt DAT-PIP2 associations. To probe this inference in silico, Lys3 and Lys5 were both 
substituted computationally with either Ala (hDAT K/A) or with Asn (hDAT K/N), and the 
resulting constructs (N-terminus of hDAT K/A and hDAT K/N) were evaluated for any 
conformational rearrangements due to the mutations. The constructs were used in the same 
computational protocols described for the hDAT model. The results for the mutant constructs 
show significantly reduced electrostatic interactions with PIP2-containing membranes for both 
hDAT K/A (Fig. 12a, compare to Fig. 8c) and hDAT K/N (Fig. 13, compare to Fig. 8c). 
 
The inferences from the computational evaluation of the N-terminus association with PIP2 lipids 
in silico were probed biochemically by determining the effect of charge neutralizing mutations of 
Lys3 and Lys5. In hDAT K/A cells, we immunoprecipitated PIP2 and immunoblotted the 
immunoprecipitates for DAT (IB: anti-DAT). The amount of DAT recovered in the PIP2 
immunoprecipitates was reduced in the hDAT K/A cells compared to the hDAT cells (Fig. 12b, 
top lane). In the absence of antibody against PIP2, no signal was detected for DAT in the 
immunoprecipitates (Fig. 12b, middle lane, IP: beads). The total DAT in the hDAT K/A cells was 
not decreased with respect to hDAT cells (Fig. 12b, bottom lane; Total DAT). These data 
demonstrate that substitution of Lys3 and Lys5 decreases DAT-PIP2 interaction, as predicted 
from the computational modeling. Quantitation of multiple experiments (n = 4) is shown in figure 
12b (bottom). Next, we determined whether substitution N-terminal Lys3 and Lys5 to Ala impairs 
the direct interaction of DAT with PIP2 in vitro. We generated a purified recombinant GST-fused 
N-terminal DAT fragment comprising the first 64 N-terminal amino acids of hDAT with Lys3 and 
Lys5 substituted to Ala (GST-64 hDAT K/A). The lipid binding analysis of the GST-fusion 
proteins (either GST-64 hDAT or GST-64 hDAT K/A) was conducted utilizing liposome-pull 
down as in figure 8. The inset in figure 12b shows the pull down of the GST fusion proteins by 
liposomes containing PIP2. Quantitation of immunoblots obtained from multiple experiments  
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Figure 12. hDAT N-terminal Lys regulate DAT-PIP2 interaction. (a) Mutating hDAT 
N-terminal residues Lys3 and Lys5 to uncharged Ala (hDAT K/A) disrupts PIP2 
segregation to the N-terminus. View from the intracellular side of the N-terminus of 
hDAT K/A adsorbing on the lipid membrane. The level of PIP2 segregation by the N-
terminus residues is expressed as the ratio of local and ambient lipid fraction values 
and illustrated in color code, with cold colors representing an enrichment of PIP2. (b) 
N-terminal Lys residues mediate hDAT-PIP2 interaction. Top: PIP2 
immunoprecipitates from hDAT and hDAT K/A cells were immunoblotted for DAT (top 
lane). The beads fraction supports absence of non-specific binding (middle lane). 
Bottom lane shows total DAT proteins. Full blot is in Supplementary Figure 9. Bottom: 
quantitation of PIP2 pulldown band intensities normalized to the respective total DAT 
and expressed as a percentage hDAT (*** = p ≤ 0.001 by Student’s t-test; n = 4; 
mean ± s.e.m.). Inset: Representative blot for GST-64 hDAT and GST-64 hDAT K/A 
in pull downs with liposomes containing PIP2. 
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Figure 13. Mutation of hDAT N-terminal residues Lys3 and Lys5 to uncharged 
Asn (hDAT K/N) disrupts PIP2 segregation to the N-terminus. View from the 
intracellular side of the N-terminus of hDAT K/N adsorbing on the lipid membrane. 
The level of PIP2 segregation by the N-terminus is expressed as the ratio of local and 
ambient lipid fraction values, and illustrated in color code with cold colors 
representing an enrichment of PIP2. 
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demonstrated that pull down of GST-64 hDAT was significantly inhibited by Lys to Ala 
substitution (GST-64 hDAT K/A was 45 ± 20% of GST-64 hDAT; p ≤ 0.037 by Student’s t-test; n 
= 4). 
 
In order to assess whether DAT physiological function is altered by disrupting DAT-PIP2 
association, we examined radioactive [3H]DA uptake in both hDAT and hDAT K/A cells. In hDAT 
K/A cells, the maximal velocity of DA influx (Vmax) and the apparent DA affinity (Km) were not 
significantly different from those of hDAT (Fig. 14a, top). A representative plot of DA uptake 
kinetics (in triplicate) for hDAT and hDAT K/A is shown in figure 14a (bottom), demonstrating 
that the uptake of substrate is not regulated by the interaction with PIP2. Consistent with the 
uptake data, no significant difference was found in the whole-cell DAT-mediated inward current 
(recorded at -60 mV) between hDAT and hDAT K/A cells upon stimulation with 10 μM DA. The 
hDAT K/A inward currents were expressed as a percent of hDAT-mediated currents (103 ± 20% 
of hDAT; p ≥ 0.97 by Student’s t-test; n = 4). 
 
Our pharmacological manipulations (Fig. 9) indicate that disrupting DAT-PIP2 association has 
no effect on DAT-mediated DA uptake or DA-induced inward currents but inhibits the ability of 
AMPH to cause DA efflux. Consistent with this, hDAT K/A cells were found to display strikingly 
reduced AMPH-induced DA efflux (Fig. 14b, top). Quantitation of the amperometric recordings 
demonstrate that the Lys to Ala substitution not only decreased DAT-PIP2 association (Fig. 12), 
but also decreased the ability of AMPH to cause DA efflux (Fig. 14b, bottom). The reduced 
AMPH-induced DA efflux was not associated with a reduction in either total or DAT surface 
expression as assessed by measuring changes in DAT proteins in the total and biotinylated 
fraction, respectively. Surface fractions were quantitated, normalized to total DAT, and 
expressed as a percent of hDAT (hDAT K/A was 122 ± 31% of hDAT; p ≥ 0.53 by Student’s t-
test; n = 7-8). The findings in the hDAT K/A cells were mirrored by those obtained in the hDAT  
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Figure 14. N-terminal Lys3 and Lys5 regulate specific modalities of hDAT 
function. (a) hDAT K/A exhibits normal DA uptake function. Top: kinetic parameters 
(Vmax and Km) for hDAT and hDAT K/A (Vmax: p ≥ 0.92 by Student’s t-test; n = 3, in 
triplicate; Km: p ≥ 0.62 by Student’s t-test; n = 3, in triplicate; mean ± s.e.m.). Bottom: 
representative plot of [3H]DA uptake kinetics in hDAT (filled squares) and hDAT K/A 
(empty squares) cells (p ≥ 0.05, by two-way ANOVA followed by Bonferroni post-test; 
in triplicate; mean ± s.e.m.). (b) hDAT K/A has reduced AMPH-induced DA efflux. 
Top: representative AMPH-induced amperometric currents recorded from hDAT and 
hDAT K/A cells. Arrows indicate application of 10 μM AMPH. Bottom: quantitation of 
AMPH-induced DA efflux. Data are represented as maximal DA efflux expressed as 
percent of the DA efflux recorded in hDAT controls (* = p ≤ 0.05 by Student’s t-test; n 
= 7-8; mean ± s.e.m.).  
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K/N cells in terms of both DAT-PIP2 association and hDAT cell surface expression (Fig. 15a and 
15b). The hDAT K/N also displayed normal uptake (Fig. 15c) and, like the hDAT K/A, had a 
significant reduction in AMPH-induced DA efflux (Fig. 15d). Furthermore, AMPH uptake assays 
revealed that hDAT, hDAT K/A, and hDAT K/N cells displayed comparable AMPH transport (see 
Methods) (hDAT K/A: 101 ± 4.9% and hDAT K/N: 93.9 ± 17% relative to hDAT; p ≥ 0.88 by one-
way ANOVA; n = 3, in triplicate). These results demonstrate that the reduced ability of AMPH to 
cause DA efflux promoted by the Lys to Ala substitutions does not involve changes in the 
surface expression or changes in ability of the DAT mutants to transport AMPH. Another 
possibility for this decrease in DA efflux is that the N-terminal Lys substitution (hDAT K/A) 
perturbs the potential AMPH-induced phosphorylation of the Ser2 and Ser4 adjacent to these 
Lys residues by altering primary sequence requirements for phosphorylation. To explore this, 
we substituted Ser2 and Ser4 with Asp (to mimic phosphorylation) in the hDAT K/A background 
(hDAT K/A-S/D). Cells expressing hDAT K/A-S/D exhibited significantly reduced AMPH-induced 
DA efflux, similar to hDAT K/A cells (Fig. 16a, top). Quantitation of the amperometric recordings 
demonstrated that Ser to Asp substitution at positions 2 and 4 in the hDAT K/A background did 
not rescue the ability of AMPH to cause DA efflux (Fig. 16a, bottom). The reduced AMPH-
induced DA efflux was not associated with a reduction in DA uptake (Fig. 16b). These data 
demonstrate that the reduction in DA efflux caused by substitution of Lys3 and Lys5 with 
uncharged amino acids cannot be attributed to impaired phosphorylation of adjacent Ser 
residues. 
 
Reduced DAT-PIP2 interaction impairs psychomotor behavior 
Locomotion is an elemental behavior regulated by DA across species, including Drosophila 
melanogaster(Pendleton et al., 2002, Wicker-Thomas and Hamann, 2008, Hamilton et al., 2013, 
Pizzo et al., 2013). Recently, locomotion in flies has been adopted to evaluate molecular  
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Figure 15. hDAT K/A findings mirrored in hDAT K/N. (a) Top: PIP2 
immunoprecipitates from hDAT and hDAT K/N cells were immunoblotted for DAT (top 
lane). The beads fraction supports absence of non-specific binding (middle lane).  
Bottom lane shows total DAT proteins. Bottom: quantitation of PIP2 pull down band 
intensities normalized to the respective total DAT and expressed as a percentage 
hDAT (*** = p ≤ 0.0001 by Student’s t-test; n = 3; mean ± s.e.m.). (b) Representative 
immunoblots for biotinylated (surface) and total protein fractions from hDAT and 
hDAT K/N cells. Immunoblots for surface NaK-ATPase and total ERK are shown as 
well. Surface fractions were quantitated, normalized to total DAT, and expressed as a 
percentage of hDAT (p ≥ 0.41 by Student’s t-test; n = 4-5; mean ± s.e.m.). (c) [3H]DA 
uptake (50 nM) in hDAT and hDAT K/N cells was expressed as a percent of uptake in 
hDAT cells (p ≥ 0.16 by Student’s t-test; n = 3, in quadruplicate; mean ± s.e.m.). (d) 
Representative AMPH-induced amperometric currents recorded from hDAT and 
hDAT K/N cells. Arrows indicate application of 10 μM AMPH. Bottom: quantitation of 
AMPH-induced DA efflux. Data are represented as maximal DA efflux expressed as a 
percent of the DA efflux recorded in hDAT cells (* = p ≤ 0.02 by Student’s t-test; n = 
6-7; mean ± s.e.m.). 
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Figure 16. hDAT K/A-S/D displayes reduced DA efflux and normal DA uptake. 
(a) hDAT K/A-S/D has reduced AMPH-induced DA efflux. Top: representative AMPH-
induced amperometric currents recorded from hDAT and hDAT K/A-S/D cells. Arrows 
indicate application of 10 μM AMPH. Bottom: quantitation of AMPH-induced DA 
efflux. Data are represented as maximal DA efflux expressed as a percent of DA 
efflux recorded in hDAT cells (* = p ≤ 0.03 by Student’s t-test; n = 5-6; mean ± 
s.e.m.). (b) hDAT K/A-S/D exhibits normal [3H]DA uptake (50 nM) function. Data 
expressed as a percent of the uptake measured in hDAT cells (p ≥ 0.2 by Student’s t-
test; n = 4-8; mean ± s.e.m.). 
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discoveries of AMPH actions mechanistically in vivo(Hamilton et al., 2013, Pizzo et al., 2013). 
Thus, Drosophila offer a powerful model for elucidating the impact of altered DAT-PIP2 
interactions on locomotion and on the psychomotor stimulant effects of AMPH. 
 
To generate fly lines expressing either hDAT or hDAT K/A selectively in DA neurons, we used 
the Gal4/UAS system to express a single copy of either hDAT or hDAT K/A in flies with a 
Drosophila DAT (dDAT) null background (dDAT KO; flies are homozygous for the dDAT null 
allele, DATfmn)(Kume et al., 2005). Using phiC31-based integration, we generated transgenic 
flies expressing comparable mRNA levels for hDAT or hDAT K/A. Locomotion of flies was 
quantified by beam crossing detection over a >24 hour period (data binned in 15 minute 
intervals) including both the light (horizontal white bar) and the dark (horizontal black bar) cycle. 
While dDAT KO flies were hyperactive(Kume et al., 2005), dDAT KO flies expressing hDAT in 
DA neurons displayed reduced basal locomotion in comparison to dDAT KO (Fig. 17a, compare 
hDAT to dDAT KO). These data demonstrate the validity of expressing hDAT in Drosophila for 
behavioral studies.  
 
We hypothesized that flies harboring the hDAT K/A would demonstrate comparable locomotion 
with respect to hDAT expressing flies, since no difference in DA uptake was observed. Figure 
17a demonstrates that Drosophila expressing hDAT and hDAT K/A displayed comparable basal 
locomotion, whereas dDAT KO flies exhibited chronically elevated locomotion. Total circadian 
locomotor activities (24 hour) of hDAT and hDAT K/A flies were not significantly different, while 
total locomotor activity of dDAT KO flies was significantly higher than hDAT and hDAT K/A (Fig. 
17b). 
 
Encouraged by the lack of hyperactivity of hDAT K/A flies under basal conditions, we 
hypothesized that these flies would have blunted AMPH-induced locomotive behaviors resulting  
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Figure 17. Expression of hDAT K/A in Drosophila dopaminergic neurons does 
not affect circadian locomotor activity yet impairs AMPH-induced locomotion 
and neuronal DA efflux. hDAT or hDAT K/A was expressed in DA neurons of dDAT 
KO flies. (a) Locomotion was assayed over 32 hours during the light (horizontal white 
bars) or dark (horizontal black bars) cycle. Flies expressing dDAT KO (blue squares) 
were hyperactive with respect to flies expressing wild type hDAT (black squares) and 
flies expressing hDAT K/A (red squares) (beam breaks binned in 15 minute intervals; 
n = 31-42; mean ± s.e.m.). (b) Quantitation of total beam crosses over 24 hours for 
hDAT, hDAT K/A, and dDAT KO flies (*** = p ≤ 0.001 by one-way ANOVA followed by 
Bonferroni post-test; n = 31-42; mean ± s.e.m.). (c) AMPH did not cause a significant 
increase in locomotion in hDAT K/A flies compared to vehicle control (p ≥ 0.05 by 
one-way ANOVA followed by Bonferroni post-test; n = 25-49; mean ± s.e.m.). In 
hDAT flies, AMPH induced a significant increase in locomotion compared to vehicle 
control (*** = p ≤ 0.001 by one-way ANOVA followed by Bonferroni post-test; n= 25-
60; mean ± s.e.m.). (d) hDAT K/A Drosophila DA neurons show reduced AMPH-
induced DA efflux. Dopaminergic neurons were selected by fluorescence microscopy 
since the expression of mCherry was driven by TH-GAL4. Top: representative 
amperometric currents from hDAT and hDAT K/A neurons. Arrows indicate 
application of 1 μM AMPH. Bottom: quantitation of total AMPH-induced DA efflux. 
Data represented as cumulative DA efflux expressed as percent of DA efflux from 
hDAT neurons (** = p ≤ 0.01 by Student’s t-test; n = 4-5; mean ± s.e.m.).  
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from reduced ability of AMPH to stimulate DA efflux. While AMPH caused a significant increase 
in locomotion in flies expressing hDAT, this increase was significantly reduced in flies 
expressing hDAT K/A (Fig. 17c). These data demonstrate, for the first time, the behavioral 
importance of the interaction of PIP2 with a plasma membrane protein. This discovery is further 
enhanced by our ability to associate blunted AMPH-induced behaviors with a decreased ability 
of AMPH to cause DA efflux in isolated DA neurons from flies expressing hDAT K/A. Ex vivo 
cultures of Drosophila DA neurons were investigated with amperometry to quantify the 
magnitude of the AMPH-induced DA efflux in the different fly lines. The DA efflux recorded from 
hDAT K/A expressing neurons was significantly reduced compared to hDAT expressing neurons 
(Fig. 17d), suggesting that the reduced AMPH-induced locomotion in flies expressing hDAT K/A 
is due to diminished DA efflux in response to AMPH.  
 
It is possible that this PIP2 regulation of DA efflux is an evolutionarily conserved mechanism that 
controls DAT function across phylogeny. To test this possibility, we utilized the APC technique 
in CHO cells expressing the dDAT (dDAT cells). In dDAT cells, intracellular perfusion of pal-
HRQKHFEKRR (3 µM, 10 minutes) was effective in reducing AMPH-induced DA efflux with 
respect to the efflux obtained with the control peptide pal-HAQKHFEAAA (34.9 ± 12.9% of 
control peptide; p ≤ 0.01 by Student’s t-test; n = 3). These results parallel those obtained in 
hDAT cells (Fig. 9). In this study, we provide the first behavioral evidence for the relevance of 
the interaction of PIP2 with a plasma membrane protein, associating AMPH behaviors to altered 
neuronal DAT function within the same organism. 
 
Discussion 
We recently demonstrated that disrupting the localization of DAT in lipid rafts impairs the ability 
of AMPH to cause both DA efflux (without altering DA uptake)(Cremona et al., 2011), and 
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associated behaviors(Pizzo et al., 2013). This led us to hypothesize that the molecular 
underpinnings required for AMPH actions reside in lipid rafts. Raft microdomains are considered 
scaffolds for PIP2 signaling, enabling PIP2 to selectively regulate different cellular 
processes(Pendleton et al., 2002, van Rheenen et al., 2005). Yet, partitioning of PIP2 into lipid 
rafts has been criticized as energetically improbable, since PIP2 consists of a polyunsaturated 
acyl side chain (arachidonic acid) that is unlikely to spontaneously partition into cholesterol-rich 
rafts(McLaughlin and Murray, 2005). Therefore, it is theorized that the partitioning of PIP2 into 
rafts is facilitated by interactions with raft-localized proteins(McLaughlin and Murray, 2005). 
Here we demonstrate that PIP2 directly interacts with hDAT, a protein that localizes to the 
rafts(Cremona et al., 2011, Gabriel et al., 2013, Sorkina et al., 2013). 
We found that the DAT N-terminus (a domain of functional importance)(Khoshbouei et al., 2004, 
Fog et al., 2006) is engaged in direct electrostatic interactions with PIP2, described by both 
computational and biochemical analysis. We demonstrate that this interaction is direct and 
distinct from the recently described association of PIP2 with SERT(Buchmayer et al., 2013). This 
DAT-PIP2 interaction, which occurs in brain tissue, involves the two most distal N-terminal Lys 
(Lys3 and Lys5). These data, combined with the regulatory nature of DAT localization to PIP2 
enriched lipid rafts, led us to hypothesize that PIP2 participates in coordinating the complex 
molecular events underlying specific DAT activities. This includes AMPH-induced DA efflux. 
Notably, this interaction does not regulate the physiological function of DAT (DA uptake), DAT 
surface expression, and AMPH uptake. Other functions of the DAT include AMPH- or DA-
stimulated inward currents that represent inward movements of ions associated with the 
transport of substrate. Therefore, we expected that substrate-induced inward currents would not 
be affected by disruption of DAT-PIP2 interaction, in the same way that DA or AMPH uptake is 
not affected. We show that disrupting DAT-PIP2 interaction by substitution of Lys3 and Lys5 with 
Ala did not impair the ability of hDAT to sustain electrical inward currents stimulated by either 
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DA or AMPH. The regulatory nature of the direct DAT-PIP2 interaction on DAT-mediated DA 
efflux is underscored by our results demonstrating that “sequestering” PIP2, with our palmitoyl-
positively charged peptide, or depleting PIP2, by stimulating PLC activity, results in diminished 
reverse transport of DA. Consistent with these findings is the notable result that intracellular 
perfusion of the palmitoyl-positively charged peptide did not impair hDAT-mediated inward 
currents stimulated by either AMPH or DA relative to control peptide. These data underscore the 
interaction between DAT and PIP2 as a key regulator of the specific DAT function of DA efflux.  
 
N-terminal phosphorylation is a requirement for the ability of AMPH to cause a robust DA 
efflux(Khoshbouei et al., 2004). The results of our specific molecular manipulations support the 
notion that Lys to Ala substitution did not impair DA efflux by altering primary sequence 
requirements for phosphorylation of Ser2 and Ser4. Indeed, pseudophosphorylation of these 
Ser residues in the hDAT K/A background failed to rescue DA efflux. Consistent with this notion, 
palmitoyl-positively charged peptide (which does not alter the N-terminus primary sequence) 
disrupts both the direct interaction of the N-terminus with PIP2 as well as DA efflux. However, 
the computational modeling reveals the possibility that the strength of the association of Lys3 
and Lys5 with PIP2 regulates the proper conformation of the DAT N-terminus and affects the 
transporter N-terminus as a whole. Therefore, we cannot exclude the possibility that the 
observed DAT-PIP2 association regulates N-terminal phosphorylation of non-adjacent Ser by 
coordinating suitable conformations. Nevertheless, this possibility does not diminish the 
importance of the discovery that DAT-interaction with PIP2 is a key determinant of AMPH-
induced DA efflux and behaviors. On the contrary, it highlights an opportunity, in future studies, 
to understand whether the DAT N-terminal interaction with PIP2 supports N-terminal 
phosphorylation and/or the importance of phosphorylation for N-terminal conformations and 
DAT-PIP2 association.  
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The Ser-Lys-Ser-Lys N-terminal sequence of the DAT is conserved across several species, 
including Drosophila, suggesting that the DAT-PIP2 association is a possible evolutionarily 
conserved mechanism that regulates specific DAT functions. Our data demonstrate that 
disruption of the dDAT-PIP2 interaction impairs DA efflux, which parallels our results in the 
hDAT. It is tempting to speculate that this mechanism of N-terminal regulation of transporter 
function through electrostatic interactions with PIP2 is a potential mode of regulation for other 
neurotransmitter transporters as well. Examination of sequences of the N-terminal regions of 
four major neurotransmitter transporters (hDAT, hSERT, hNET, and hVMAT2) reveals that the 
positively charged residues are not only abundant in this region, but are also often clustered. In 
the hDAT, we revealed the consequences of this clustering in a structural context, where one of 
these clusters contains Lys3 and Lys5, which enables this region to attract PIP2 lipids. 
Therefore, a mechanism of PIP2 regulation, similar to the one outlined here for DAT function, 
may apply to other neurotransmitter transporters with charged clusters in their N-terminal 
sequences.  
 
Recently we discovered that the AMPH-induced 5-HT efflux mediated by SERT also relies on 
PIP2 interactions with positively-charged residues(Buchmayer et al., 2013). However, these 
residues are not localized to the N-terminus of SERT. These data do not exclude a possible role 
of SERT N-terminus basic residues in SERT-PIP2 interaction and AMPH-induced 5-HT efflux. In 
contrast, in DAT, mutation (to Ala) of the corresponding SERT-PIP2 binding sites causes 
substantial trafficking of DAT away from the plasma membrane, disrupting its membrane 
expression. Thus, this trafficking phenomenon prevents our ability to determine the significance 
of these residues in the mechanistic aspects of the DAT transport cycle. However, it is clear that 
they do not functionally replace Lys3 and Lys5 in terms of DA efflux. 
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Prior to this work, it was unclear whether the association and/or dissociation of plasma 
membrane proteins with PIP2 played a role in the regulation of behaviors of complex organisms. 
Here, we took advantage of an animal model (Drosophila melanogaster) to determine the 
behavioral consequences of disrupting direct interactions of DAT with PIP2. Drosophila 
expressing hDAT K/A solely in DA neurons did not display altered circadian locomotor activity. 
This is not surprising, since the cells expressing hDAT K/A have both normal DA uptake and DA 
affinity. However, hDAT K/A flies exhibit significant reductions in the behavioral psychomotor 
responses to AMPH. These data convey the significance of the interaction between PIP2 and 
plasma membrane proteins (i.e. DAT) in fundamental organismal behaviors, such as 
locomotion. The discovery of this PIP2 regulation of the psychomotor actions of AMPH is further 
enhanced by our ability to record DA efflux (for the first time) directly from DA neurons cultured 
from the same Drosophila lines utilized in our behavioral assays. DA neurons expressing hDAT 
K/A have a significant reduction in DA efflux with respect to neurons expressing hDAT. This 
enhances our molecular discoveries outlining the DAT-PIP2 interaction as required for DA efflux 
and obligatory in the ability of AMPH to cause psychomotor behaviors. These data promote PIP2 
and its synthetic pathway from its canonical role as a modulator of cell function and metabolism 
to a new role as a regulatory agent of both elemental behaviors, such as locomotion, and 
maladaptive behaviors, such as psychostimulant abuse. 
 
Materials and Methods 
Cell culture and transfection. The GFP-hDAT-pCIHygro expression vectors containing hDAT, 
hDAT K/A (Lys3 and Lys5 to Ala), hDAT K/N (Lys3 and Lys5 to Asn), or hDAT K/A-S/D (Lys3 
and Lys5 to Ala and Ser2 and Ser4 to Asp) sequence were generated, confirmed and 
transiently transfected into Chinese hamster ovary (CHO) cells. The Drosophila DAT cDNA was 
generously provided by the laboratory of Dr. Satinder Singh (Yale University). In some 
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experiments (noted in figure legend), stably transfected hDAT CHO cells were used. These cells 
were generated as previously described(Bowton et al., 2010). Cells were maintained in a 5% 
CO2 incubator at 37°C and maintained in Ham’s F-12 medium supplemented with 10% fetal 
bovine serum (FBS), 1 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. 
Stably transfected hDAT CHO cells were kept under selection with 250 µg/mL hygromycin B 
(Corning Cellgro). Fugene-6 (Roche Molecular Biochemicals) in serum-free media was used to 
transfect cells using a 6:1 transfection reagent:DNA ratio. Assays were conducted 24-48 hours 
post transfection.  
Drosophila neuron culture. Drosophila neurons were cultured from 1-3 day old males. Brains 
were dissected in Schneider’s medium with 1.5% bovine serum albumen (BSA) and optic lobes 
were removed. Brains were washed with Schneider’s medium and incubated for 40 minutes in 
collagenase (0.3%) and trypsin (0.125%). They were washed in Schneider’s medium 
supplemented with 10% heat inactivated FBS. Dissociated cells were obtained by brain 
trituration in medium. Cells from each brain were plated on one poly-D-lysine coated MatTek® 
dish treated with collagen (type IV). Assays were performed the next day. 
 
Cell imaging. We used the pleckstrin homology (PH) domain from phospholipase Cδ (PHPLCδ-
mRFP) that binds to PIP2 at the plasma membrane and has been used to monitor pools of PIP2 
at the plasma membrane(Varnai and Balla, 1998). Cells on poly-D-lysine coated MatTek® 
dishes were co-transfected with GFP-DAT and PHPLCδ-mRFP and, after 48 hours, were 
deprived of serum overnight. Single confocal image sections were generated by using a LSM 
510 inverted confocal microscope (Zeiss) by sequential imaging of live cells.  
 
Co-immunoprecipitations. Cells were grown to confluence in 25 cm2 culture flasks and serum 
deprived overnight prior to assay. On the day of the assay, cells were washed three times with 
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4˚C phosphate-buffered saline (Gibco) containing 1 mM EGTA and 1 mM EDTA and lysed in 
RIPA buffer (100 mM NaCl, 1.0% IGEPAL CA-630 (NP-40), 0.5% sodium deoxycholate, 0.1% 
SDS, 50 mM Tris, pH = 8.0, supplemented with a protease inhibitor cocktail (Sigma Aldrich)). 
Lysates were passed twice through a 27.5 gauge needle and centrifuged at 15,000 x g for 30 
minutes. With a portion of the total cell lysate (TCL) collected to run as the totals, 1 mL of the 
remaining supernatant was incubated at 4°C for 4 hours with Sepharose-G beads (Fisher 
Scientific), previously washed with 1% BSA in RIPA buffer and preincubated with 2.5 µg PIP2 
antibody (mouse monoclonal, Enzo Life Sciences). For the negative control, TCL supernatant 
was incubated with BSA-blocked Sepharose-G beads alone. Beads were spun down, washed 
with cold RIPA buffer, and samples eluted with Laemmli sample buffer at 95˚C for 5 minutes. 
TCL and eluates were analyzed by SDS-PAGE and immunoblotting (see below for antibody 
details). Band intensity was quantified using ImageJ software (National Institutes of Health). The 
association between PIP2 and hDAT variants was represented as the ratio of eluate:TCL band 
intensity, normalized to the eluate:TCL ratio observed in hDAT and expressed as a percent. For 
the mouse DAT-PIP2 co-immunoprecipitations from striatum, the same protocol was used with 
the following modifications: striatum was dissected from either wild-type or DAT KO mice, 
solubilized in RIPA buffer (1:10 weight/volume), homogenized, lysed on ice for 30 minutes and 
then centrifuged. The remaining protocol was performed as described above. The mice used for 
these experiments were handled in compliance with IACUC protocols. 
 
Cell surface biotinylation and protein immunoblot. Cells were cultured in 6-well plates. For cell 
surface biotinylation assays, cells were labeled with sulfo-NHS-SS-biotin (1.0 mg/ml; Pierce) 
before purification and analysis via SDS-PAGE/immunoblots(Mazei-Robison et al., 2008). hDAT 
was detected using a rat monoclonal primary antibody to the N-terminus of hDAT (1:1000) 
(Millipore Bioscience Research Reagents) and a goat-anti-rat-HRP-conjugated secondary 
antibody (1:5000; Jackson ImmunoResearch). 
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Gluthathione transferase (GST) fusion proteins. GST and GST fused to the first 64 N-terminal 
amino acids of hDAT were purified as described previously(Binda et al., 2008) with some 
modifications. Briefly, GST and the GST fusion proteins were produced in Escherichia coli BL21 
DE3 LysS. The culture was grown at 30°C, expression induced by the addition of 1 mM 
isopropylβ-d-1-thiogalactopyranoside at 18°C, and the culture was harvested 8 hours after 
induction. The frozen pelleted bacteria was thawed in Tris-buffered saline (TBS) containing 10% 
glycerol and a Bacterial Protease inhibitor cocktail (Roche Diagnostics)(pH 7.4) and treated with 
1 mg/mL lysozyme followed by 15 mM CHAPS. It was then sonicated and cleared by 
centrifugation. The lysate was passed over glutathione Sepharose 4B beads (GE Healthcare) 
and washed several times with TBS, followed by 10 mM Tris containing 10% glycerol and eluted 
with TBS containing 10 mM gluthathione. The quality, size, and amount (relative to BSA) of GST 
fusions were determined by SDS-PAGE and Bio-Safe Coomassie G-250 Stain. The amount 
was determined by analysis of imaged gels using ImageQuantTL. 
 
Liposome binding. GST and GST fusion proteins where incubated with or without liposomes for 
10 minutes at room temperature, centrifuged at 100,000 x g for 20 minutes at 4°C, and analyzed 
by immunoblot analysis using anti-GST antibodies (The Vanderbilt Antibody and Protein 
Resource Core). Liposomes were formed by extrusion of synthetic lipids at a final concentration 
of 1 mM. Liposomes were formed in 10 mM HEPES/TRIS, 100 mM NaCl with 95% 
phosphatidylcholine (DOPC; Echelon) and 5% PIP2 (Phosphatidylinositol 4,5-bisphosphate 
diC16) at a pH of 7.4. 
 
Amperometry and patch clamp electrophysiology. Cells were plated at a density of ~20,000 per 
35-mm culture dish. To preload cells with DA, dishes were washed with KRH assay buffer (130 
mM NaCl, 1.3 mM KCl, 1.2 mM KH2PO4, 10 mM HEPES, and 2.2 mM CaCl2, pH 7.4) containing 
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10 mM dextrose, 100 µM pargyline, 1 mM tropolone, and 100 µM ascorbic acid, and incubated 
with 1 µM DA in KRH assay buffer for 20 minutes at 37°C. To preload Drosophila neurons, 
dishes were washed with KRH assay buffer (as above) containing 100 nM raclopride, and 
incubated with 1 µM DA in KRH assay buffer for 20 minutes at 26°C. All dishes were washed 
three times with the external bath solution (130 mM NaCl, 10 mM HEPES, 34 mM dextrose, 1.5 
mM CaCl2, 0.5 mM MgSO4, 1.3 mM KH2PO4, adjusted pH to 7.35, and 300 mOsm).  
 
To deliver DA (2 mM, Sigma Aldrich), PIP2 inhibitory/control peptides (3 µM pal-HRQKHFEKRR 
or pal-HAQKHFEAAA), and/or PIP2 (50 µM, phosphatidylinositol 4,5-bisphosphate diC8, 
Echelon Biosciences), a programmable puller (model P-2000, Sutter Instruments, Novato CA) 
was used to fabricate quartz recording pipettes with a resistance of 3-5 MΩ. These pipettes 
were filled with an internal solution containing: 120 mM KCl, 10 mM HEPES, 0.1 mM CaCl2, 2 
mM MgCl2, 1.1 mM EGTA, 30 mM dextrose, pH 7.35, and 275 mOsm. Upon gaining access to 
the cells, the internal solution was allowed to diffuse into the cell for 10 minutes.  
 
Experiments involving perfusion of AMPH or DA (Fig. 3b and inward current experiments) 
utilized double-barrel quartz tubing with an inner diameter of 250 µm (Polymicro Technologies, 
Phoneix AZ) placed ~80 µm from the cell. DAT-mediated inward currents were recorded at -60 
mV.  
 
To record DA efflux, a carbon fiber electrode (ProCFE; fiber diameter of 5 µm; obtained from 
Dagan Corporation) juxtaposed to the plasma membrane and held at +700 mV (a potential 
greater than the oxidation potential of DA) was used to measure DA flux through oxidation 
reactions. Amperometric currents in response to the addition of AMPH were recorded using an 
Axopatch 200B amplifier (Molecular Devices, Union City, CA) with a low-pass Bessel filter set at 
1 kHz; traces were digitally filtered offline at 1 Hz using Clampex9 software (Molecular Devices, 
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Union City, CA). DA efflux was quantified as the peak value of the amperometric current for all 
experiments except for recordings from Drosophila neurons. For Drosophila neurons, total DA 
efflux was quantified as the integral of the trace for a fixed 15 minute window. Dopaminergic 
neurons were recognized by fluorescence microscopy since the TH-GAL4 drives the expression 
of mCherry in dopaminergic neurons. 
 
[3H]DA uptake. Cells were plated on poly-D-lysine coated, 24-well plates and grown to ~90% 
confluence. On the day of the experiment, cells were washed once with 37°C KRH buffer 
containing 10 mM dextrose, 100 µM pargyline, 1 mM tropolone, and 100 µM ascorbic acid, and 
equilibrated for 5 minutes at 37°C. Saturation kinetics of DA uptake was determined using a 
mixture of [3H]DA (PerkinElmer Life Sciences, Waltham, MA) and unlabeled DA diluting to final 
DA concentrations of 0.01 µM - 10 µM. Uptake was initiated by bath addition of the dilution row 
mixture. Uptake was terminated after 10 minutes by washing twice in ice-cold KRH buffer. 
Scintillation fluid (Optiphase HiSafe 3, PerkinElmer Life Sciences) was added to the wells and 
the plates were counted in a Wallac Tri-Lux -scintillation counter (Wallac). Nonspecific binding 
was determined in the presence of 10 µM cocaine. Km and Vmax values were derived by fitting 
Michaelis-Menten kinetics to the background corrected uptake data, using GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA). All determinations were performed in triplicates.  
 
Computational Modeling. To evaluate the interactions between PIP2-enriched membranes and 
the N-terminal region of the hDAT (residues 1-59), as well as the hDAT K/A and hDAT K/N 
mutants, molecular models were constructed with the knowledge-based structure-prediction tool 
Rosetta(Das and Baker, 2008). 1,000 different structures obtained from the structure prediction 
protocols in Rosetta were filtered through clustering according to a criterion of maximization of 
common structure conservation implemented in the in-house algorithm RMSDTT, which has 
been introduced into the molecular graphics program, visual molecular dynamics 
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(VMD)(Humphrey et al., 1996). Clusters with the largest numbers of conformations (usually 2−3 
top clusters for each construct) were selected for further refinement with atomistic molecular 
dynamics (MD) simulations, to find the motifs within each cluster that were most frequently 
found in the Rosetta prediction. Predicted structures of the hDAT N-terminus, incorporating 
these most frequent motifs, were then subjected to both unbiased MD and replica exchange 
MD(Earl and Deem, 2005) simulations to assess the stability of the overall fold of the N-
terminus, as well as of the individual structural elements identified with Rosetta.  
 
The top structures that underwent the filtering process, described above, were further examined 
for suitability in the complete model of the hDAT transmembrane bundle (TMB)(Beuming et al., 
2008, Kniazeff et al., 2008, Bisgaard et al., 2011). The structures were embedded into a 
compositionally-asymmetric lipid membrane model (5:45:50 mixture of PIP2/POPE 
(phosphatidylethanolamine) / POPC (phosphatidylcholine) on the intracellular leaflet, and 30:70 
mixture of sphingomyelin / POPC on the extracellular leaflet(Kiessling et al., 2009). Docking of 
the N-terminus (1-59 residues) to the TMB (residues 57-590) was carried out with Modeller(Sali 
and Blundell, 1993). Specific poses for the N-terminal constructs, relative to the TMB, were 
selected based on the criterion of positioning the largest positive electrostatic potential 
isosurfaces (EPIs) towards the membrane surface. As shown before(Khelashvili et al., 2012), 
such configurations not only result in the strongest electrostatic interactions between the protein 
and the PIP2-containing membrane, but also produce the highest levels of concomitant PIP2 
sequestration by the N-terminal peptide. These juxtamembrane poses of the N-terminus served 
as starting configurations for subsequent studies of the dynamics of PIP2 lipids near the hDAT 
N-terminus, as detailed below.  
 
The protocol used to evaluate the interaction of the hDAT N-terminus with PIP2-containing 
membranes is based on the application of the self-consistent mean-field model (SCMFM) that 
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evaluates the steady state distributions of charged lipid species (PIP2, in this case) under the 
influence of electrostatic forces from a membrane-adsorbing macromolecule (here, the hDAT N-
terminus) and quantifies the corresponding adsorption energies. As described in 
detail(Khelashvili et al., 2008, Khelashvili et al., 2009, Khelashvili et al., 2012), the SCMFM is a 
mesoscale approach, based on the non-linear Poisson-Boltzmann (NLPB) theory of 
electrostatics(Sharp and Honig, 1990) and Cahn-Hilliard dynamics, in which the protein is 
considered in 3-dimensional full atomistic detail, and the lipid membrane is considered as a 2-
dimensional, tensionless, incompressible low-dielectric elastic slab in which the equilibrium 
distribution of different lipid species around adsorbing protein is obtained by self-consistent 
minimization. The governing free energy function contains contributions from electrostatic 
interactions, lipid mixing entropy, and mixing entropy of mobile salt ions in the solution. The 
SCMFM calculation of the membrane interaction of the hDAT N-terminus constructs (hDAT and 
the hDAT K/A or hDAT K/N mutants) considered in full atomistic detail (with partial charge and 
atomic radii taken from the all-atom CHARMM27 force field with CMAP corrections for 
proteins(Mackerell et al., 2004), was carried out with the N-terminus positioned 2Å away from 
the lipid surface with average surface charge density of -0.0031e (corresponding to a lipid 
mixture with 5% PIP2). The NLPB equation was then solved numerically as 
described(Khelashvili et al., 2008, Khelashvili et al., 2009, Khelashvili et al., 2012), in a 0.1 M 
ionic solution of monovalent counterions (corresponding to λ=9.65Å Debye length), and using a 
dielectric constant of 2 for membrane interior and protein, and 80 for the solution. 
 
AMPH Uptake. Plated hDAT, hDAT K/N, and hDAT K/A cells, as well as untransfected cells (to 
account for non-specific AMPH uptake) were washed with KRH assay buffer and incubated for 
5 min at 37 °C with 10 nM AMPH. Cells were washed three times with ice-cold KRH and AMPH 
was extracted with acidic organic solvent. AMPH was quantified by reversed-phase HPLC using 
the Waters AccQ·Tag® method which uses pre-column derivatized reagents that help separate 
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and easily detect fluorescence adducts (Waters Corporation, Milford, MA). AMPH uptake (with 
non-specific uptake subtracted) was normalized to hDAT levels and expressed as a percent. 
 
Drosophila Genetics, Molecular Biology, and Construction of UAS hDAT. Flies lacking the 
Drosophila dopamine transporter (DATfmn)(Kume et al., 2005) and flies harboring TH-
Gal4(Friggi-Grelin et al., 2003) were outcrossed to a control line (Bloomington Indiana (BI) 
6326) and selected by PCR or by eye color. TH-GAL4 (Bl 8848) and M{vas-int.Dm}ZH-2A, 
M{3xP3-RFP.attP'} ZH-22A (Bl 24481) were obtained from the BI stock center and outcrossed 
to flies lacking the Drosophila DAT (DATfmn) and carrying the white (w1118) mutation (BI stock 
number 6236) for 5–10 generations. Transgenes (hDAT or hDAT K/A) were cloned into pBI-
UASC(Wang et al., 2012), and constructs were injected into embryos from M{vas-int.Dm}ZH-2A, 
M{3xP3-RFP.attP'}ZH-22A (Bl 24481). Initial potential transformants were isolated by selecting 
for red eyes and lack of GFP signal in the head. Transformants were also verified by RFP 
fluorescence and outcrossed 5-8 times to DATfmn flies. The presence of DATfmn lesion was 
verified by PCR. Flies were maintained on a standard cornmeal/molasses/yeast media at 25°C 
and 65% humidity with a 12 hour/12hour light/dark cycle. Lights came on at 8 AM and off at 8 
PM.  
 
Behavioral Analysis. Three-day-old males were collected and placed into tubes with food for 
three days. After three days locomotion was recorded for 32 hours by beam breaks and 
analyzed using equipment/software from Trikinetics (www.trikinetics.com). For the AMPH-
induced locomotion, males were starved for 6 hours and then fed sucrose (10 mM) containing 
either AMPH (1 mM) or vehicle.  
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Statistical Analysis. Compiled data are expressed as normalized mean values ± standard error. 
For statistical analysis, we used either a Student’s t-test or one-way ANOVA depending on the n 
of the experimental groups. P < 0.05 was considered statistically significant.  
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CHAPTER III 
DE NOVO MUTATION IN THE DOPAMINE TRANSPORTER GENE ASSOCIATES DOPAMINE 
DYSFUNCTION WITH AUTISM SPECTRUM DISORDER† 
 
Preface 
This chapter explores the effect of an ASD-associated de novo variation within the DAT gene on 
DAT protein function. A complete presentation of these data can be found in Hamilton and 
Campbell et al.(Hamilton et al., 2013). 
 
Genetic factors are commonly implicated as important components of ASD. However, despite 
the considerable heritability, few genetic risk factors for ASD pathogenesis have been identified. 
Mounting evidence suggests that de novo genetic variation, affecting hundreds of genes across 
the exome, contributes to the overall genetic risk for ASD. This chapter describes the first ASD-
associated de novo mutation in the hDAT gene (SLC6A3). We show that this de novo mutation 
causes profound functional abnormalities in hDAT function, including an anomalous, persistent, 
and exaggerated reverse transport of DA (ADE). To test our molecular discoveries 
mechanistically in vivo, we developed a behavioral model in Drosophila. Flies expressing the 
hDAT T356M in DA neurons lacking the dDAT display hyperlocomotion as compared to flies 
expressing hDAT. These data strongly support the notion that the abnormal function of this 
                                                          
† The work presented in this chapter is in press as Hamilton PJ*, Campbell NG*, Sharma S, Erreger K, Hansen FH, 
Saunders C, Belovich AN, NIH ARRA Autism Sequencing Consortium, Sahai M, Cook EH, Gether U, Mchaourab HS, 
Matthies HJG*, Sutcliffe JS*, Galli A*. (2013). De novo mutation in the dopamine transporter gene associates 
dopamine dysfunction with autism spectrum disorder. Molecular Psychiatry 18(12): 1315–23. 
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hDAT variant, stemming from this de novo mutation, confers anomalous phenotypic behaviors 
of an intact organism. 
 
In this chapter, a variety of techniques are utilized to define, functionally and structurally, the first 
ASD-associated de novo missense mutation in the hDAT. Our work outlines a potential 
mechanism by which altered DA homeostasis, due to aberrant hDAT function, plays a role in the 
etiology of ASD. Collectively, these studies present the first structural and functional analysis of 
an ASD-identified de novo variant and implicate altered regulation of DA homeostasis as a 
potential liability in ASD risk. 
 
Abstract 
De novo genetic variation is an important class of risk factors for autism spectrum disorder 
(ASD). Recently, whole exome sequencing of ASD families has identified a novel de novo 
missense mutation in the human dopamine (DA) transporter (hDAT) gene, which results in a Thr 
to Met substitution at site 356 (hDAT T356M). The dopamine transporter (DAT) is a presynaptic 
membrane protein that regulates dopaminergic tone in the central nervous system by mediating 
the high-affinity re-uptake of synaptically released DA, making it a crucial regulator of DA 
homeostasis. Here, we report the first functional, structural, and behavioral characterization of 
an ASD-associated de novo mutation in the hDAT. We demonstrate that the hDAT T356M 
displays anomalous function, characterized as a persistent reverse transport of DA (substrate 
efflux). Importantly, in the bacterial homolog leucine transporter, substitution of A289 (the 
homologous site to T356) with a Met promotes an outward-facing conformation upon substrate 
binding. In the substrate-bound state, an outward-facing transporter conformation is a required 
for substrate efflux. In Drosophila melanogaster, expression of hDAT T356M in DA neurons 
lacking Drosophila DAT leads to hyperlocomotion, a trait associated with DA dysfunction and 
 60 
ASD. Taken together, our findings demonstrate that alterations in DA homeostasis, mediated by 
aberrant DAT function, may confer risk for ASD and related neuropsychiatric conditions. 
 
Introduction 
Genetic factors have been implicated as important components in the etiology of autism 
spectrum disorder (ASD). It is now accepted that rare genetic variation affecting single 
nucleotides of protein-coding DNA, as well as rare genomic copy number variants (CNVs), are 
significant ASD risk factors(Sebat et al., 2007, Sanders et al., 2011, Devlin and Scherer, 2012, 
Sanders et al., 2012). In particular, increasing evidence suggests that de novo genetic variation 
is a risk factor in ASD and other neuropsychiatric diseases(Cook and Scherer, 2008, Pinto et 
al., 2010, Levy et al., 2011, Sanders et al., 2011, Devlin and Scherer, 2012). Several groups 
have conducted whole exome sequencing (WES) on ASD families, and collectively, these 
studies indicate that discrete de novo mutation (single nucleotide variation (SNV) or small 
indels) contribute to the overall genetic risk of ASD(Iossifov et al., 2012, Neale et al., 2012, 
O'Roak et al., 2012, Sanders et al., 2012). Among these variations is the first ASD-associated, 
de novo mutation found in the human dopamine (DA) transporter (hDAT) gene (SLC6A3)(Neale 
et al., 2012). This mutation results in a Thr to Met substitution at position 356 (hDAT T356M). 
The consequences of this de novo mutation and its impact on DA neurotransmission have yet to 
be elucidated.  
 
The neurotransmitter DA plays an important role in the central nervous system by regulating a 
variety of functions, including motor activity, motivation, attention, and reward(Carlsson, 1987, 
Giros and Caron, 1993, Bjorklund and Dunnett, 2007, Palmiter, 2008). Disrupted DA function is 
implicated in a number of neuropsychiatric disorders, including bipolar disorder, schizophrenia, 
attention-deficit hyperactivity disorder (ADHD)(Seeman and Niznik, 1990, Volkow et al., 2007, 
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Cousins et al., 2009) and, more recently, ASD(Nieminen-von Wendt et al., 2004, Anderson et 
al., 2008, Nakamura et al., 2010, Tassone et al., 2011). The dopamine transporter (DAT) is a 
presynaptic membrane protein that regulates DA neurotransmission via the high-affinity 
reuptake of synaptically released DA(Kristensen et al., 2011). It is the major molecular target of 
cocaine, amphetamine (AMPH; Adderall™), and methylphenidate (Ritalin™)(Giros et al., 1996, 
Jones et al., 1998, Khoshbouei et al., 2004, Kahlig et al., 2005, Sulzer et al., 2005). Due to 
DAT’s role in DA neurotransmission, SLC6A3 variants have been a focus of genetic association 
studies linking the etiology of brain disorders to dysregulated DA neurotransmission(Kurian et 
al., 2009, Kurian et al., 2011). Recent studies have identified a rare, inherited, functional 
missense SLC6A3 variant, hDAT A559V (rs28364997)(Grunhage et al., 2000, Mazei-Robison et 
al., 2005), that has been associated with ADHD, which is commonly comorbid in ASD 
subjects(Roman et al., 2004, Leyfer et al., 2006, de Bruin et al., 2007, Ronald et al., 2008). 
These studies point to a contribution of DAT genetic variants in complex brain disorders.  
 
While the role of DA in ADHD has been established(Nemoda et al., 2011), DA’s role in ASD is 
poorly understood(Dichter et al., 2012). Many individuals with ASD exhibit co-occurrence of 
ADHD symptoms (~20-45%)(Goldstein and Schwebach, 2004, Sturm et al., 2004, Yoshida and 
Uchiyama, 2004, Gadow et al., 2006). The comorbid nature of ADHD with ASD points to 
dysregulation of common signaling pathways (e.g. DA) as a mechanism underlying these 
neuropsychiatric disorders(Di Martino et al., 2013). 
 
Here, we characterized the first ASD-identified, de novo mutation in hDAT by presenting 
structural, functional, and behavioral analysis of this de novo variant. These results implicate 
altered DA homeostasis as a potential liability in ASD risk. 
 
Results 
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T356M de novo DAT variant has impaired function 
A recent study assessed the role of de novo variation in ASD by using WES in 175 ASD parent-
child trios(Neale et al., 2012). In this study, a de novo SLC6A3 variant was identified, resulting 
in a Thr to Met substitution at site 356(Neale et al., 2012). Given the rarity of non-synonymous 
de novo events, it is not surprising that this mutation was absent in the ~1,000 unrelated ASD 
cases and controls(Neale et al., 2012) and has not been deposited in 1,000 genomes(Genomes 
Project et al., 2012), dbSNP (build 137)(Sherry et al., 2001), or the NHLBI Exome Sequencing 
Project. The subject carried no other coding de novo mutations. The T356 is completely 
conserved across several species (Fig. 18a). Importantly, the T356 residue is located in the 
seventh transmembrane domain of hDAT and resides in a highly conserved region implicated in 
ion binding(Yamashita et al., 2005). The molecular modeling of hDAT and in silico mutagenesis 
of T356 is shown in figure 18b. 
 
The subject harboring this de novo mutation is the elder male child of healthy 
nonconsanguineous Caucasian parents (proband has a healthy younger sibling). There is no 
immediate family history of ASD or related psychiatric conditions. The subject has a normal IQ 
(94) and has no history of seizures or other co-morbidites. By the age of 6 years-old, the 
proband was diagnosed with ASD (see supplemental material for full clinical reports). 
 
To evaluate whether the T356M variant may be a risk factor in the proband’s ASD, we 
compared the activities of hDAT and hDAT T356M in a heterologous expression system. We 
examined radioactive [3H]DA uptake and affinity. In hDAT T356M cells, the maximal velocity of 
DA influx (Vmax) was significantly reduced, whereas the apparent DA affinity (Km) of hDAT 
T356M was not significantly different from that of hDAT (Fig. 19a, top). A representative plot of 
DA uptake kinetics for hDAT and hDAT T356M is shown in figure 19a (bottom). The reduced  
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Figure 18. Cross-species conservation and in silico mutagenesis of T356. (a) 
Alignment of the DAT amino acid sequence across multiple species. Threonine 356 is 
represented in red. (b) In an equilibrated three-dimensional homology model of 
hDAT, the T356M mutation is located on transmembrane domain 7 (TM7). Top: 
Schematic views representing a 180° rotation show T356M with respect to the TM 
helices. TM7 is shown in dark blue. Bottom: Critical residues that interact with DA are 
shown, as well as the bound Na+ and Cl- ions. The methionine is rendered together at 
position 356 with the wild type threonine (green). 
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[3H]DA transport capacity was not associated with a reduction in either total or DAT surface 
expression (Fig. 19b, top), as assessed by measuring changes in DAT proteins in the total and 
biotinylated fraction, respectively. The total fraction for hDAT and hDAT T356M contained both 
glycosylated and non-glycosylated forms of the DAT. Surface fractions were quantitated, 
normalized to total DAT (glycosylated), and expressed as a percent of hDAT (Fig. 19b, bottom). 
Furthermore, normalizing the total DAT fraction (glycosylated) to actin loading control yielded no 
significant differences between hDAT and hDAT T356M total expression (data are expressed as 
a percentage of hDAT; hDAT 100 ± 17.6% versus hDAT T356M 96.4 ± 13.7%; p ≥ 0.87 by 
Student’s t-test; n = 8-11).  
 
hDAT T356M displays ADE 
 Although hDAT T356M displays similar surface expression to that of hDAT, it demonstrates 
reduced ability to accumulate intracellular DA. One possibility is that constitutive DA efflux, here 
referred to as anomalous DA efflux (ADE), contributes to this reduced DA uptake in the hDAT 
T356M cells. This efflux would impede the intracellular accumulation of DA.  
 
To determine whether hDAT T356M exhibits ADE, cells were whole cell patch clamped and 
perfused for 10 minutes with an internal solution containing 2 mM DA(Bowton et al., 2010). The 
electrode, in current clamp configuration, allows the cell to control its membrane voltage. In 
addition, this technique ensures that cells expressing either hDAT or hDAT T356M were equally 
loaded with DA. DA efflux was quantified through amperometry(Bowton et al., 2010). We have 
previously shown that, in the presence of ADE, cocaine decreases the amperometric signal 
through blockade of DAT(Mazei-Robison et al., 2008). In hDAT cells, amperometric currents 
were unaffected by application of cocaine (Fig 20a, top, hDAT, COC), indicating no ADE. In 
contrast, amperometric signals from hDAT T356M cells were significantly reduced by the  
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Figure 19. hDAT T356M has impaired function. (a) Top: Kinetic parameters (Vmax 
and Km) for hDAT and hDAT T356M (Vmax: p ≤ 0.005; by Student’s t-test; n = 3, in 
triplicate; Km: p ≥ 0.20; by Student’s t-test; n = 3, in triplicate). Bottom: Representative 
plot of [3H]DA uptake kinetics in hDAT (filled squares) or hDAT T356M (empty 
squares) cells (** = p ≤ 0.01, *** = p ≤ 0.001; by two-way ANOVA followed by 
Bonferroni post-test; n = 3, in triplicate). (b) Representative immunoblots for 
biotinylated (surface) and total protein fractions from hDAT and hDAT T356M cells. 
Surface fractions were quantitated, normalized to total DAT (Glycosylated), and 
expressed as a percent of hDAT (p ≥ 0.05; by Student’s t-test; n = 8-11). 
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Figure 20. hDAT T356M exhibits robust anomalous DA efflux (ADE). (a) Top: 
representative amperometric currents recorded from hDAT and hDAT T356M cells. 
Arrows indicate application of 10 μM cocaine (COC). Bottom: quantitation of the 
cocaine-induced reduction in the amperometric current (ADE). Data are reported as 
maximal current (*** = p ≤ 0.001 by Student’s t-test; n = 4-5). (b) hDAT T356M cells 
do not display altered resting membrane potential with respect to hDAT cells (p ≥ 0.05 
by Student’s t-test, n = 9-25). (c) Representative AMPH-induced amperometric 
currents recorded from hDAT and hDAT T356M cells. Arrows indicate application of 
10 μM AMPH. Bottom: quantitation of AMPH-induced DA efflux. Data are represented 
as maximal current expressed as percent of the current recorded in hDAT cells (** = p 
≤ 0.01 by Student’s t-test; n = 5-7).  
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application of cocaine (Fig. 20a, top, hDAT T356M, COC), revealing ADE. hDAT T356M-
expressing cells displayed a significant increase in ADE, compared to hDAT transfected cells 
(Fig. 20a, bottom).  
 
 Cell membrane depolarization has been shown to support DA efflux(Khoshbouei et al., 2003). 
Figure 20b reveals that there is not a significant difference in resting membrane potential 
(measured in current clamp) between cells expressing hDAT or hDAT T356M. This indicates 
that differences in the function of hDAT and hDAT T356M are not due to resting membrane 
potential. 
 
Next, we determined possible changes in the ability of AMPH to cause DA efflux by patch 
delivering DA into hDAT or hDAT T356M cells while recording DA efflux with amperometry. 
AMPH dose-response assays (measuring the peak of the amperometric current at different 
AMPH concentrations) revealed that hDAT T356M and hDAT cells have comparable AMPH 
EC50 (EC50; hDAT: 0.15 ± 0.05 µM; hDAT T356M: 0.16 ± 0.07 µM; n = 4; p ≥ 0.95 by Student’s t-
test). Then, using a saturating AMPH concentration (10 µM) we determined DA efflux in either 
hDAT or hDAT T356M cells (Fig. 20c, top). AMPH-induced DA efflux was significantly reduced 
in hDAT T356M cells in comparison to hDAT cells (Fig. 20c). These results strongly suggest 
that ADE does not share common mechanisms with AMPH-induced DA efflux.  
 
In LeuT, substitution of Ala289 with a Met promotes an outward-facing conformation 
To investigate the structural consequences of the T356M de novo mutation in a DAT homolog 
with a known crystal structure, we analyzed changes in the conformational cycle of the leucine 
transporter (LeuT). We substituted A289 (the homologous amino acid to T356) with a Met (LeuT 
A289M). We measured distances between pairs of spin labels (r (Å)) and the distance 
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distribution (P(r), the probability of a given distance between the two labels) monitoring the intra- 
and extracellular gates by double electron electron resonance (DEER)(McHaourab et al., 2011). 
First, we examined the pair 309/480 (Fig. 21a, left) that monitors the relative movement of the 
extracellular loop 4 (EL4) in LeuT. This loop obstructs the permeation pathway in the Apo 
conformation(Claxton et al., 2010), as indicated by the close proximity of the pair 309/480 (Fig. 
21a, middle, Apo black line). Upon Na+ binding, the distance between EL4 and TM12 
increases(Claxton et al., 2010), indicating opening of the extracellular vestibule and enabling 
substrate access (data not shown)(Claxton et al., 2010). Subsequent Leu binding resets the 
closed EL4 conformation in the occluded conformation of the transporter (Na+ and Leu bound in 
the vestibule) (Fig. 21a, right; +Na/L black line). The extracellular Apo state (Fig. 21a, middle; 
Apo; compare red and black lines) as well as Na+ bound state (data not shown) are similar in 
LeuT and LeuT A289M. Yet, LeuT A289M with Na+ and Leu bound in the vestibule has a 
destabilized bound structure with fluctuations on the extracellular side (Fig. 21a, right; +Na/L; 
compare red and black lines). The probability distribution in the Na/Leu bound state contains 
distinct populations of conformations that indicate fluctuations of LeuT A289M to a permeation 
pathway that has increased probability to be open to the outside, relative to LeuT (Fig. 21a, 
right; red line, arrows).  
 
We then examined the pair 7/86 (Fig. 21b, left), to determine the distance between the N-
terminus and intracellular loop 1 (IL1) and to monitor fluctuation dynamics on the intracellular 
side(McHaourab et al., 2011). This is necessary to describe changes in the population of 
transporters with an inward facing conformation(McHaourab et al., 2011). In the LeuT 
background, distance distributions between spin(McHaourab et al., 2012) or fluorescent 
probes(Zhao et al., 2011) in the Apo state are bimodal, reflecting the equilibrium of this 
intracellular gate between closed and open conformations (Fig. 21b, middle; Apo; black lines). 
Introduction of the A289M leads to a shift in the equilibrium to favor the closed conformation  
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Figure 21. In the leucine transporter (LeuT), substitution of Ala289 with a Met 
supports an outward-open facing conformation. Distance distributions of 
extracellular and intracellular spin labeled Cys pairs in LeuT reveal changes in the 
conformational equilibrium caused by mutating Ala289 to a Met. (a) Left: extracellular 
reporter pairs (309-480) tagged on three-dimensional structure of LeuT. Right: 
distance of the extracellular reporter pair for LeuT (black) and A289M (red), in the 
Apo conformation (Apo) and in the presence of Na+ and Leu (+NaL). (b) Left: 
intracellular reporter pairs (7-86) tagged on the three-dimensional structure of LeuT. 
Right: distance of the intracellular reporter pair for LeuT (black) and A289M (red), in 
the Apo conformation (Apo) and in the presence of Na+ and Leu (+NaL). The LeuT 
structure was obtained from PDB 2A65. The structures were generated using 
PyMOL. 
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side (Fig. 21b, middle; Apo; compare red and black lines, arrow). Na+ binding does not alter the 
equilibrium between the two conformations (data not shown), while Na+ and Leu binding resets 
this shift to LeuT-like conformations (Fig. 21b, middle; +Na/L; compare red and black lines).  
 
Our results demonstrate that, because of the A289M, the presence of substrate and Na+ fails to 
completely close the extracellular pathway as in LeuT, inducing fluctuations on the extracellular 
side. These fluctuations to an open-to-the-outside permeation pathway persist, possibly 
enabling substrate release. This is in contrast to LeuT, where substrate binding closes the 
extracellular permeation pathway.  
 
Drosophila expressing hDAT T356M in DA neurons are hyperactive 
 Locomotion is an elemental behavior regulated across species, including Drosophila 
melanogaster, by DA(Pendleton et al., 2002, Wicker-Thomas and Hamann, 2008, Pizzo et al., 
2013). Thus, locomotion in flies offers a powerful model for elucidating the behavioral impact of 
ADE associated with hDAT T356M. 
 
We expressed hDAT or hDAT T356M in flies homozygous for the Drosophila DAT null allele, 
DATfmn (dDAT KO)(Kume et al., 2005), by using the Gal4/UAS system to express a single copy 
of hDAT or hDAT T356M in a dDATfmn mutant background, selectively in DA neurons(Matthies 
and Broadie, 2003). To generate the transgenic flies, we used phiC31 based integration, which 
leads to the expression of comparable levels of mRNA for the relevant transgenes (hDAT or 
hDAT T356M). Locomotion was quantitated by beam crossing detection over a >24 hour period 
(data binned in 15 minute intervals) during both the light (horizontal white bar) and dark 
(horizontal black bar) cycle. While dDAT KO are hyperactive(Kume et al., 2005), flies expressing 
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hDAT in DA neurons have reduced locomotion as compared to dDAT KO, demonstrating the 
behavioral significance of our approach (Fig. 22a, compare hDAT to dDAT KO).  
 
We hypothesized that flies harboring the hDAT T356M would be hyperactive with respect to 
hDAT expressing flies due to an increase in extracellular DA promoted by ADE. This is shown in 
figure 22a. Figure 22b shows total (24 hour) locomotor activity in the different fly lines. Total 
activity (24 hours) of hDAT T356M and dDAT KO flies is significantly higher than hDAT flies 
(Fig. 22b).  
 
hDAT T356M cells display compromised AMPH-induced DA efflux (Fig. 20c). This suggests a 
reduced ability of AMPH to increase locomotion in flies expressing hDAT T356M. Changes in 
locomotion were determined upon AMPH or vehicle exposure (15 minutes) and calculated as 
beam crosses. We observed no significant increase in locomotion in hDAT T356M flies when 
exposed to AMPH as compared to vehicle control (hDAT T356M (vehicle) 9.7 ± 0.7 beam 
breaks versus hDAT T356M (AMPH) 12.7 ± 1.6 beam breaks; n = 24; p ≥ 0.05). This is in 
contrast to flies expressing hDAT, where AMPH induced a significant increase in locomotion 
(hDAT (vehicle) 6.2 ± 0.9 beam breaks versus hDAT (AMPH) 18.2 ± 1.0 beam breaks; n = 24; p 
≤ 0.001). Moreover, in the dDAT KO flies, similar to the hDAT T356M flies, AMPH failed to 
induce a significant increase in locomotion (data not shown). 
 
Discussion 
Alterations in DA tone underlie multiple neuropsychiatric disorders, including bipolar disorder, 
schizophrenia, and ADHD(Seeman and Niznik, 1990, Volkow et al., 2007, Cousins et al., 2009). 
With respect to ADHD, altered DA signaling, including changes in DAT function, may contribute  
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Figure 22. Expression of hDAT T356M in Drosophila leads to hyperactivity. hDAT or 
hDAT T356M was expressed in DA neurons of dDAT KO flies. (a) Locomotor activity was 
assayed over 32 hours during the light (horizontal white bars) or dark (horizontal black 
bars) cycle. Flies expressing hDAT T356M (red squares), as well as dDAT KO flies (blue 
squares), were hyperactive throughout the 32 hour period with respect to flies expressing 
wild type hDAT (black squares) (n = 32; beam breaks binned in 15 minute intervals). (b) 
Quantitation of total beam crosses over 24 hours for hDAT, hDAT T356M, and dDAT KO 
flies (**** = p ≤ 0.0001; n = 32). 
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to the cognitive and hyperactive traits of the disorder(Mazei-Robison et al., 2008, Bowton et al., 
2010). ASD, like ADHD, is phenotypically and etiologically complex. However, there is mounting 
evidence that risk for ASD resides, at least in part, in dopaminergic factors. Variants in DA 
receptor (DRD) sub-type genes, including DRD1, DRD3, and DRD4, have been associated with 
increased risk for ASD(Hettinger et al., 2008) as well as with specific phenotypic behavior within 
ASD. These include repetitive or stereotyped behaviors(de Krom et al., 2009, Gadow et al., 
2010, Staal et al., 2012), oppositional defiant disorder, and separation anxiety disorder(Gadow 
et al., 2010). Male children carrying four tandem repeats in the promoter region of the MAOA 
gene (the gene product responsible for degrading amine neurotransmitters, including DA) 
showed elevated risk for developing ASD(Tassone et al., 2011). It must be noted that none of 
these genes are significant in genome-wide association studies of ASD. However, in positron 
emission tomography (PET) studies in adults with ASD, DAT binding was significantly elevated 
in the orbitofrontal cortex(Nakamura et al., 2010). 
 
Genes harboring de novo events are highly significant for understanding the etiology of 
ASD(Neale et al., 2012). This is not surprising since rate of reproduction is typically low in 
individuals with autism. Consequently, genetic variants would be subject to negative 
selection(Devlin and Scherer, 2012). This suggests that the biological networks identified from 
these de novo events, and the broader pathways they function within, are candidate risk factors 
for ASD. In this study, we examine the functional, structural, and behavioral consequences of 
the first identified de novo hDAT missense variant associated with ASD.  
 
Our amperometric recordings demonstrate that the de novo hDAT T356M mutation confers 
cocaine sensitive ADE. We also show that ADE does not share common mechanisms with 
AMPH-induced DA efflux since hDAT T356M has an impaired AMPH response. It is intriguing to 
speculate that anomalous transporter-mediated neurotransmitter efflux may be an 
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unappreciated source of risk for mental illness, especially in disorders associated with altered 
DA signaling. It is possible that ADE, driven by DAT variants or variants in other genes in the 
DAT regulatory network (such as DRD subtypes), could impact risk for ASD. A similar point for 
ADE has been argued previously, in the context of ADHD, for the hDAT variant A559V, in its 
functional identification(Mazei-Robison et al., 2008) and original characterization(Bowton et al., 
2010). 
 
The question remains as to how the hDAT T356M de novo mutation perturbs transporter 
structure to trigger ADE. Since the crystal structure of hDAT is unavailable, we analyzed 
changes in the conformational cycle of the hDAT bacterial homolog, LeuT. In LeuT A289M, we 
measured the distances between pairs of spin labels monitoring the intra- and extracellular 
gates by DEER. The spin labels monitoring the extracellular gate clearly show that in LeuT 
A289M, in contrast to LeuT, the presence of Na+ and leucine promotes a permeation pathway 
unoccluded to the outside. In terms of transporter function, it is difficult to draw parallels 
between hDAT T356M and LeuT A289M. Nevertheless, it is compelling to speculate that the 
mechanism by which the substrate promotes an outward open conformation in LeuT A289M, 
could also support the ability of hDAT T356M to promote ADE when cytoplasmic DA is 
available. This would suggest that the mechanism of ADE for hDAT T356M is distinct from that 
of hDAT A559V, which is a result of a tonic activation of DRD2 and the downstream kinase 
CaMKII(Bowton et al., 2010). Thus, there may be multiple mechanistic routes to promote hDAT-
mediated ADE, and yet ADE might support the comorbid nature of ASD with ADHD.  
 
In an in vivo context, hDAT T356M may alter extracellular DA levels and, as a consequence, 
increase locomotion(Kume et al., 2005). We selectively expressed hDAT T356M specifically in 
DA neurons of dDAT KO flies. Drosophila expressing hDAT T356M exhibited prominent 
hyperactivity as compared to Drosophila expressing hDAT. In addition, AMPH has an impaired 
 75 
ability to increase locomotion in hDAT T356M and dDAT KO flies. This might stem from the 
decreased ability of AMPH to cause DA efflux in hDAT T356M cells.  
 
Here, we report novel and profound functional abnormalities associated with the hDAT de novo 
mutation T356M, resulting in enhancement of non-vesicular, DAT-dependent DA release, 
referred to as ADE. Our data raise the possibility that ADE could impact the risk for ASD. 
 
Materials and Methods 
Subjects and clinical assessment. Subjects from this family correspond to the proband, 
unaffected sibling, and both parents (AC04-0029-01, AC04-0029-02, AC04-0029-03, AC04-
0029-04), who were recruited by the Boston-based Autism Consortium(Wolfson, 2007). Clinical 
assessment followed standard research criteria for ASD diagnosis. The proband was classified 
as having a comparatively “narrow” diagnosis (as opposed to a “broader ASD”) based on 
diagnostic algorithms from the Autism Diagnostic Interview Revised (ADI-R)(Lord et al., 1994) 
using criteria described by Risi et al.(Risi et al., 2006), and classification resulting from the 
diagnostic algorithm of the Autism Diagnostic Observational Session (ADOS)(Lord et al., 2000). 
Proband IQ was assessed at age 5 years, 9 months using the Wechsler Preschool and Primary 
Scale of Intelligence (WPPSI; Wechsler, D. (1967)). The Social Responsiveness Scale (SRS; 
Western Psychological Services) was performed on both parents to index the presence and 
severity of broader autism phenotype traits, followed by medical and family history provided by 
the biological mother.  
 
SLC6A3 T356M de novo discovery. Methodological details and validation of the de novo 
mutation are published(Neale et al., 2012). Briefly, DNA derived from whole blood of both 
parents and the probands was subjected to whole exome sequence analysis. The T356M 
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variant, identified as a heterozygote in the proband and absent in both parents, was 
experimentally validated and confirmed to be a de novo mutation that does not appear in the 
unaffected sibling.  
 
Cell culture and transfection. The GFP-hDAT-pCIHygro expression vectors containing either 
hDAT or hDAT T356M sequence were generated, confirmed and transiently transfected into 
Chinese hamster ovary cells using FuGENE-6 (Promega). Assays were conducted 24-48 hours 
post transfection. 
 
Amperometry and patch clamp electrophysiology. hDAT and hDAT T356M cells were plated at 
a density of ~30,000 per 35-mm culture dish and experiments conducted as previously 
described(Mazei-Robison et al., 2008, Bowton et al., 2010). 
 
[3H]DA uptake. hDAT and hDAT T356M cells were seeded (50,000 cells/well) into polyornithine 
coated, 24-well plates, 48 hours before assaying. Uptake kinetic assays were performed as 
described in the supplementary information of Rickhag et al.(Rickhag et al., 2013) and in 
Rasmussen et al.(Rasmussen et al., 2009).  
 
AMPH uptake. Plated hDAT and hDAT T356M cells were washed with KRH buffer and 
incubated for 5 min at 37°C with 10 nM AMPH. Cells were washed three times with ice-cold 
KRH. AMPH was quantified using a HPLC system previously described(Siuta et al., 2010). 
 
Cell surface biotinylation and western blot. For cell surface biotinylation assays and Western 
blots, hDAT and hDAT T356M cells were cultured in 6-well plates and experiments conducted 
as in Mazei-Robinson et al.(Mazei-Robison et al., 2008).  
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Homology Modeling of hDAT and construction of the T356M simulation system. As the 
template, the homology model uses the known crystal structure for the cognate and 
homologous structure of the recent outward-open crystal structure of LeuT(Krishnamurthy and 
Gouaux, 2012). The substrate DA, two Na+ ions and a Cl- ion were positioned as described in 
Shan et al.(Shan et al., 2011). To model the mutant hDAT construct with T356M, the mutation 
was introduced using the free energy perturbation (FEP) method(Guptaroy et al., 2009).  
 
Double Electron Electron Resonance. Cysteine residues were introduced using site directed 
mutagenesis into LeuT and LeuT A289M constructs(Claxton et al., 2010). Experiments were 
conducted as in Claxton et al.(Claxton et al., 2010). Apo refers to ion Na+ and leucine-free 
transporter while the +NaL state was obtained by addition of 200 mM NaCl and 4-fold molar 
excess of Leu relative to LeuT. Double Electron Electron Resonance (DEER)(Jeschke and 
Polyhach, 2007) was performed at 83K on a Bruker 580 pulsed EPR spectrometer operating at 
Q-band frequency using a standard 4-pulse sequence(Zou and McHaourab, 2010). DEER echo 
decays were analyzed to obtain distance distributions(Jeschke et al., 2002).  
  
Drosophila Genetics. Drosophila homozygotes for the DAT null allele DATfmn (dDAT KO)(Kume 
et al., 2005) and flies harboring TH-Gal4(Friggi-Grelin et al., 2003) were outcrossed to a control 
line (Bloomington Indiana (BI) 6326) and selected by PCR or eye color. TH-GAL4 (Bl 8848) and 
M{vas-int.Dm}ZH-2A, M{3xP3-RFP.attP'} ZH-22A (Bl 24481) were obtained from the BI stock 
center and outcrossed to dDAT KO flies carrying the white (w1118) mutation (BI stock number 
6236) for 5–10 generations. Transgenes (hDAT or hDAT T356M) were cloned into pBI-
UASC(Wang et al., 2012) and constructs were injected into embryos from M{vas-int.Dm}ZH-2A, 
M{3xP3-RFP.attP'}ZH-22A (Bl 24481). Initial potential transformants were isolated and selected.  
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Behavioral Analysis. Three-day-old males were collected and placed into tubes with food for 72 
hours. Locomotion was recorded by beam breaks and analyzed using equipment/software from 
Trikinetics (www.trikinetics.com). For the AMPH-induced locomotion, males were starved for six 
hours and then fed sucrose (5 mM) containing either AMPH (10 mM) or vehicle. Data were 
analyzed by One-way ANOVA followed by a Newman-Keuls Multiple Comparison Post-test. 
 
Clinical Information 
Proband (male) is the eldest of two children and heterozygous for the mutation described 
herein. 
Patient ID: AC04-0029-01 (proband) 
Event: SLC6A3 de novo missense (T356M) mutation  
At the time of testing, patient was a 66-69-month-old non-Hispanic male Caucasian diagnosed 
with autism (on both ADOS and ADIR). Maternal interview on pregnancy provided the following 
details: Mother experienced anemia during pregnancy (gestational age = 39 weeks). Labor was 
induced (use of Pitocin) because of failure to progress (Note: no C-section was done). Child 
was born 8 lbs 6 oz (134 ounces), with no other delivery issues.  
Subset and composite scores on the Wechsler Preschool and Primary Scale of Intelligence 
(WPPSI) indicate normal intelligence. Full Scale IQ was Average (94), and the subsets of 
Verbal-IQ and Performance-IQ was scored as Average (101) and Low Average (86) 
respectively, indicating normal intelligence.  
ADIR revealed deficits across all four subsets: (1) Reciprocal Social Interaction (score=13; 
cutoff=10); (2) Abnormalities in Communication (score=13; cutoff=8); (3) Restricted, Repetitive 
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and Stereotyped Patterns of Behavior (score=4; cutoff=3); (4) Development Evident at or before 
36 Months (score=1; cutoff=1). 
Patient experienced a delay in speech requiring therapy. No history of seizures, gastrointestinal 
conditions, sleep deficits, and no diet restrictions. Currently taking multivitamins, with no use of 
other medications (besides amoxicillin, Tylenol, and Benadryl).  
No family history for psychiatric illness requiring hospitalization. Known history of Asperger’s 
Disorder (Mother’s cousin’s son), and depression (Father’s paternal uncle). 
Patient ID: AC04-0029-02 (father) 
Father is an adult non-Hispanic Caucasian male. Age at conception of proband is 36. Slightly 
above normative range of intelligence (IQ=118; Wechsler Adult Intelligence Scale). No presence 
of broader autism phenotype, and no psychiatric medication use current or past. No co-morbid 
diagnoses. He holds a postgraduate degree and reports an annual household income of $81-
101k.  
Patient ID: AC04-0029-03 (mother) 
Mother is an adult non-Hispanic Caucasian female. Age at conception of proband is 32. Above 
normative range of intelligence (IQ=131; Wechsler Adult Intelligence Scale); no presence of 
broader autism phenotype, and no psychiatric medication use current or past. No co-morbid 
diagnoses. She holds a postgraduate degree and reports an annual household income of $81-
101k. No medication use reported for mother before, during, or after pregnancy except for 
epidural during labor. 
Patient ID: AC04-0029-04 (sibling) 
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Sibling is a non-Hispanic Caucasian 3 year old (37 months) of unspecified sex. Normative 
intelligence (IQ=118; WPPSI). No behavioral problems reported. No medication use endorsed 
for current or past. No comorbid diagnoses. 
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CHAPTER IV 
ZN2+ REVERSES FUNCTIONAL DEFECITS IN A DE NOVO DOPAMINE TRANSPORTER 
VARIANT ASSOCIATED WITH AUTISM SPECTRUM DISORDER‡ 
 
Preface 
This chapter explores the role of Zn2+ exposure in ameliorating the deficits observed in the 
hDAT T356M. The work presented in this chapter is currently submitted to Molecular Autism.  
 
Chapter III outlined the recently characterized and novel ASD-associated de novo missense 
mutation in SLC6A3 (hDAT T356M). This hDAT variant exhibits significantly decreased DA 
uptake, as well as reduced reverse transport of DA. These dysfunctional transport properties 
are hypothesized to contribute to DA dysfunction in ASD. Previous biophysical studies have 
shown that binding of Zn2+ to an endogenous hDAT binding site can regulate hDAT functions 
and conformations (Fig. 4). 
 
In this chapter, we report that in the hDAT T356M variant, Zn2+ enhances both DA uptake 
(forward transport) and DA efflux (reverse transport). Engaging a Zn2+ activated switch in the 
conformation of the hDAT transporter reverses, at least partially, the functional deficits of ASD-
associated hDAT T356M variant. Our work suggests that the molecular mechanism targeted by 
                                                          
‡ The work presented in this chapter is submitted as Peter J. Hamilton*, Aparna Shekar*, Andrea N. Belovich, Nicole 
Bibus Christianson, Nicholas G. Campbell, James S. Sutcliffe, Aurelio Galli, Heinrich J.G. Matthies*, Kevin Erreger*. 
(2014). Zn2+ reverses functional deficits in a de novo dopamine transporter variant associated with autism 
spectrum disorder. Molecular Autism. 
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Zn2+ to restore partial function in hDAT T356M is a novel therapeutic target to rescue functional 
deficits in hDAT variants associated with ASD. 
 
Abstract 
Alterations in dopamine (DA) homeostasis may represent a complication associated with autism 
spectrum disorder (ASD) and related neuropsychiatric conditions. Rare variants of the human 
dopamine transporter (hDAT) gene (SLC6A3) have been associated with a range of 
neuropsychiatric disorders, including ASD. Our laboratory recently characterized a novel ASD-
associated de novo missense mutation in SLC6A3 (hDAT T356M). This hDAT variant exhibits 
significantly decreased DA uptake, as well as reduced reverse transport of DA. These 
dysfunctional transport properties may contribute to DA dysfunction in ASD. Previous 
biophysical studies have shown that binding of Zn2+ to an endogenous hDAT binding site can 
regulate hDAT functions and conformations. Here we report that in the hDAT T356M variant, 
Zn2+ enhances both DA uptake (forward transport) and DA efflux (reverse transport). Our work 
suggests that the molecular mechanism targeted by Zn2+ to restore partial function in hDAT 
T356M as a novel therapeutic target to rescue functional deficits in hDAT variants associated 
with ASD. 
 
Introduction 
The dopamine (DA) transporter (DAT) tunes DA neurotransmission by active re-uptake of DA 
from the synapse(Kristensen et al., 2011). Rare variants in the human DAT (hDAT) (including 
the first identified de novo mutation in the DAT gene) have been demonstrated to disrupt DA 
neurotransmission, contributing to the etiology of a number of neuropsychiatric disorders, 
including schizophrenia, bipolar disorder, attention deficit hyperactivity disorder 
(ADHD)(Seeman and Niznik, 1990, Volkow et al., 2007, Cousins et al., 2009), and autism 
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spectrum disorder (ASD)(Anderson et al., 2008, Gadow et al., 2008, Hamilton et al., 2013, 
Bowton et al., 2014). Extracellular zinc (Zn2+) inhibits DAT-mediated DA uptake(Norregaard et 
al., 1998). Three amino acid side chains have been identified in DAT which co-ordinate zinc: 
H193 in extracellular loop 2 (EL2), H375 in the first helical part of extracellular loop 4 (EL4A) 
and E396 in the second helix of extracellular loop 4 (EL4B)(Norregaard et al., 1998, Loland et 
al., 1999)(Fig. 4). Structural data from the DAT-homolog LeuT in the inward- and outward-facing 
conformation suggests that the relative orientation of H375 and E396 shifts during the transport 
cycle(Krishnamurthy and Gouaux, 2012). Binding of Zn2+ to the coordinating residues in the DAT 
(H193, H375 and E396) alters the conformational equilibrium between the inward- and outward-
facing state of the DAT(Loland et al., 2002, Stockner et al., 2013). However, mutation of an 
intracellular tyrosine to alanine (Y335A) converts the inhibitory Zn2+ switch into an activating Zn2+ 
switch, whereby Zn2+ rescues functions of the mutant transporter(Loland et al., 2002, Kahlig et 
al., 2006). 
 
Our laboratory has recently characterized the first de novo mutation in the hDAT reported in a 
patient diagnosed with ASD, which results in a Thr to Met substitution at site 356 (hDAT 
T356M). hDAT T356M displays decreased both forward and reverse-transport function 
compared with wild-type hDAT(Hamilton et al., 2013). The reduced transport capacity of the 
mutant was not associated with a reduction in hDAT surface expression. Amphetamine (AMPH) 
is a psychostimulant that targets the hDAT causing reverse transport of DA (DA efflux)(Sulzer et 
al., 2005). hDAT T356M exhibits impaired AMPH-induced DA efflux. Here we show that the 
presence of Zn2+ partially rescues both the DA uptake and the AMPH-induced DA efflux 
impairments of hDAT T356M. Rescue of hDAT function by Zn2+ might reveal new molecular 
mechanism for pharmacological interventions in patients with ASD. 
 
Results 
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Zn2+ enhances [3H]DA uptake in hDAT T356M  
CHO cells were transiently transfected with either wild-type hDAT or hDAT T356M. Cells were 
incubated with 50 nM [3H]DA at 37°C for 5 min in the presence of varying concentrations of 
Zn2+. Consistent with previous reports(Norregaard et al., 1998, Loland et al., 1999), Zn2+ 
decreases the DA uptake rate for wild-type hDAT (Fig. 23a, filled squares). In contrast, for 
hDAT T356M cells, Zn2+ increases DA uptake, partially reversing the functional deficit of this 
variant (Fig. 23a, open circles). 
 
Zn2+ enhances AMPH-induced DA efflux in hDAT T356M  
To specifically measure reverse transport, DA was loaded into the cytoplasm of hDAT T356M 
cells by a whole-cell patch clamp pipette held in current-clamp mode. This configuration 
supplies intracellular DA directly to the cell independent of forward transport by hDAT and 
allows the cell to control its membrane voltage. The whole-cell patch pipette was filled with an 
internal solution containing 2 mM DA as described previously(Hamilton et al., 2013). DA efflux in 
response to 10 µM AMPH was measured by amperometry with a carbon fiber 
electrode(Hamilton et al., 2013). Zn2+ increases AMPH-induced DA efflux in hDAT T356M 
compared to absence of Zn2+ (Fig. 23b), indicating an enhancement of reverse transport DA in 
the presence of Zn2+. Representative amperometric traces are shown in figure 23b (top). The 
peak of DA efflux normalized to vehicle control is shown in figure 23b (bottom). 
 
Discussion 
Here we explore the potential for Zn2+ in rescuing the biophysical abnormalities in the hDAT 
variant T356M that we recently reported in Hamilton et al. 2013(Hamilton et al., 2013). These 
functional deficits in hDAT T356M may contribute to the dysfunction in DA neurotransmission 
associated with ASD. Zn2+ was previously shown to partially restore DA uptake function in DAT  
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Figure 23. Zn2+ partially reverses the hDAT T356M deficits in [3H]DA uptake and 
AMPH-induced efflux. (a) [3H]DA uptake counts (cpm) are plotted for hDAT and 
hDAT T356M over a range of Zn2+ concentrations. While Zn2+ inhibits hDAT [3H]DA 
uptake, Zn2+ instead increases hDAT T356M [3H]DA uptake (* = p < 0.05 by one-way 
ANOVA followed by Dunnett's test compared to 0 Zn2+ control; n = 4). (b) Top: 
representative AMPH-induced amperometric currents (reflecting DA efflux) are 
displayed in the presence or absence of 100 µM Zn2+. Arrows indicate application of 
10 µM AMPH. Bottom: maximal DA efflux amperometric current recorded in the 
presence of Zn2+ normalized to maximal current recorded in the presence of vehicle. 
(* = p < 0.05 by Student’s t-test; n = 5). 
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mutant Y335A, which exhibits low uptake under basal conditions(Kahlig et al., 2006). Here, we 
demonstrate that Zn2+ reverses deficits in both forward and reverse transport in the T356M 
variant. This is a novel and intriguing finding in terms of ameliorating irregularities in DAT 
function in a de novo ASD-associated mutation.  
 
Clinical data has previously established that mean serum Zn2+ levels are significantly lower in 
children diagnosed with ASD compared to unaffected children, and that there exist disturbances 
in Zn2+ metabolism in patients diagnosed with ASD(Jackson and Garrod, 1978, Faber et al., 
2009)(Li et al., 2014). Whether or not Zn2+ regulation of hDAT may be directly relevant for the 
etiology of ASD is presently unknown. However, our work suggests that the molecular 
mechanism engaged by Zn2+ to partially restore function in hDAT T356M may be a novel 
therapeutic target to rescue, at least in part, functional deficits in hDAT variants associated with 
ASD. 
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CHAPTER V 
AUTISM ASSOCIATED VARIANTS REVEAL SYNTAXIN 1 PHOSPHORYLATION AND THE 
DOPAMINE TRANSPORTER AS REGULATORS OF DOPAMINE NEUROTRANSMISSION 
AND BEHAVIORS§ 
 
Preface 
This chapter explores the role of ASD-associated variations in the DAT and DAT-interacting 
proteins and how these variations can affect the DAT function and related behaviors. The work 
presented in this chapter is currently in preparation to be submitted to Lancet Psychiatry. 
 
As introduced in chapter I, STX1 is a protein expressed in the CNS that participates in synaptic 
vesicle fusion. STX1 has been observed to regulate SLC6 transporter function, including the 
DAT. In this chapter, we characterize two separate variations identified in an ASD population. 
One variation is present in the STX1A gene and one variation is in the hDAT gene. The 
functional consequences of these variations converge to disrupt the molecular mechanisms that 
regulate reverse transport of DA, resulting in DA dysfunction and associated behavioral 
abnormalities. We observe that the STX1 variant is hypo-phosphorylated at a key regulatory 
residue, resulting in a reduction in the capacity of the DAT to reverse transport DA. In parallel, 
we observe that the hDAT variant has reduced interactions with STX1, which also results in a 
reduction in the capacity of the DAT to transport DA in reverse. 
                                                          
§ The work presented in this chapter is in preparation to be submitted as Etienne Cartier*, Peter J. Hamilton*, 
Andrea Belovich, Aparna Shekar, Nicholas Campbell, Christine Saunders, Ulrik Gether, Jeremy Veenstra-
Vanderweele, Jim S. Sutcliffe, Paula G. Ulery-Reynolds, Kevin Erreger#, Heinrich J.G. Matthies#, and Aurelio Galli#. 
(2014) Autism associated variants reveal syntaxin 1 phosphorylation and the dopamine transporter as regulators of 
dopamine neurotransmission and behaviors. Lancet Psychiatry  
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This chapter reveals STX1 phosphorylation at Ser14, mediated by the activity of casein kinase 2 
(CK2), as a novel regulator of DAT reverse transport. In Drosophila melanogaster, we evaluated 
the behavioral significance of our molecular discoveries by exploring their relevance in AMPH-
induced behaviors. We report that hindering STX1 phosphorylation at Ser14 or obstructing the 
STX1/DAT interaction in the dopaminergic neurons of these flies reduces the psychomotor 
effects of AMPH exposure. 
 
This study presented within this chapter has broad implications, including: 1) presenting the first 
amperometric recording of DAT-mediated reverse transport of DA at the level of a synaptic 
bouton; 2) defining phosphorylation of STX1 at Ser14 as a posttranslational modification that 
dictates specific aspects of DAT transport cycle via its direct STX1/DAT interactions; 3) further 
implicating alterations in DA neurotransmission, induced by rare variations in DA-related genes, 
in the pathogenesis of ASD. 
 
Abstract 
Syntaxin 1 (STX1) is a plasma membrane protein that coordinates synaptic vesicle fusion. STX1 
also regulates the function of neurotransmitter transporters, including the dopamine (DA) 
transporter (DAT). The DAT is a presynaptic membrane protein that controls DA homeostasis 
through the high-affinity re-uptake of synaptically released DA. Here, we characterize two 
independent autism-associated mutations in the genes that encode STX1 and the DAT. We 
demonstrate that each variant dramatically alters DAT function. We identify molecular 
mechanisms that converge to inhibit reverse transport of DA and DA-associated behaviors. 
These mechanisms include decreased phosphorylation of STX1 at Ser14 mediated by casein 
kinase 2 as well as a reduction in STX1/DAT interaction. These findings implicate alterations in 
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DA homeostasis, promoted by aberrant STX1/DAT interactions and STX1 phosphorylation, in 
the pathogenesis of autism.  
 
Introduction 
Release of neurotransmitter by synaptic vesicle fusion requires the concerted action of the 
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex, which 
includes the plasma membrane protein syntaxin 1 (STX1)(Sudhof and Rothman, 2009). Aside 
from being a member of the SNARE complex, STX1 plays a pivotal role in regulating the 
functions of neurotransmitter:sodium symporters (NSS)(Quick, 2006), including the serotonin 
transporter (SERT)(Quick, 2002, Quick, 2003), the norepinephrine transporter (NET)(Binda et 
al., 2006, Dipace et al., 2007, Sung and Blakely, 2007), the γ-aminobutyric acid transporter 
(GAT)(Wang et al., 2003, Fan et al., 2006), and the dopamine (DA) transporter (DAT)(Lee et al., 
2004, Binda et al., 2008, Cervinski et al., 2010). The DAT regulates DA neurotransmission via 
high-affinity reuptake of synaptically released DA(Kristensen et al., 2011). Therefore, at the 
dopaminergic synapse, the actions of STX1 may converge on DAT to regulate DA clearance 
and, as a consequence, DA neurotransmission and associated behaviors. 
 
Single nucleotide polymorphisms (SNPs) in genes encoding STX1 have been associated with 
high functioning autism (HFA)(Nakamura et al., 2008, Nakamura et al., 2011) and Asperger 
syndrome(Durdiakova et al., 2014). STX1A mRNA expression is reduced in the anterior 
cingulate gyrus in the post-mortem brain tissue of autism spectrum disorder (ASD) 
individuals(Nakamura et al., 2011) and increased in lymphoctyes of people with HFA(Nakamura 
et al., 2008). These data suggest that altered STX1 expression and function may be important 
in the pathogenesis of ASD. Parallel to the involvement of STX1 in ASD, variations in genes 
encoding DA receptors(Reiersen and Todorov, 2011, Hettinger et al., 2012, Qian et al., 2013), 
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enzymes involved both in DA synthesis and catabolism(Yoo et al., 2013, Nguyen et al., 2014), 
and the DAT(Hamilton et al., 2013, Bowton et al., 2014) have been associated with ASD. These 
data point to DA dysfunction as an emerging and under-appreciated risk in ASD. Here, we 
examine the impact of two separate rare, inherited, ASD-identified missense variants. One in 
the gene that encodes STX1 (STX1A; resulting in an Arg to Gln substitution at site 26) and 
another in the gene that encodes DAT (SLC6A3; resulting in an Arg to Trp substitution at site 
51). Both these variations disrupt the molecular mechanisms that regulate reverse transport of 
DA, resulting in DA dysfunction and associated behavioral abnormalities.   
 
ASD is defined by impairments in social communication, including deficits in social interaction, 
nonverbal communication, and establishing relationships, as well as the presence of restricted 
and repetitive behaviors and interests, with repetitive behaviors being among the first signs of 
ASD. Recently, it has been reported that in childhood, the abnormal increase in the growth rate 
of striatal structures in individuals with ASD correlates with the severity of the repetitive 
behaviors(Langen et al., 2014). Consistent with the involvement of striatal dysfunction in ASD, 
there is evidence that individuals with ASD display neural dysfunction in response to 
reward(Damiano et al., 2012, Dichter et al., 2012) that stems from striatal hypofunction(Kohls et 
al., 2013, Kohls et al., 2014) and disproportionate impairment in social reward(Lin et al., 2012). 
The striatum, a brain structure rich in dopaminergic innervation, expresses high levels of DAT. 
Several genes within the DA network are required for the development of the striatum(Novak et 
al., 2013), play a fundamental role in reward, and are suggested as important in the etiology of 
ASD, including the human DAT (hDAT)(Hamilton et al., 2013, Bowton et al., 2014) and 
STX1(Binda et al., 2008).  
 
In this study, we identify novel molecular events involved in the STX1 regulation of DAT. We 
show that ASD-associated variation in both the DAT and STX1 genes impair the molecular 
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events leading to disruption in reverse transport of DA which manifests in specific behavioral 
abnormalities. Our results outline a coordinated molecular network, including STX1 and DAT, in 
which dysfunction induced by SNPs is associated with the pathogenesis of ASD and possibly 
other related neuropsychiatric conditions. Considering that DAT and STX1 directly associate, a 
disruption of the coordinated interaction of DAT and STX1 caused by SNPs could lead to DA 
dysfunction as a complication of ASD. 
 
Results 
Autism-associated hDAT and STX1 variants alter DA transport 
Exome capture and sequencing analysis has identified two families harboring separate rare and 
inherited SNPs. One family was found to be harboring a SNP in the gene that encodes hDAT 
(SLC6A3; resulting in an Arg to Trp substitution at site 51; hDAT R/W) (Fig. 24a, left panel). The 
other family was revealed to be harboring a SNP in the gene that encodes STX1A (STX1A; 
resulting in an Arg to Gln substitution at site 26; STX1 R/Q) (Fig. 24a, right panel). Both of these 
SNPs were identified in ASD samples (n = 1722), absent in a control comparison cohort (n = 
1463), and not deposited in the NHLBI Exome Sequencing Project (URL: 
http://evs.gs.washington.edu/EVS/) [3 (November, 2014) accessed], thus we are classifying 
these variations as ASD-specific. All ASD cases were ascertained using the Autism Diagnostic 
Interview-Revised (ADIR), the Autism Diagnostic Observation Schedule-Generic (ADOS), and 
the DSM-IV diagnosis of pervasive developmental disorder(Neale et al., 2012, Lim et al., 
2013)(Liu et al., 2013). The hDAT Arg51 is located at the N-terminus in a region highly 
conserved across multiple species (Fig. 24b). STX1A Arg26 is located at the N-terminus and is 
also conserved across several species as well other STX1 isoforms, including STX1B (Fig. 
24c). The two redundant neuronal STX1 isoforms (STX1A and STX1B) are 84% identical(Teng 
et al., 2001).  
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b cSLC6A3 STX1A
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Figure 24. Pedigree and cross-species conservation of hDAT R/W and STX1 
R/Q. (a) Variant inheritance is shown for the families harboring the hDAT R/W and the 
STX1 R/Q genotypes. Filled symbols indicate individuals with an ASD diagnosis, 
while open symbols reflect individuals without an ASD diagnosis. (b) Alignment of the 
DAT amino acid sequence across multiple species. Arginine 51 is represented in red. 
(c) Alignment of the STX1 amino acid sequence across isoforms and multiple 
species. Arginine 25 is represented in red. 
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Both isoforms are present in DA neurons and striatal DA terminals(Ruiz-Montasell et al., 1996) 
and colocalize with DAT (Fig. 25). In this study we utilize STX1B, here simply referred as STX1. 
 
To evaluate whether the STX1 R/Q variant is a potential risk factor for DA dysfunction in ASD, 
we determined the impact of this variant on a STX1 regulatory site (Ser14) involved in 
neuropsychiatric disorders(Castillo et al.) and hDAT function. hDAT cells (see Methods) 
expressing STX1 R/Q show reduced STX1 phosphorylation at Ser14, a key STX1 regulatory 
site (Fig. 26a). A documented function of STX1 is to regulate the DAT-mediated reverse 
transport of DA in response to AMPH(Binda et al., 2008). Therefore, we used AMPH as a tool to 
probe whether STX1 R/Q has an altered ability to regulate DA efflux. We probed DA efflux with 
amperometry in hDAT cells expressing STX1 R/Q. The amperometric electrode, a carbon fiber 
electrode juxtaposed to the cell membrane, measures DA efflux by oxidation/reduction 
reactions, with DA efflux represented as a positive current. hDAT cells expressing STX1 R/Q 
display a significantly reduced AMPH-induced DA efflux as compared to hDAT cells expressing 
STX1 (Fig. 26b). It is important to point out that in hDAT cells expressing STX1 R/Q, the Vmax of 
DA uptake was significantly increased, whereas the Km of DA was not significantly different from 
that of hDAT cells expressing STX1 (Fig. 26c, top). A representative plot of DA uptake kinetics 
is shown in figure 26c (bottom). These data indicate that the STX1 R/Q variant asymmetrically 
regulates hDAT function by selectively impairing DA efflux. 
 
In order to determine whether ASD-associated variants in genes involved in DA 
neurotransmission can disrupt DAT function by similar mechanisms, we explored changes in 
hDAT function in cells expressing hDAT R/W. The AMPH-induced reverse transport of DA was 
reduced in hDAT R/W cells with respect to hDAT cells (Fig. 27a). These data parallel the 
reduction in DA efflux observed in hDAT cells expressing the STX1 R/Q variant (Fig. 26b). This 
reduction in AMPH-induced DA efflux in the hDAT R/W is not mirrored by a significant reduction  
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Figure 25. STX1A and STX1B colocalize with the DAT. In mouse striatal slices, 
DAT (green) co-localizes with STX1A, STX1B, and pSTX1 (red). 
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Figure 26. STX1 R to Q missense mutation decreases STX1 phosphorylation 
and reverse   transport of DA without decreasing DA uptake. (a) Top: stably 
transfected hDAT cells expressing either STX1 or STX1 R/Q were immunoblotted 
with a phospho-specific antibody directed against STX1 at Ser14 (top lane).  The 
mock transfection of GFP alone (mock) supports absence of non-specific binding.  
Bottom lane shows total STX1 proteins. Bottom: quantitation of band intensities of 
phospho-STX1 (p-STX1) normalized to the respective total STX1 and expressed 
as a percentage STX1 (** = p < 0.01 by Student’s t-test; n = 5, in triplicate). (b) 
Top: representative AMPH-induced DA efflux recorded from stably transfected 
hDAT cells expressing either STX1 or STX1 R/Q. Arrows indicate application of 10 
μM AMPH. Bottom: quantitation of AMPH-induced DA efflux. Data are represented 
as maximal current expressed as percent of the current recorded in hDAT cells 
expressing STX1 (* = p < 0.05 by Student’s t-test; n = 7). (c) STX1 R/Q promotes 
DAT-mediated DA uptake. Top: kinetic parameters (Vmax and Km) for stably 
transfected hDAT cells expressing either STX1 or STX1 R/Q (Vmax: p < 0.05 by 
Student’s t-test; n = 3, in triplicate; Km: p > 0.46 by Student’s t-test; n = 3, in 
triplicate). Bottom: representative plot of [3H]DA uptake kinetics in stably 
transfected hDAT cells expressing STX1 (filled squares) and STX1 R/Q (empty 
squares) cells (*** = p < 0.001, by two-way ANOVA followed by Bonferroni post-
test; in triplicate). 
 96 
 
0 .0 2 .5 5 .0 7 .5 1 0 .0
0 .0
0 .5
1 .0
hDAT hDAT R/W
Vmax 
(pmol/min/105 cells)
1.00 ± 0.03 1.03 ± 0.03
Km (µM) 0.74 ± 0.07 0.70 ± 0.08
[DA] (μM)
D
A
 U
p
ta
k
e
(p
m
o
l/
m
in
/1
0
5
 c
e
ll
s
)
b
0
50
100
 
IB
 /
 S
T
X
1
 /
 h
D
A
T
 
(%
 o
f 
h
D
A
T
)
*
c
IB:
STX1
beads
total
STX1
total
hDAT
0
50
100
 
A
M
P
H
-i
n
d
c
e
d
 D
A
 e
ff
lu
x
(%
 o
f 
h
D
A
T
)
*
a
0
.2
 p
A
5 min
 
Figure 27. hDAT R to W missense mutation has decreased STX1 association, 
reduced reverse transport of DA, but normal DA uptake. (a) Top: representative 
AMPH-induced DA efflux recorded from hDAT or hDAT R/W cells expressing STX1. 
Arrows indicate application of 10 μM AMPH. Bottom: quantitation of AMPH-induced 
DA efflux. Data are represented as maximal current expressed as percent of the 
current recorded in hDAT cells (* = p < 0.05 by Student’s t-test; n = 5). (b) hDAT R/W 
exhibits normal DA uptake function. Top: kinetic parameters (Vmax and Km) for hDAT 
and hDAT R/W (Vmax: p > 0.92 by Student’s t-test; n = 3, in triplicate; Km: p > 0.62 by 
Student’s t-test; n = 3, in triplicate). Bottom: representative plot of [3H]DA uptake 
kinetics in hDAT (filled squares) and hDAT R/W (empty squares) cells (p > 0.05, by 
two-way ANOVA followed by Bonferroni post-test; in triplicate). The difference in Vmax 
between figure 2C is primarily due to a difference in the expression of hDAT in the 
cell lines. (c) Top: hDAT immunoprecipitates from either hDAT or hDAT R/W cells 
expressing STX1 were immunoblotted for STX1 (top lane).  The beads fraction 
supports the absence of non-specific binding.  Third lane shows an immunoblot for 
total STX1 proteins. Bottom lane shows an immunoblot for total hDAT proteins. 
Bottom: quantitation of hDAT pulldown band intensities normalized to the respective 
total STX1 and total hDAT; expressed as a percentage hDAT cells (* = p < 0.05 by 
Student’s t-test; n = 5).  
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in DA uptake or DA apparent affinity (Fig. 27b), indicating the hDAT R/W variant also 
asymmetrically regulates hDAT function by selectively impairing DA efflux.  
 
Previously, we determined that reverse transport of DA induced by AMPH is tightly regulated by 
the interaction of STX1 at the DAT N-terminus(Binda et al., 2008). Therefore, we explored 
whether the reduced reverse transport of DA in hDAT R/W cells stemmed from a decreased 
association of STX1 to hDAT R/W. We immunoprecipitated hDAT and immunoblotted the 
immunoprecipitates for STX1 (Fig. 27c). The amount of STX1 recovered in the DAT 
immunoprecipitates was reduced in the hDAT R/W cells compared to the hDAT cells (Fig. 27c, 
IB: STX1). In the absence of antibody against DAT, no signal was detected for STX1 in the 
immunoprecipitates (Fig. 27c, beads). The total STX1 and hDAT in the hDAT R/W cells was not 
decreased with respect to hDAT cells (Fig. 27c, total STX1 and total hDAT). These data 
demonstrate that the hDAT R/W variant has a reduced STX1/DAT interaction. Quantitation of 
multiple experiments is shown in the bar graph of figure 27c. These data highlight that the ASD-
associated hDAT and STX1 variants both impair reverse transport of DA without inhibiting DAT-
mediated DA uptake functions. Yet, it is unknown whether these variants converge on a 
common molecular mechanism to impair reverse transport of DA.  
 
STX1 phosphorylation regulates STX1/DAT interaction 
STX1 is phosphorylated at Ser14 by the kinase CK2(Hirling and Scheller, 1996, Foletti et al., 
2000), a posttranslational modification involved in the functional regulation of STX1(Rickman 
and Duncan, Dubois et al., 2002, Khelashvili et al., 2012). Figure 26a shows that the STX1 R/Q 
variant promotes a reduction in STX1 phosphorylation at Ser14. Therefore, we sought to 
determine the functional consequences of impaired Ser14 phosphorylation. First, we 
demonstrated that the highly selective ATP/GTP-competitive inhibitor of CK2, 4,5,6,7-
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tetrabromobenzotriazole (TBB, 10 µM), effectively reduces p-STX1 in hDAT cells. p-STX1 levels 
were determined either under TBB treatment or control conditions with a phospho-specific 
antibody that recognizes phosphorylation of Ser14(Castillo et al.) (Fig. 28a). TBB significantly 
decreases basal levels of p-STX1, demonstrating that CK2 regulates the phosphorylation state 
of STX1 at Ser14. 
 
Next, we investigated whether STX1 phosphorylation at Ser14 regulates the association of 
STX1 with the DAT. hDAT cells were treated with either TBB (10 µM for 20 minutes) or vehicle 
control, and the cell lysates were immunoprecipitated for DAT and subsequently immunoblotted 
for STX1. Inhibition of STX1 phosphorylation with TBB reduces STX1/DAT association (Fig. 
28b), demonstrating that phosphorylation promotes the STX1/DAT interaction. TBB (10 µM for 
20 minutes) did not change the level of DAT available at the cell surface (hDAT surface 
expression for TBB exposure was 89.0 ± 12.9 % of vehicle control; p > 0.40 by Student’s t-test; 
n = 4), indicating that the reduced STX1/DAT interaction following CK2 inhibition is not due to 
DAT trafficking away from the plasma membrane. Collectively, these results are consistent with 
a coordinated signaling complex whereby phosphorylation of STX1 at Ser14 promotes its 
association to DAT.  
 
STX1 can be phosphorylated at residues other than Ser14. For example, casein kinase 1 can 
promote STX1 phosphorylation at Thr21(Dubois et al., 2002). Therefore, we validated whether 
the level of phosphorylation of Ser14 alone supports STX1/DAT interactions. We generated 
STX1 constructs that either prevent Ser14 phosphorylation, by mutating Ser14 to Ala (STX1 
S14A), or mimic Ser14 phosphorylation, by mutating Ser14 to Asp (STX1 S14D). We performed 
immunoprecipitation experiments in hDAT cells transfected with the different STX1 constructs. 
We observed that the STX1/DAT association is blunted in hDAT cells expressing STX1 S14A as 
compared to hDAT cells expressing STX1 (Fig. 28c). Furthermore, the pseudo-phosphorylated  
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Figure 28. CK2-mediated phosphorylation of STX1 at S14 promotes STX1/DAT 
interaction. (a) Stably transfected hDAT cells transfected with STX1 were treated 
with either vehicle or 10 µM TBB for 20 minutes. STX1 proteins were immunoblotted 
for p-STX1 (with a phospho-specific antibody directed against Ser14) and STX1. p-
STX1 band densities were normalized to the corresponding total STX1 band densities 
and expressed as a percentage of vehicle control. CK2 inhibition with TBB 
significantly decreased the levels of p-STX1 (* = p < 0.05 by Student’s t-test; n = 4). 
(b) Stably transfected hDAT cells transfected with STX1 were treated with either 
vehicle or 10 µM TBB for 20 minutes. hDAT proteins were immunoprecipitated and 
immunoblotted for STX1 and DAT. STX1 band densities were normalized to DAT and 
expressed as a percentage of vehicle control. CK2 inhibition significantly decreased 
STX1/DAT interaction (* = p < 0.05 by Student’s t-test; n = 4). (c) Stably transfected 
hDAT cells were transfected with either STX1, STX1 S14A, or STX1 S14D. hDAT 
immunoprecipitates were immunoblotted for either STX1 (top band) or hDAT (middle 
band). Input (bottom band) serves as loading control. All STX1 isoform band densities 
were normalized to hDAT and expressed as a percentage of STX1. STX1 S14A 
displays a significantly decreased association with DAT (* = p < 0.05 by one-way 
ANOVA followed by Newman-Keuls Multiple Comparison Test; n = 6). (d) Purified 
STX1ΔTM peptides (S14A or S14D) were incubated with a GST fusion protein of the 
first 64 amino acids of the hDAT N-terminus (N64) or with GST alone. The samples 
were then immunoblotted for STX1. STX1 band densities were expressed as a 
percentage of STX1ΔTM S14D. STX1ΔTM S14A displays reduced binding to the 
hDAT N-terminus (* = p < 0.05 by Student’s t-test; n = 5). 
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STX1 S14D exhibits increased interaction with hDAT with respect to STX1 S14A. Thus, 
phosphorylation of STX1 at Ser14 supports STX1/DAT association. Plasma membrane levels of 
hDAT, as measured by biotinylation, were not altered by the expression of either STX1 S14A or 
STX1 S14D when compared to STX1 (STX1 S14A: hDAT surface expression was 101 ± 39% 
and STX1 S14D: hDAT surface expression was 88 ± 16% relative to hDAT cells expressing 
STX1; p > 0.89 by one-way ANOVA; n = 5-6).    
 
To determine whether Ser14 phosphorylation regulates the direct association between STX1 
and DAT, we used an in vitro GST pull-down assay as described in Binda et al.(Binda et al., 
2008), which previously demonstrated that the hDAT N-terminus directly interacts with 
STX1(Binda et al., 2008). Therefore, in this study, we used a GST hDAT N-terminal fusion 
protein (hDAT N64, see Methods) to pull down recombinant soluble constructs of STX1 lacking 
the transmembrane domain (STX1ΔTM) with Ser14 mutated to Ala (STX1ΔTM S14A) or Asp 
(STX1ΔTM S14D) (Fig. 28d). hDAT N64 robustly pulled down STX1ΔTM S14D. However, 
hDAT N64 pull down of STX1ΔTM S14A was dramatically blunted. GST alone did not pull down 
either STX1ΔTM construct. Quantitative analysis of band densities in figure 28d demonstrates 
that the STX1ΔTM S14A peptide exhibits a significantly reduced direct association with the DAT 
N-terminus relative to the STX1ΔTM S14D peptide. Input bands show that the STX1ΔTM 
constructs were of expected size and exhibited minimal degradation. These data further support 
the notion that STX1 phosphorylation at Ser14 is a key regulator of the dynamic, direct 
interaction between STX1 and DAT. 
 
STX1 phosphorylation supports reverse transport of DA 
Figure 26b shows that the STX1 R/Q variant promotes a reduction in DA efflux. Therefore, it is 
possible that the CK2-mediated phosphorylation of STX1 at Ser14 support reverse transport of 
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DA. We first determined whether AMPH causes an increase in STX1 phosphorylation. To test 
this, p-STX1 levels were measured in hDAT cells transfected with STX1 and treated either with 
vehicle, AMPH, or AMPH in the presence of TBB (Fig. 29a). AMPH treatment increased the 
level of p-STX1 with respect to vehicle control. Pre-treatment of cells with TBB (10 µM for 20 
minutes) prevented the AMPH-induced phosphorylation of STX1 at Ser14, demonstrating that 
AMPH induces phosphorylation of STX1 in a CK2-dependent manner. Quantitation of the band 
density of p-STX1, normalized to total STX1 and expressed as a percent of control is shown in 
figure 29a (bottom).  
 
These findings implicate CK2 and phosphorylation of STX1 at Ser14 as possible novel 
molecular mediators of reverse transport of DA. Thus, we investigated the role of CK2 function 
and STX1 phosphorylation at Ser14 in AMPH-induced DA efflux. DA efflux was quantified by 
amperometry in hDAT cells expressing STX1 under control conditions or pharmacological 
inhibition of CK2 with TBB (10 µM for 20 minutes). TBB reduced AMPH-induced DA efflux as 
compared to vehicle control treated cells (Fig. 29b). These data support our hypothesis that 
STX1 phosphorylation at Ser14 regulates reverse transport of DA. To further test this 
hypothesis, we determined if the ability of TBB to regulate DA efflux is altered by preventing or 
mimicking phosphorylation of STX1. We expressed STX1 S14A or STX1 S14D constructs in 
hDAT cells and measured AMPH-induced DA efflux in the presence or absence of TBB. In 
hDAT cells expressing STX1 S14A, AMPH-induced DA efflux was not sensitive to 
pharmacological inhibition of CK2, and the absolute DA efflux in vehicle control was comparable 
to TBB treated hDAT cells expressing STX1 (Fig. 29c, compare to Fig. 29b TBB treated). 
Further, in hDAT cells expressing STX1 S14D, AMPH-induced DA efflux was also not sensitive 
to TBB. However, the absolute DA efflux in the presence of TBB was comparable to vehicle 
treated hDAT cells expressing STX1 (Fig. 29d, compare to Fig. 29b vehicle treated). These 
results demonstrate that preventing STX1 phosphorylation (STX1 S14A) parallels  
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Figure 29. STX1 phosphorylation promotes reverse transport of DA. (a) Top: 
stably transfected hDAT cells expressing STX1 were treated with either vehicle or 10 
µM TBB for 20 minutes. This was followed by an additional treatment with vehicle or 
10 µM AMPH for 15 minutes.  STX1 immunoprecipitates were immunoblotted for 
either p-STX1 (Ser14) or STX1. Bottom: the immunoprecipitated band densities were 
quantified, normalized to the corresponding density of total precipitated STX1, and 
expressed as a percentage of vehicle control (* = p < 0.05 by one-way ANOVA 
followed by Newman-Keuls Multiple Comparison Test; n = 3). (b) Representative 
AMPH-induced DA efflux recorded from stably transfected hDAT cells expressing 
STX1 treated with either vehicle or 10 µM TBB for 20 minutes just before the 
amperometric recordings. Arrows indicate application of 10 μM AMPH. Bottom: 
quantitation of AMPH-induced DA efflux. Data are represented as maximal oxidative 
current (* = p < 0.05 by Student’s t-test; n = 5). (c) Representative AMPH-induced 
amperometric currents recorded from stably transfected hDAT cells expressing STX1 
S14A treated with either vehicle or 10 µM TBB for 20 minutes. Arrows indicate 
application of 10 μM AMPH. Bottom: quantitation of maximal oxidative current (p > 
0.05 by Student’s t-test; n = 4-7). (d) Representative AMPH-induced amperometric 
currents recorded from stably transfected hDAT cells expressing STX1 S14D treated 
with either vehicle or 10 µM TBB for 20 minutes. Arrows indicate application of 10 μM 
AMPH. Bottom: quantitation of AMPH-induced DA efflux. Data are represented as 
maximal oxidative current (p > 0.05 by Student’s t-test; n = 6). 
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pharmacological inhibition of CK2, and mimicking STX1 phosphorylation (STX1 S14D) obscures 
the ability of TBB to inhibit DA efflux. It also points to the phosphorylation state of STX1 at 
Ser14 as a determining factor in the magnitude of reverse transport of DA, further supporting 
our hypothesis that the STX1 R/Q variation alters DA neurotransmission via reduced 
phosphorylation. 
 
The data described thus far provide clear mechanistic evidence that CK2-mediated 
phosphorylation of STX1 promotes STX1/DAT interaction and reverse transport of DA, in a 
controlled and well-defined heterologous expression system. Use of this expression system 
yields feasibility for mechanistic insights in a timely fashion(Hamilton et al., 2013, Hamilton et 
al., 2014). However, it is important to translate these discoveries to neuronal release sites, the 
site of DAT actions. Cultured catecholamine neurons from the superior cervical ganglion (SCG) 
have large presynaptic boutons that are amenable to imaging approaches, allowing us to 
determine whether AMPH drives STX1 phosphorylation at these release sites. SCG neurons 
natively express the NET, which has 66% amino acid sequence homology with the DAT, as well 
as the accompanying catecholamine presynaptic machinery(Matthies et al., 2009). We and 
others have shown that NET is a useful marker of catecholaminergic presynaptic terminals in 
cultured SCG neurons(Matthies et al., 2009). Here, we utilized confocal imaging of SCG 
presynaptic boutons coupled with immunofluorescence to reveal the presence of endogenous p-
STX1, closely localized to the NET (Fig. 30a). Consistent with our findings in hDAT cells, AMPH 
treatment (10 µM for 20 minutes) enhances STX1 phosphorylation at Ser14 in SCG presynaptic 
terminals (Fig. 30b). SCG cultured neurons also express endogenous CK2α, the catalytic 
domain of CK2 required for the phosphorylation of STX1 at Ser14 (Fig. 30c). Lastly and notably, 
in mouse striatal slices, a brain region enriched in DA projections, there is a similar profile of 
endogenous STX1 and p-STX1 expression compared to cultured SCG neurons (Fig. 30c). 
These data demonstrate that AMPH stimulates phosphorylation of endogenous STX1 at  
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Figure 30. AMPH treatment increases p-STX1 levels in boutons. (a) Mouse 
superior cervical ganglion (SCG) neurons were fixed and p-STX1 (green) was 
visualized by immunoflourescence. The norepinephrine transporter (NET, red) was 
used as a marker of presynaptic boutons. The merge shows that p-STX1 is present in 
presynaptic boutons of cultured catecholamine neurons. Inset: Confocal sections of a 
single presynaptic bouton (arrow). (b) Top: SCG neurons were treated with either 
vehicle or 10 µM AMPH for 20 minutes. Cells were fixed and immunostained for p-
STX1 (green) and for the NET (red). AMPH increases the intensity of p-STX1 in 
presynaptic boutons. Bottom: p-STX1 levels were quantified by the ratio of p-STX1 
pixel intensity normalized to NET pixel intensity. AMPH significantly increases the 
intensity of p-STX1 in presynaptic boutons (* = p < 0.05 by Student’s t-test; n = 5-6). 
(c) In SCG neurons cultured from NET KO mice, p-Stx1 colocalizes with CK2. (d) In 
mouse striatal slices, DAT co-localizes with STX1 and p-STX1. 
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neuronal release sites, presenting SCG neurons as a biologically relevant preparation in which 
to observe the functional role of STX1 in reverse transport of DA. 
 
STX1 phosphorylation regulates reverse transport of DA at neuronal release sites  
Next, we explored the role of STX1 phosphorylation in DAT-mediated reverse transport of DA at 
the level of the SCG presynaptic boutons. Since SCG neurons do not natively express DAT, we 
used neurons cultured from NET knockout mice transiently transfected with hDAT labeled with a 
GFP tag (Fig. 31a, inset). GFP fluorescence was used to identify neurons positive for hDAT 
expression. AMPH-induced DA efflux was recorded with amperometry from individual synaptic 
boutons (Fig. 31a). This DA efflux was cocaine sensitive, indicating its DAT dependence (data 
not shown). TBB (10 µM for 20 minutes) reduced AMPH-induced DA release as compared to 
vehicle control (Fig. 31a). These data demonstrate, for the first time at the level of a single 
bouton, that CK2 function and STX1 phosphorylation are critical mediators of AMPH-induced 
DAT-mediated DA release.  
 
We then determined the importance of STX1 for reverse transport of DA in ex vivo preparations. 
In mouse striatal slices, pre-incubation in botulinum toxin serotype C (BoNT/C, 100 nM for 60 
minutes), a protein known to cleave STX1(Schiavo et al., 1995), inhibits AMPH-induced DA 
efflux as measured by high speed chronoamperometry (Fig. 31b). Importantly, this BoNT/C pre-
incubation paradigm was not effective in significantly altering DA uptake (Fig. 31c). These data 
demonstrate the pivotal role of STX1 in supporting DA efflux without altering forward transport of 
DA in neuronal tissues. 
 
STX1 phosphorylation and STX1/DAT association regulates dopaminergic behaviors 
For a complete understanding of how ASD-associated variants affect DA neurotransmission, it  
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Figure 31. Inhibition of either STX1 phosphorylation or cleavage of STX1 
inhibits DA efflux but not uptake. (a) Inset: Image of a single GFP-hDAT 
transfected SCG neuron; arrows indicate the site of amperometric recording (i.e. the 
presynaptic bouton). Top: representative AMPH-induced amperometric currents 
recorded from a single presynaptic bouton of SCG neurons expressing GFP-hDAT 
after treatment with either vehicle or 10 µM TBB for 20 minutes. Bottom: quantitation 
of the maximal oxidative current normalized to vehicle treatment (* = p < 0.05 by 
Student t-test; n = 5). (b) AMPH (10 μM)-induced DA efflux recorded in mouse striatal 
slices preincubated (1 hr) either with vehicle or BoNT/C (100 nM) (* = p < 0.05 by 
two-way ANOVA; n = 6). (c) [3H]DA uptake measure in striatal slices receiving 
identical treatment as in panel (c) (p > 0.05 by Student’s t-test; n = 4). 
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is imperative to translate our molecular discoveries in vivo. Drosophila melanogaster offer a 
powerful genetic model for elucidating the importance of targeted molecular manipulations. In 
adult Drosophila males, we developed locomotor assays for an in vivo mechanistic examination 
of DAT-mediated reverse transport of DA and how ASD variants affect this transport process. 
First, we explored how impairments in STX1 phosphorylation, which affects STX1/DAT 
associations, regulate DA associated behaviors. In Drosophila, locomotion requires functional 
DA neurotransmission(Pendleton et al., 2002, Wicker-Thomas and Hamann, 2008, Hamilton et 
al., 2013, Pizzo et al., 2013, Hamilton et al., 2014). To probe for changes in locomotion, we 
developed a behavioral assay in which adult males were fed a sucrose solution containing 
either AMPH (1 mM) or vehicle. We observed that AMPH significantly stimulated locomotion in 
wild-type (WT) Drosophila (Fig. 32a). However, AMPH did not significantly increase locomotion 
in flies lacking dDAT (DAT KO)(Kume et al., 2005), indicating that AMPH-induced locomotion is 
a DAT-dependent behavior (Fig. 32a). These data strongly support this assay as a model in 
which functional DAT is critical for AMPH-induced behavior.  
 
CK2 function promotes STX1 phosphorylation at Ser14, STX1/DAT interaction, and reverse 
transport of DA. Thus, to probe the behavioral significance of impaired STX1 phosphorylation at 
Ser14 and STX1/DAT interaction, we evaluated whether inhibited CK2 function alters AMPH-
induced locomotion. We expressed a dominant negative form of CK2 (CK2DN) in flies by using 
the Gal4/UAS system to express a single copy CK2DN in a WT background, selectively in DA 
neurons(Friggi-Grelin et al., 2003, Matthies and Broadie, 2003). We compared the AMPH-
induced behavioral responses of flies expressing CK2DN to WT flies. AMPH did not significantly 
increase locomotor activity in flies expressing dominant negative CK2 mutant (Fig. 32b). 
Furthermore, vehicle treatment did not modify locomotion of flies expressing CK2DN with 
respect to WT flies, suggesting that extracellular DA level did not change under basal 
conditions. Consistent with this, CK2 inhibition by TBB treatment (10 µM for 15 minutes) did not  
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Figure 32. AMPH induced behavior in Drosophila is regulated by STX1 phosphorylation 
in DA neurons. (a) DAT knockout (KO) flies demonstrate that AMPH-induced locomotor 
behavior is DAT-dependent. Locomotor activity in response to vehicle (open symbols) or 
(1mM) AMPH (filled symbols) in either wild-type (WT) (squares) or in DAT KO flies (triangles). 
WT flies exhibit a significant AMPH-induced increase in locomotion while DAT KO flies do not 
exhibit this significant increase (* = p < 0.05 for vehicle vs AMPH, two-way ANOVA followed 
by Bonferroni post-test; n = 5). (b) Drosophila were generated expressing a dominant-
negative (DN) version of CK2α expressed specifically in dopaminergic neurons. Locomotor 
activity in response to vehicle (open symbols) or AMPH (filled symbols) in either wild-type 
(WT) (squares) or in CK2 dominant negative flies (CK2DN) (triangles). WT flies exhibit a 
significant increase in AMPH-induced locomotion while CK2DN flies do not (* = p < 0.05 for 
vehicle vs AMPH, two-way ANOVA followed by Bonferroni post-test; n = 5). (inset) DA uptake 
in intact fly brains in the presence of 10 μM TBB or vehicle. The absence of uptake in the 
dDAT KO fly brains shows the dependence of DA uptake on the dDAT (*** = p < 0.0001 by 
one-way ANOVA followed by Newman-Keuls Multiple Comparison Test; n = 3). (c) hDAT R/W 
expressing flies have blunted locomotor responses to AMPH. Changes in locomotion were 
determined upon AMPH or vehicle exposure over 30 minutes and calculated as beam 
crosses. AMPH (1 mM) caused a significant increase in locomotion in both hDAT flies (p < 
0.001 by one-way ANOVA followed by Newman-Keuls Multiple Comparison Test; n = 24) and 
hDAT R/W flies (p < 0.05 by one-way ANOVA followed by Newman-Keuls Multiple 
Comparison Test; n = 24). However, in hDAT R/W flies, AMPH exposure led to a less 
hyperactivity than in hDAT flies (* = p < 0.05 by one-way ANOVA followed by Newman-Keuls 
Multiple Comparison Test; n = 24). 
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alter DA uptake in intact Drosophila brains (Fig. 32b, inset). Importantly, brains obtained from 
dDAT KO fly shows robustly reduced DA uptake, demonstrating the DAT dependence of DA 
uptake in our newly developed uptake assay. Collectively, these data point to CK2 activity, 
STX1 phosphorylation at Ser14, and STX1/DAT association as critical mediators of reverse 
transport of DA and associated behaviors.  
 
Next, we explored how the ASD-associated hDAT R/W variant which impairs STX1/DAT 
association affects DA-dependent behaviors in our Drosophila model system. We expressed 
hDAT or hDAT R/W in DA neurons of dDAT KO flies as described above. We fed male 
Drosophila a sucrose solution containing either AMPH (1 mM) or vehicle and quantified 
locomotion in 30 minute intervals. AMPH exposure induced an increase in locomotion in both 
the hDAT and hDAT R/W expressing flies (Fig. 32c). However, AMPH exposure led to 
significantly reduced locomotion in hDAT R/W expressing flies as compared to hDAT 
expressing flies (Fig. 32c, compare hDAT +AMPH versus hDAT R/W +AMPH). These data are 
consistent with the reduced ability of AMPH to cause DA efflux in hDAT R/W expressing cells. 
Also, it is important to note that basal locomotion of flies expressing hDAT R/W did not 
significantly differ from that of hDAT expressing flies.  
 
Discussion 
Alterations in DA neurotransmission are thought to underlie several neuropsychiatric disorders, 
including bipolar disorder, schizophrenia, attention deficit hyperactivity disorder (ADHD), and 
ASD(Seeman and Niznik, 1990, Volkow et al., 2007, Cousins et al., 2009)(Volkow et al., 2007, 
Nguyen et al., 2014). Defining the disruptions in signaling molecules and mechanisms that 
underlie impairments in DA neurotransmission may help in understanding the etiology of these 
DA-associated disorders. Recently, we demonstrated that an ASD-associated hDAT de novo 
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variant displays dramatically altered DAT function, including constitutive reverse transport of 
DA, which leads to hyperlocomotion(Hamilton et al., 2013). Thus, we hypothesized that novel 
DAT variation (or variation in the genes known to regulate the DAT) that affects DA 
neurotransmission might contribute to the pathology and/or complications of ASD. Here, we 
identify and describe two novel gene variants from two separate ASD families. One variation is 
located in STX1A (resulting in a missense mutation in STX1; an Arg to Gln substitution at site 
26) and the other variation is located in SLC6A3 (resulting in a missense mutation in hDAT; an 
Arg to Trp substitution at site 51). These variations are in separate gene products, yet converge 
mechanistically to disrupt DAT function and associated behaviors, with distinct mechanisms 
regulating either STX1 phosphorylation or STX1/DAT interaction.  
 
We found that the STX1 R/Q variant has decreased phosphorylation of Ser14, a key residue 
involved in the functional regulation of STX1(Rickman and Duncan, Dubois et al., 2002, 
Khelashvili et al., 2012). This hypo-phosphorylated STX1 acts to inhibit DAT-mediated reverse 
transport of DA without inhibiting DA uptake function. In hDAT cells expressing STX1 R/Q, we 
observe a significantly increased Vmax of DA uptake. This ability of STX1 R/Q to alter DAT-
mediated uptake is not surprising since STX1 has been observed to decrease DAT uptake 
activity(Cervinski et al., 2010). In parallel experiments in mouse striatal slices, cleaving STX1 
with BoNT/C promotes a decrease in reverse transport of DA with a trend towards increased DA 
uptake. These data suggest that STX1 function asymmetrically regulates reverse transport of 
DA and DA uptake. Importantly, STX1 R/Q displays reduced level of CK2-mediated 
phosphorylation of Ser14. Therefore, to define how hypo-phosphorylation of STX1 R/Q impairs 
DA reverse transport, we studied the regulatory effects of CK2 function on DA efflux.  
 
The expression of CK2, as well as the phosphorylation state of STX1 at Ser14, has been shown 
to be decreased in the post-mortem brain tissue of subjects with schizophrenia(Castillo et al., 
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Aksenova et al., 1991). CK2 phosphorylates STX1 at Ser14 to regulate STX1 function and 
protein interactions(Rickman and Duncan, Hirling and Scheller, 1996, Foletti et al., 2000, Dubois 
et al., 2002). Here, we discovered that CK2-mediated phosphorylation of STX1 at Ser14 
increases the direct association between STX1 and the hDAT N-terminus to potentiate reverse 
transport of DA. Thus, we present CK2 as a key player involved in DA efflux and implicate its 
function in ASD. To have a more complete understanding of how ASD-associated variants 
within the DA network alter behaviors, we translated our molecular discoveries to an in vivo 
context. We selectively expressed CK2DN specifically in DA neurons of WT flies. Drosophila 
expressing CKDN exhibited a robust reduction in AMPH-induced hyperlocomotion as compared 
to WT flies. These data underscore the importance of CK2 function and STX1 phosphorylation 
in regulating behaviors sustained by reverse transport of DA. Interestingly, inhibiting CK2 
function did not regulate basal locomotion or DA uptake in intact Drosophila brains. 
 
Parallel to STX1 R/Q, we found that the hDAT R/W variant displays inhibited reverse transport 
of DA without impairments in uptake function. Thus, we strove to determine whether these ASD-
associated variants disrupt the molecular mechanisms that converge in regulating reverse 
transport of DA, resulting in DA dysfunction and associated behavioral abnormalities. It is 
important to note that CK2 function, in addition to phosphorylating STX1 at Ser14, also 
promotes STX1/DAT interactions. Here, we show that hDAT R/W has reduced association with 
STX1, resulting in altered DA-related behaviors. Indeed, Drosophila expressing hDAT R/W 
selectively in DA neurons demonstrate reduced sensitivity to the psychomotor effects of AMPH, 
as observed in a significantly lower AMPH-induced locomotion when compared to hDAT 
expressing flies. Interestingly, basal locomotion remained unaltered in hDAT R/W flies, 
indicating normal DAT-mediated uptake function as supported by our uptake data. These data 
suggest that the phosphorylation state of STX1 at Ser14 and STX1/DAT interaction 
asymmetrically regulate reverse transport of DA over DAT-mediated uptake functions. 
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It is widely accepted that DAT primarily regulates synaptic DA concentration via DA re-
uptake(Kristensen et al., 2011). Mounting evidence also demonstrates that reverse transport of 
DA and associated behaviors can be promoted by changes in the association between DAT and 
STX1(Binda et al., 2008), as well as by signaling molecules such as CaMKII, which drive DAT 
N-terminus phosphorylation(Fog et al., 2006, Pizzo et al., 2013, Pizzo et al., 2014). Therefore, it 
has been suggested that reverse transport of DA might participate in shaping DA 
neurotransmission(Leviel, 2011). Here, we used AMPH as a tool to induce the molecular events 
that are required for reverse transport of DA to determine whether ASD-associated variants 
disrupt these events. In both in vitro and ex vivo preparations, CK2 function is the key molecular 
event that promotes phosphorylation of STX1 at Ser14 and STX1/DAT interaction to cause 
reverse transport of DA. We bring the study of CK2 function and its relationship to DA efflux for 
the first time at the level of a single active site, the SCG bouton.  
 
Several ASD-associated variants have now been found to impact DAT-mediated DA efflux, 
including the STX1 R26Q and DAT R51W variants reported here, each of which interferes with 
STX1 phosphorylation the STX1/DAT interaction and thereby ablates AMPH-induced efflux. 
Interestingly, two other variants were previously found to cause dysregulated, anomalous DAT 
efflux, including a de novo DAT T356M variant and the recurrent DAT A559V variant seen in 
two boys with ASD, as well as in individuals with bipolar disorder and ADHD. These seemingly 
contradictory findings align with other examples of neurodevelopmental risk emerging from 
genetic variants causing opposite effects on gene expression or signaling cascades (Weiss et 
al., 2008, Sanders et al., 2011)(Cook et al., 1997, Auerbach et al., 2011)(Van Esch et al., 2005). 
The physiological importance of DA efflux has only recently emerged and remains incompletely 
understood. These convergent data from ASD variants direct our attention to 
neurodevelopment, when DAT blockade or receptor stimulation at different time periods leads to 
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long-lasting changes in brain function(Stanwood and Levitt, 2007), as well as adult social 
behavior, including pair-bonding(Hostetler et al., 2011) and aggression(Yu et al., 2014). 
Understanding the impact of these variants on AMPH sensitivity may also shape the use of 
psychostimulants in children with ASD, since psychostimulant medications including AMPH 
(Adderall™) are frequently prescribed as a pharmocotherapy to treatment frequently co-
occurring hyperactivity and inattention in ASD(Mahajan et al., 2012). This altered sensitivity to 
AMPH observed in the ASD-associated variants may help to interpret changes in the efficacy of 
these psychostimulant-based therapies for ASD. 
 
Materials and Methods 
Subjects and clinical assessment. Subjects from this family correspond to the proband, 
unaffected sibling, and both parents (AC04-0029-01, AC04-0029-02, AC04-0029-03, AC04-
0029-04), who were recruited by the Boston-based Autism Consortium(Wolfson, 2007). Clinical 
assessment followed standard research criteria for ASD diagnosis. The proband was classified 
as having a comparatively “narrow” diagnosis (as opposed to a “broader ASD”) based on 
diagnostic algorithms from the Autism Diagnostic Interview Revised (ADI-R)(Lord et al., 1994) 
using criteria described by Risi et al.(Risi et al., 2006), and classification resulting from the 
diagnostic algorithm of the Autism Diagnostic Observational Session (ADOS)(Lord et al., 2000). 
Proband IQ was assessed at age 5 years, 9 months using the Wechsler Preschool and Primary 
Scale of Intelligence (WPPSI; Wechsler, D. (1967)). The Social Responsiveness Scale (SRS; 
Western Psychological Services) was performed on both parents to index the presence and 
severity of broader autism phenotype traits, followed by medical and family history provided by 
the biological mother.  
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SLC6A3 R/W and STX1A R/Q discovery. Methodological details and validation of the de novo 
mutation are published(Neale et al., 2012). Briefly, DNA derived from whole blood of both 
parents and the probands was subjected to whole exome sequence analysis. The T356M 
variant, identified as a heterozygote in the proband and absent in both parents, was 
experimentally validated and confirmed to be a de novo mutation that does not appear in the 
unaffected sibling.  
 
Cell culture and transfection. STX1 constructs in the pcDNA3.1(-) expression vector and the 
GFP-hDAT-pCIHygro expression vectors containing hDAT or hDAT R/W (Arg51 to Trp) 
sequence were generated, confirmed and transiently transfected into Chinese hamster ovary 
(CHO) cells. In some experiments (noted in figure legend), stably transfected hDAT CHO cells 
were used. These cells were generated as described in Bowton et al.(Bowton et al., 2010). Cells 
were maintained in a 5% CO2 incubator at 37°C and maintained in Ham’s F-12 medium 
supplemented with 10% fetal bovine serum (FBS), 1 mM l-glutamine, 100 U/mL penicillin, and 
100 μg/mL streptomycin. Stably transfected hDAT CHO cells were kept under selection with 250 
µg/mL hygromycin B (Corning Cellgro). Fugene-6 (Roche Molecular Biochemicals) in serum-
free media was used to transfect cells using a 6:1 transfection reagent:DNA ratio. Assays were 
conducted 24-48 hours post transfection.  
 
Superior Cervical Ganglion neuron culture and transfection. SCG neurons were cultured from 1-
3 day old male mouse pups. SCGs were dissected in complete Ultraculture medium (Lonza) 
supplemented with 20 ng/mL nerve growth factor (NGF). SCGs were washed with PBS and 
incubated for 20 minutes in collagenase (3%) and trypsin (2.5%) at 37°C. They were washed in 
complete Ultraculture medium with NGF. Dissociated cells were obtained by SCG trituration in 
medium. Cells plated on poly-D-lysine coated MatTek® dish treated with collagen (type IV). 24 
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hours post-plating, the media was replaced with Ultraculture medium with NGF and 10 µM 5-
fluoro-2-deoxyuridine (FDU). SCGs were transfected via intranuclear microinjection of DNA. 
 
Cell surface biotinylation and protein immunoblot. Cells were cultured in 6-well plates. For cell 
surface biotinylation assays, cells were labeled with sulfo-NHS-SS-biotin (1.0 mg/ml; Pierce) 
before purification and analysis via SDS-PAGE/immunoblots(Mazei-Robison et al., 2008). hDAT 
was detected using a rat monoclonal primary antibody to the N-terminus of hDAT (1:1000) 
(Millipore Bioscience Research Reagents, catalog number MAB369) and a goat-anti-rat-HRP-
conjugated secondary antibody (1:5000) (Jackson ImmunoResearch, catalog number sc-2006). 
The phosphorylation level of STX1 at Ser14 was detected using a rabbit polyclonal antibodies to 
phospho-S14 either from Castillo et al.(Castillo et al.) or with a commercially available antibody 
(1:2500) (abcam, catalog number ab63571) and a goat-anti-rabbit-HRP-conjugated secondary 
antibody (1:5000) (Jackson ImmunoResearch, catalog number sc-3837). Total STX1 was 
detected using a mouse monoclonal antibody (1:5000) (Sigma, catalog number S 0664) and a 
goat-anti-mouse-HRP-conjugated secondary antibody (1:5000) (Jackson ImmunoResearch, 
catalog number sc-2005). 
 
Immunostaining. SCG neurons (at least 14 days in culture) were serum starved for one hour in 
DMEM:F12 and treated with vehicle or AMPH for 20 minutes. Neurons were subsequently fixed 
with PBS plus Ca2+/Mg2+ and 4% paraformaldehyde, washed three times with PBS plus 
Ca2+/Mg2+, permeabilized, and blocked with PBS with 4% bovine serum albumin (BSA)/0.15% 
Tween 20, and immunostained with the appropriate antibody dissolved in PBS plus 4% BSA 
and 0.05% Tween 20. NET was detected using a mouse monoclonal antibody (1:5000) (Mab 
technologies; NET05-2) and pSTX1 with an affinity purified rabbit polyclonal (1:1000), anti pSTX 
at Ser14(Castillo et al.). Primary antibodies were visualized with the appropriate covalently 
Alexa-labeled secondary antibody from Invitrogen.  
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Mouse brain slices were prepared as outlined in High Speed Chronoamperometry method 
section, except recovery was in aCSF was for one hour at 37°C. Slices were fixed, 
permeabilized, washed, and blocked as outlined above. DAT was visualized using rat 
monoclonal against DAT and STX1A and STX1B were detected using rabbit polyclonal 
antiserum from SYSY catalogs # 110 302 STX1A and 110 402 STX1B respectively. pSTX at 
Ser14 was detected using an affinity purified rabbit polyclonal(1:1000)(Castillo et al.). Primary 
antibodies were visualized with the appropriate covalently Alexa-labeled secondary antibody 
from Invitrogen. 
 
Immunofluorescence was imaged by capturing Z-series using a Zeiss using a •63x / 1.40 Plan-
APOCHROMAT oil lens (Vanderbilt University Medical Center Cell Imaging Shared Resource). 
All images shown are always from single confocal sections, and image processing was 
performed using ImageJ and Adobe Photoshop. 
 
Co-immunoprecipitations. Cells were grown to confluence in 25 cm2 culture flasks and serum 
deprived for one hour prior to assay. Cells were washed three times with 4˚C phosphate-
buffered saline (Gibco) containing 1 mM EGTA and 1 mM EDTA, and then lysed in RIPA buffer 
(100 mM NaCl, 1.0% IGEPAL CA-630 (NP-40), 0.5% sodium deoxycholate, 0.1% SDS, 50 mM 
Tris, pH = 7.4, supplemented with a protease inhibitor cocktail (Sigma)). Lysates were passed 
twice through a 27.5 gauge needle, and centrifuged at 15,000 x g for 30 minutes. With a portion 
of the total cell lysate (TCL) collected to run as the totals, 1 mL of the remaining supernatant 
was incubated at 4°C for 4 hours with Sepharose-G beads (Fisher Scientific), previously 
washed with 1% BSA in RIPA buffer, and then preincubated with 2.5 µg DAT antibody (rat 
monoclonal, #MAB369, Millipore). For the control, supernatant was incubated with BSA-blocked 
Sepharose-G beads alone (no DAT antibody). After the 4 hour incubation, beads were spun 
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down, washed with cold RIPA buffer, and eluted with Laemmli sample buffer at 37˚C for 30 
minutes. TCL and bead eluates were analyzed by SDS-PAGE (10%) and immunoblotted for 
total STX1 and DAT. Band intensity was quantified using ImageJ software (National Institutes of 
Health).  
 
Expression and purification of STX1. The cDNAs encoding STX, STX S14D and STX S14A 
lacking the transmembrane domain (STX ΔTM, STX1ΔTM S14A and STX1ΔTM S14D) were 
inserted into the bacterial expression vector pGEX, thereby adding an N-terminal GST-tag 
followed by a thrombin cleavage site. The resulting fusion proteins were produced in 
Escherichia coli BL21 DE3 LysS. The culture was grown at 30°C to OD 0.8 and expression was 
induced with 1 mM isopropylβ-d-1-thiogalactopyranoside at 30°C, and the culture was 
harvested 4 hours after induction. The frozen pelleted bacteria was lyzed in buffer (PBS, 0,1% 
TX-100, 20µg/mL DNAse I, 1mM DTT, mix protease inhibitor (GE Healthcare). The lysate was 
cleared by centrifugation followed by incubation with 100 μl glutathione sepharose beads (GE 
Healthcare, Uppsala, Sweden) at 4°C for 1½ h. The beads were pelleted at 3000 rpm for 5 min. 
and washed 3 times in buffer (PBS, 0,1% TX-100, 1 mM DTT) before elution by cleavage with 
1μl thrombin (GE Healthcare, Uppsala, Sweden) O/N at 4°C. PMSF (1 mM) was added and the 
beads were filtered through a P200 tip. The concentration of the purified STX1B was measured 
by BCA assay (Thermo Fisher Scientific, Waltham, MA).  
 
GST pull-down assay. A DAT GST fusion protein containing the 64 N-terminal residues of the 
transporter (GST hDAT 1-64) was expressed and bound to glutathione sepharose beads as 
described (Binda et al., 2008). For the pull-down, 20 μl beads with either GST or GST hDAT 1-
64 bound were incubated with 2 μg of purified STX ΔTM, STX1ΔTM S14A or STX1ΔTM S14D 
in 500 μl buffer (PBS, 0.1% TX-100, 0.1% BSA) for 30 minutes at 4°C and washed 3 times in 
buffer without BSA. Bound protein was eluted by incubation of beads for 1 hour at RT with 1 μl 
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thrombin in 15 μl buffer (PBS, 0.1% TX-100) followed by addition of SDS loading buffer + 
100mM DTT and incubation for 25 min. at 70°C. Each sample was split in two and loaded on 
two different Any-kD precast gels (BioRad, Hercules, CA). One gel was used as a Coomassie 
loading control and the other was transfered to a PDVF membrane and immunoblotted with 
primary mouse STX antibody (Sigma Aldrich. St. Louis, MO) 1:1000 and anti-mouse HRP-
conjugated secondary antibody (Thermo Fisher Scientific, Waltham, MA) 1:5000.  
 
Amperometry. Cells were plated at a density of ~20,000 per 35-mm culture dish. To load cells 
with DA, dishes were washed with KRH assay buffer (130 mM NaCl, 1.3 mM KCl, 1.2 mM 
KH2PO4, 10 mM HEPES, and 2.2 mM CaCl2, pH 7.4) containing 10 mM dextrose, 100 µM 
pargyline, 1 mM tropolone, and 100 µM ascorbic acid, and incubated with 1 µM DA in KRH 
assay buffer for 20 min at 37°C. To preload SCG neurons, dishes were washed with KRH assay 
buffer (as above) containing 100 nM raclopride. Dishes were washed three times with the 
external bath solution (130 mM NaCl, 10 mM HEPES, 34 mM dextrose, 1.5 mM CaCl2, 0.5 mM 
MgSO4, 1.3 mM KH2PO4, adjusted pH to 7.35, and 300 mOsm). A carbon fiber electrode 
(ProCFE; fiber diameter of 5 µm; obtained from Dagan Corporation) juxtaposed to the plasma 
membrane and held at +700 mV (a potential greater than the oxidation potential of DA) was 
used to measure DA flux through oxidation reactions. Amperometric currents in response to the 
addition of 10 µM AMPH were recorded using an Axopatch 200B amplifier (Molecular Devices, 
Union City, CA) with a low-pass Bessel filter set at 1 kHz; traces were digitally filtered offline at 1 
Hz using Clampex9 software (Molecular Devices, Union City, CA). DA efflux was quantified as 
the peak value of the amperometric current for all experiments except for recordings from SCG 
neurons. For SCG neurons, total DA efflux was quantified as the integral of the trace for a fixed 
15 minute window. 
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High Speed Chronoamperometry. Striatal hemislices (300 µm) from 6-10 week old C57Bl6 mice 
were prepared with a vibratome (Leica VT1000S) in an ice cold oxygenated (95% O2 / 5% CO2) 
sucrose cutting solution consisting of (in mM): 210 sucrose, 20 NaCl, 2.5 KCl, 1 MgCl2, 1.2 
NaH2PO4, 10 glucose, 26 NaHCO3. Slices were then transferred to oxygenated artificial 
cerebrospinal fluid (aCSF) at 28°C for a minimum of 1 hour. The aCSF consisted of (in mM): 
125 NaCl, 2.5 KCl, 1 MgCl2, 2 CaCl2, 1.2 NaH2PO4, 10 glucose, 26 NaHCO3, 0.25 ascorbic acid. 
Striatal slices were treated at 37°C for 1 hour with either 100 nM BONT/C or vehicle control. 
Dopamine concentration was measured by chronoamperometry in striatal slices as previously 
described(Hoffman and Gerhardt, 1999, Gerhardt and Hoffman, 2001). Briefly, carbon fiber 
electrodes (100 μm length × 30 μm O.D.) coated with nafion for dopamine selectivity were 
lowered into the desired recording site or sites so that the tip of the recording electrode was 
positioned at a depth of 75-100 μm. The voltage was stepped from 0 mV to 550 mV for 100 ms 
and then back to 0 mV and the charging current of the carbon fiber electrode was allowed to 
decay for 20 ms before the signals were integrated. Data were collected at a frequency of 1 Hz 
with an Axopatch 200B amplifier. The integrated charge was converted to dopamine 
concentration based on in vitro calibration with dopamine.  
 
[3H]DA uptake. For DA uptake in a heterologous expression system: cells were plated on poly-
D-lysine coated, 24-well plates and grown to ~90% confluence. On the day of the experiment, 
cells were washed with 37°C KRH buffer containing 10 mM dextrose, 100 µM pargyline, 1 mM 
tropolone, and 100 µM ascorbic acid, and equilibrated for 5 minutes at 37°C. Saturation kinetics 
of DA uptake was determined using a mixture of [3H]DA (PerkinElmer Life Sciences, Waltham, 
MA) and unlabeled DA (Sigma Aldrich) diluting to final DA concentrations of 0.05 µM - 10 µM. 
Uptake was initiated by bath addition of the dilution row mixture. Uptake was terminated after 10 
minutes by washing twice in ice-cold KRH buffer. Scintillation fluid (Optiphase HiSafe 3, 
PerkinElmer Life Sciences) was added to the wells and the plates were counted in a Wallac Tri-
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Lux -scintillation counter (Wallac). Nonspecific binding was determined in the presence of 10 
µM cocaine. Km and Vmax values were derived by fitting Michaelis-Menten kinetics to the 
background corrected uptake data, using GraphPad Prism 5.0 (GraphPad Software, San Diego, 
CA). All determinations were performed in triplicates.  
 
For DA uptake in striatal slices: striatal hemislices (prepared as previously mentioned) were 
treated at 37°C for 1 hour with either 100 nM BONT/C or vehicle control. Slices were then 
exposed to 50 nM [3H]DA for 10 minutes. DAT-specific DA uptake was determined by 
subtracting the non-specific signal in the presence of 3 µM GBR12909. At the end of the [3H]DA 
treatment, the slices were washed with cold aCSF and the striatum dissected. Tissue samples 
were then homogenized in 200 µL of lysis buffer consisting of 150 mM NaCl, 25 mM HEPES, 2 
mM sodium orthovanadate, 2 mM sodium fluoride, 1% Triton-100. The homogenate was 
centrifuged at 13,000g 4°C for 30 minutes and the supernatant added to 500 µL of buffer 150 
mM NaCl, 25 mM HEPES, 2 mM sodium orthovanadate, 2 mM sodium fluoride, 0.1% Triton-
100. The protein concentration of each sample was measured and 500 µL of each sample was 
added to scintillation vials to count [3H]DA. Counts were expressed as a ratio to protein content 
and normalized to the mean value for the control condition within each experiment. 
 
For DA uptake in dissected Drosophila brains: 2-5 day old males were collected, anesthetized 
with CO2, and brains were dissected in Schneider’s medium (GIBCO) with 1.5% BSA. The 
retina were removed, and four brains per condition were pooled in Millipore Millicell inserts in 24 
well plates. Brains were washed with Schneider’s medium, then washed in a standard fly saline 
solution (HL3)(Feng et al., 2004) plus 1.5% BSA and 10 mM MgSO4. For 15 minutes at room 
temperature, brains were exposed to 200 nM [3H]DA in HL3 plus 1.5% BSA and 115 uM 
ascorbic acid. Brains were then washed six times with 1.4 mL HL3 plus 1.5% BSA at 4°C. 
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Brains were placed into scintillation vials in 100 uL 0.1% SDS. Scintillation fluid was added to 
count [3H]DA. 
 
Drosophila Genetics, Molecular Biology, and Construction of UAS hDAT. Flies lacking the 
Drosophila dopamine transporter (DATfmn)(Kume et al., 2005) and flies harboring TH-
Gal4(Friggi-Grelin et al., 2003) were outcrossed to a control line (Bloomington Indiana (BI) 
6326) and selected by PCR or by eye color. TH-GAL4 (Bl 8848) and M{vas-int.Dm}ZH-2A, 
M{3xP3-RFP.attP'} ZH-22A (Bl 24481) were obtained from the BI stock center and outcrossed 
to flies lacking the Drosophila DAT (DATfmn) and carrying the white (w1118) mutation (BI stock 
number 6236) for 5–10 generations. Transgenes (hDAT or hDAT R/W) were cloned into pBI-
UASC(Wang et al., 2012), and constructs were injected into embryos from M{vas-int.Dm}ZH-2A, 
M{3xP3-RFP.attP'}ZH-22A (Bl 24481). Initial potential transformants were isolated by selecting 
for red eyes and lack of GFP signal in the head. Transformants were also verified by RFP 
fluorescence and outcrossed 5-8 times to DATfmn flies. The presence of DATfmn lesion was 
verified by PCR. Flies were maintained on a standard cornmeal/molasses/yeast media at 25°C 
and 65% humidity with a 12 hour/12hour light/dark cycle. Lights came on at 8 AM and off at 8 
PM.  
  
Behavioral Analysis. Three day old males were collected and placed into tubes with food for 
three days. After three days locomotion was recorded for 32 hours by beam breaks and 
analyzed using equipment/software from Trikinetics (www.trikinetics.com). For the AMPH-
induced locomotion, males were starved for 6 hours and then fed sucrose (10 mM) containing 
either AMPH (1 mM) or vehicle.  
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Statistical Analysis. Compiled data are typically expressed as normalized mean ± s.e.m. For 
statistical analysis, we used either a Student’s t-test or one-way ANOVA depending on the n of 
the experimental groups. P < 0.05 was considered statistically significant.  
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CHAPTER VI 
FUTURE DIRECTIONS 
 
The results presented herein outline multiple molecular and structural regulators of the reversal 
of DAT function. Identifying and understanding these regulatory events is a vital research 
priority, and may lead to valuable pharmacotherapies for treating psychostimulant abuse, ASD, 
and related neuropsychiatric disorders. Each chapter presents a different mechanism of DAT 
molecular regulation, yet it is possible that some of these regulators converge mechanistically to 
fine-tune DAT functions. In this chapter, I will describe potential future mechanistic experiments 
to determine the role of N-terminal phosphorylation and how this posttranslational modification 
transmits the actions of AMPH. I will focus this discussion particularly in the context of the 
research outlined in chapter II. 
 
Chapter II identified the N-terminus of the hDAT as a structural domain that directly interacts 
with PIP2. I propose that this interaction may be an anchor for the N-terminus of the hDAT, 
targeting its localization to the plasma membrane and regulating its conformations. This may 
preferentially prime the hDAT for forward transport function. Experiments targeted at observing 
the consequences of the steric constraint of the N-terminus to the plasma membrane may help 
clarify how the mobility of the N-terminus regulates the transporter cycle (experiments could 
include probing for changes in the voltage dependence of DA efflux and/or hDAT affinity for 
substrates). It has been stated that the N-terminus of DAT is a “lever” required for the actions of 
AMPH(Sucic et al.); therefore, I hypothesize that irreversibly anchoring the N-terminus of the 
hDAT to the plasma membrane would selectively impair the ability of AMPH to cause DA efflux, 
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without altering hDAT-mediated DA uptake. These experiments would help clarify the role of 
hDAT N-terminal mobility in AMPH actions. 
 
Our lab and others have demonstrated that that phosphorylation of five key Ser residues on the 
hDAT N-terminus is an event required for AMPH to induce DA efflux(Khoshbouei et al., 2004, 
Fog et al., 2006). I predict that hDAT-PIP2 interactions are required for the phosphorylation of 
these N-terminal residues by presenting the hDAT N-terminus at a membrane localization or 
conformation conducive to phosphorylation by kinases such as PKC and CaMKII. Thus, I 
hypothesize that PIP2 depletion or interfering with the hDAT-PIP2 interaction would block hDAT 
N-terminal phosphorylation and the subsequent DA efflux. Consistently, I anticipate hDAT 
mutants with reduced PIP2 interactions (e.g. hDAT K/N or hDAT K/A) would be resistant to the 
ability of AMPH to cause N-terminal phosphorylation. This would explain the observed reduction 
in DA efflux presented in chapter II.  
 
It is possible that AMPH-induced phosphorylation uncouples the hDAT N-terminus from PIP2, to 
support DA efflux. Therefore, I further predict that there is a series of molecular events required 
for the reversal of hDAT function, and that hDAT N-terminal phosphorylation would circumvent 
the requirements for hDAT to interact with PIP2 to support DA efflux. One experiment that may 
elucidate this series of events would involve the use of an hDAT construct with all five distal Ser 
residues mutated to Asp, to mimic phosphorylation at these residues (hDAT S/D). Expressing 
the hDAT S/D in heterologous cells and introducing the PIP2-inhibitory peptide through the 
whole-cell pipette in the APC setup while recording the magnitude of the AMPH-induced DA 
efflux (similar to the setup in Fig. 9) would allow me to clarify the role of hDAT N-terminal 
phosphorylation and PIP2 interaction in the AMPH-induced reverse transport of DA. I predict that 
the cells expressing hDAT S/D would be impervious to a decrease reverse transport of DA 
induced by interfering with hDAT-PIP2 membrane interactions with the PIP2-inhibitory peptide. 
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The hDAT S/D would not depend on PIP2 interactions to induce reverse transport of DA 
because transporter is already pseudo-phosphorylated. Therefore, it would not require PIP2 
interactions to promote hDAT N-terminal phosphorylation. This would indicate that PIP2 
interactions with the hDAT N-terminus are a necessary precursor for phosphorylation of key Ser 
residues, and would shed light onto the temporal sequence of events that are required for 
AMPH to induce a reversal in hDAT function.  
 
The work outlined in this thesis advances the understanding of the molecular mechanisms 
involved in AMPH actions. This understanding may allow for the development of small 
molecules that selectively inhibit AMPH’s ability to induce DA efflux without affecting the 
physiological function of DAT uptake. At first glance, it might seem reasonable to inhibit the 
kinases involved in hDAT N-terminal phosphorylation, in order to reduce the efficacy of AMPH 
actions at the hDAT. This is a complex solution since these kinases (e.g. PKC and CaMKII) are 
ubiquitous in the CNS and involved in many processes. Alternatively, specifically inhibiting the 
hDAT-PIP2 interaction may prove to be a more targeted and effective strategy for reducing 
AMPH-induced DA efflux while leaving DA uptake intact. This may prove to be effective 
treatment for AMPH abuse, where there currently is none. 
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